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Résumé : La haute sensibilité et l’analyse 
simultanée de plusieurs biomarqueurs (multiplexage) 
sont des enjeux essentiels pour permettre des 
avancées significatives pour le diagnostic médical. 
De telles avancées permettraient d’augmenter la 
précocité des diagnostics pour de nombreuses 
maladies comme le cancer ou des maladies 
cardiaques. Les immunodosages de FRET (transfer 
d’énergie par resonance de type Förster) sont basées 
sur la reconnaissance de biomarqueurs par des 
anticorps marqués avec des fluorophores et le FRET 
qui résulte du processus de reconnaissance 
immunologique. Aujourd’hui des telles 
immunodosages sont établis en utilisant des 
lanthanides comme donneurs de FRET et des 
fluorophores organiques comme accepteurs de 
FRET. 
 
Néanmoins, ils ne permettent pas de réaliser un 
multiplexage efficace car l’utilisation de plusieurs 
différents fluorophores organiques résulte dans un 
recouvrement spectral. Ce projet a pour but de mettre 
en application les propriétés optiques exceptionnelles 
des complexes de terbium (Tb) et des boîtes 
quantiques (QDs) pour parvenir à des analyses 
biologiques de FRET multiplexées et ultrasensibles. 
Nous avons également étudié les propriétés optiques 
et morphologiques de nouvelles nanoparticules à 
conversion ascendante de type coeur et 
coeur/coquille dopées à l'ytterbium (Yb) et des ions 
d'erbium (Er) comme donneurs de FRET.  
 
 
Title : Quantum dots and upconverting nanoparticles: Bioconjugation and time-resolved multiplexed FRET 
spectroscopy for cancer diagnostics 
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Abstract : Combining high sensitivity with 
simultaneous analysis of numerous biomarkers 
(multiplexing) is an essential requirement for 
significantly improving the field of biomedical 
diagnostics. Such progresses would allow earlier 
diagnosis, which is required for numerous diseases 
such as cancer or cardiac diseases. FRET-
immunoassays are based on biomolecular 
recognition events that occur between biomarkers 
and two specific antibodies conjugated with 
different fluorophores. The spatial proximity of the 
two fluorophores can lead to Förster resonance 
energy transfer (FRET), which can be detected for 
biomarker quantification. To date, such assays are 
established using lanthanide complexes as FRET 
donors and fluorescence dyes as FRET acceptors. 
 
However, these assays do not provide sufficient 
multiplexing capability due to spectral overlap, 
when several acceptor dyes are used. This project 
aims at exploiting the exceptional photophysical 
properties of terbium complexes (Tb) and 
semiconductor quantum dots (QDs) to provide 
ultrasensitive multiplexed FRETimmunoassays. We 
also studied the optical and morphological 
properties of novel core and core/shell upconverting 
nanoparticles doped with ytterbium (Yb) and 
erbium (Er) ions as possible FRET-donors for 
biosensing. 
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1.  General introduction 
1.1 Introduction 
“There is plenty of room at the bottom”. Richard P. Feynman, December 1959 
The physicist Richard Phillips Feynman, in December 1959, during a talk to the American 
Physical Society in Pasadena, expressed a hypothesis that there is plenty of room at the 
bottom. He was undoubtedly referring to the nanoworld, where he imagined the possibilities of 
man manipulating and controlling individual atoms and molecules but had not the appropriate 
instruments to validate his hypothesis at that time. Decades later, the advent of the scanning 
tunneling microscope and of atomic force microscopy became the fundamental events in the 
history of nanoscience and nanotechnology [1]. To quote Michael Berger: “The development of 
nanotechnologies is not based on a few big and bold discoveries or inventions. Rather it is a 
painstakingly slow journey of gradual development; at result of which will be some truly 
revolutionary products and applications”. These novel materials and their applications have 
already appeared and by exploiting the new phenomena that take place only at the nanometer 
scale, scientists and engineers are bringing considerable improvement and revolution in 
different fields from information technology to medicine. In the medical field, nanoscience and 
nanotechnology have interesting assets as they represent the ideal scale that biological 
molecules and structures inside living cells operate. One way of probing inside the infinitely 
small biological world is by using nano-biosensors. A biosensor is a sensor that contains a 
biological element capable of recognizing and signaling the presence of an activity of a specific 
biological molecule in solution. A transducer, which in our case are fluorescent nanoparticles, is 
used to convert the biochemical signal into a quantifiable signal [2]. Designing nano-biosensors 
would therefore provide tools for better disease prevention, diagnosis and finding the 
appropriate treatment faster. This would furthermore enable to realize earlier and more 
refined diagnosis providing tailor-made effective treatments and therefore reduce the recourse 
to biopsies and surgeries. These nano-biosensors would therefore be of tremendous utility for 
the quantification of very low concentrations of cancer biomarkers (also referred to as tumor 
markers) in bodily fluids and tissues. Detection of these markers would not only allow early 
prognosis of different cancers and diseases, hence improving the survival rate, but also provide 
treatment with little or no side-effects on the human body as compared to harsh treatment as 
chemotherapy when cancer is already at an advanced stage. Blood is the “Alibaba cave” of 
biomarkers that can reveal the current physiological state of all tissues and the simultaneous 
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detection in blood/plasma/serum-based samples of ultra-low concentrations of different cancer 
biomarkers, which are secreted by tumors at the very early stages of growth where treatments 
are more efficient, are very challenging as they contain loads of different proteins in relatively 
high content [3–5]. In order to discriminate between the low-abundance of the desired tumor 
markers we want to identify from a complex mixture of proteins and for the direct application 
of the sensor in clinical applications, the nano-biosensor should be specific, simple to use, rapid, 
able to perform multiplexing (i.e detection of several targets from a single sample), high-
throughput and be highly sensitive.  
Förster Resonance Energy Transfer (FRET)-based biosensors are among the sensitive 
techniques, which are currently used for a number of sensing applications in the medical field 
as they meet with the aforementioned demands. FRET is a non-radiative energy transfer 
between two molecules and is strongly distance-dependent. Non-radiative energy transfer 
occurs from an excited donor (FRET-donor) molecule to an acceptor molecule (FRET-acceptor) 
in its ground state through long-range dipole-dipole interactions. The FRET-donor must be a 
fluorophore and the FRET acceptor should be able to absorb light at the emission wavelength(s) 
of the donor but does not necessarily have to remit photons.  In order for FRET to occur, the 
emission spectrum of the donor must overlap with the absorption spectrum of the acceptor, so 
great care should be taken while choosing the appropriate FRET-pairs (FRET-donor and FRET-
acceptor) for the planned experiments. This spectral overlap can be described in terms of 
Förster distance (R0), which defines the distance between the donor and acceptor at which 
FRET efficiency is 50%. There exists a multitude of FRET-pairs for bioanalysis, among which 
we can find organic dyes, fluorescent proteins, metal chelates (e.g, lanthanide complexes), 
upconverting nanoparticles and, semiconductor nanocrystals (quantum dots). The typical R0 
between dyes and/or fluorescent proteins are generally between 2 - 5 nm and can extend to     
11 nm by using lanthanides and quantum dots. Ruled by the physics of molecular proximity, 
the strong distance dependency to r-6, where r corresponds to the distance between the     
FRET-pairs, allows obtaining information on small structural changes in biological processes, 
kinetic data of reactions and binding events among others. FRET generally takes place at a 
distance range of c.a 1-10, nm which is comparable to the dimensions of most biological 
interactions. In the case of antibody-antigen association, when a FRET-pair labelled on specific 
antibodies for specific target recognition are brought close together, changes in the 
photophysical properties of the FRET-pairs appears due to the extent of energy transfer, which 
depends on the distance between the FRET-pairs [6–9].  
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FRET-based immunosensing can be heterogeneous or homogeneous immunoassays. In this 
thesis we will focus exclusively on homogeneous time-resolved (TR) sandwich based FRET 
immunoassays since they are sensitive, require no separation or purification steps, allow for 
short incubation times due to fast solution-phase kinetics and are less time consuming, while 
the time-resolved mode allows for efficient suppression of short-lived autofluorescence. Briefly, 
in one-step homogeneous immunoassays the FRET-pairs are “simply” conjugated to specific 
antibodies and incubated in a solution containing the targeted antigens and upon biological 
recognition, specific FRET signals can be recorded with no washing steps required[10]. Organic 
dyes and/or fluorescent proteins are generally the most commonly used FRET-pairs in assays 
but they are usually pH sensitive, prone to photobleaching and chemical degradation, low 
quantum yields (QY), and their broad emission spectra leading to spectral crosstalk [11] thus 
limiting multiplexing capabilities, significantly complicate FRET formats. Furthermore, their 
short luminescence lifetimes in the nanosecond (ns) range limit their application to steady-
state spectroscopy rather than time-resolved spectroscopy, which can be more sensitive [9,12]. 
Luminescent lanthanide complexes (LLC) as FRET-donor represent an excellent choice in 
combination to different FRET-acceptors, such as organic dyes, fluorescent proteins and 
quantum dots (QDs), because the lanthanide ions (for e.g, samarium, europium, terbium) offers 
unique photophysical properties. Upon chelation with ligands, a large Stokes shift arises and 
due to the forbidden f-f transitions in the lanthanide ions, LLC emit with very characteristic 
and narrow emission lines in the visible and near-infrared regions, with luminescence lifetimes 
up to the millisecond (ms) range [13,14]. Upconverting nanoparticles are lanthanide-doped 
crystals which have the ability of upconversion emission [15]. Upconversion is a process where 
low energy light (near-infrared (NIR) or infrared (IR)) is converted to higher energies (UV to 
NIR) by means of stepwise absorption and energy transfer processes. Similar to lanthanide 
complexes, lanthanide-doped upconversion nanoparticles (UCNPs) possess very narrow 
emission bands in the broad wavelength region spanning the UV, visible and NIR allowing 
them to function as energy donors with an assortment of acceptors in FRET-based biosensing 
[16–19]. Quantum dots are semiconductor nanocrystals that possess exceptional optical 
properties and offer several advantages over traditional organic fluorescent dyes such as higher 
absorption cross-sections, fluorescence quantum yields and photostability. As the size of the 
QDs is reduced, the phenomena of quantum confinement arises which results in size-tunable 
absorption and emission bands. The narrow symmetrical Gaussian emission and broad 
excitation spectra, nanosecond lifetimes together with the aforementioned properties of the 
QDs (FRET-acceptor), and in combination with luminescent terbium complexes (Tb, FRET-
donor) and TR-FRET spectroscopy (the long decay time in the millisecond range of Tb can be 
 
4 
 
time-gated after pulse excitation to allow for suppression of short-lived sample fluorescence and 
fluorescence from directly excited QDs), make these FRET-pairs ideal for sensitive and 
multiplexed detection with large R0 (7 – 11 nm). Moreover, the ratiometric format, by analyzing 
the photoluminescence (PL) intensities of the FRET-pairs in presence of FRET, can be very 
advantageous for analytical applications as they offer an instantaneous suppression of sample 
and excitation source fluctuations [13,20–22].  
1.2 Summary 
The aim of this thesis is to utilize the exceptional photophysical properties of Tb complexes and 
QDs systems for ultrasensitive multiplexed TR-FRET immunoassays of cancer protein 
biomarkers detection, and the study of the optical and morphological properties of novel core 
and core/shell upconverting nanoparticles doped with ytterbium (Yb) and erbium (Er) ions as 
possible FRET-donors for biosensing. For TR-FRET sandwich immunoassays, monoclonal 
antibodies (ABs) against differently sized antigens - carcinoembryonic antigen (CEA), neuron-
specific enolase (NSE) and total prostate specific antigen (TPSA) - have been labelled to Tb and 
different emitting QDs. The immunoassay gives rise to the formation of [donor-AB]-antigen-
[acceptor-AB] complexes and a close proximity of Tb and QD results in FRET as depicted in 
Scheme 1.1. It should be noted in our FRET system that the FRET efficiency for multiple Tb-
donor per QD-acceptor does not change as compared to a single-donor/acceptor system.  
 
 
Scheme 1.1. Principle of a sandwich Tb-to-QD FRET immunoassay which contains (left) monoclonal Tb- 
and QD-antibody conjugates against an antigen. (Middle) Formation of [Tb-AB]-antigen-[QD-AB] 
complexes upon addition of antigen resulting in FRET due to a close proximity of Tb and QD. (Right) The 
assay leads to a typical immunoassay calibration curve, for which the FRET signal increases with 
increasing antigen concentration until a saturation point when antigen concentration equals to Tb-ABs 
or QD-ABs concentration.  
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However, there is an increased probability of QD FRET-sensitization with an increasing 
number of Tb-donors due to the long luminescence lifetimes of Tb [23,24]. The use of bulky QDs 
and large biomolecules such as full sized IgGs and relatively large antigens, in a sandwich 
based format might affect the FRET efficiency, hence the sensitivity of detection due to the 
strong distance dependency between the FRET-pairs [7]. 
The first study (Chapter 3) demonstrates the possibility to overcome the large distances in 
homogeneous FRET immunoassays and providing at the same time high sensitivity and 
multiplexing capability in the use of luminescent terbium complexes as FRET-donors for thick 
polymer PEG coated QD-acceptors. Tb-AB conjugates were obtained by a fully random labeling 
of Tb-NHS via various amino groups available on the antibody surface. In a less random 
coupling, three commercially available QDs with emission maxima at 605, 655 and 705 nm 
(denoted as QD605, QD655 and QD705 respectively) from Life Technologies possessing a thick 
polymer poly(ethylene) glycol (PEG) coating and surface amino functionalized were conjugated 
to fragmented antibodies (F(ab)) through sulfhydryl chemistry [25]. The amine-reactive QDs 
were converted to maleimide-reactive QDs by using the heterobifunctional crosslinker sulfo-
EMCS having NHS ester and maleimide reactive groups [26]. The maleimide activated QDs 
were then conjugated to the F(ab) via free sulfhydryl groups which showed to be advantageous 
for FRET immunoassays due to their smaller size and the higher amount of ABs per QD [25]. 
The performance of our immunoassays were evaluated with QD605, QD655 and QD705 as 
acceptors in FRET assays with Tb donors because the variations in shapes, sizes, spectral 
overlap and PL wavelength  range leads to differences in FRET and detection efficiencies. The 
photophysical properties (steady-state and time-resolved) of the assay constituents (Tb and QD 
AB-conjugates) and their performance in Tb-QD FRET immunoassays for the detection of PSA 
in low volume serum samples were carried-out. Such characterization and assay evaluation 
within comparable immunoassays for the same antigen are indispensable for designing and 
optimizing such homogeneous FRET immunoassays, in particular for multiplexed detection 
with different QD colors. Calculation of the overlap integrals resulted in large R0 for all the Tb-
QD systems and provided measurable QD-FRET sensitization within the                                
[Tb-AB]-PSA-[QD-AB] binding system even with the thick QD polymer coatings. All three Tb-
to-QD FRET systems showed increasing time-gated FRET signals with increasing PSA 
concentrations and immunoassay calibration curves could be successfully recorded. Limits of 
detection (LODs) calculated using the calibration curves showed the highest sensitivity (low 
LOD) for the Tb-QD705 system followed by Tb-QD655 and Tb-QD605 systems. We also show 
that factors as labeling ratios, R0, and Tb PL background were found to influence the detection 
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sensitivity. Multiplexed capability using different Tb-QD FRET-pairs were demonstrated by 
preparing a duplexed immunoassay against PSA that contained the two QD-conjugates (QD655 
and QD705) with the lowest LODs and their calibration curves were observed to follow a 
similar trend as the single Tb-QD FRET-pairs. The LODs for PSA in 50 µL serum samples 
measured on a commercially available clinical fluorescence plate reader were in the sub-
nanomolar concentration range and below the clinical cut-off value of 4 ng/mL for the QD655 
and QD705 based FRET-pairs. As most biomarkers have different clinical cut-off values, we 
also concluded that QD705 should be used for the biomarker with the lowest cut-off and QD605 
for the one with the highest cut-off. Duplexing capability was demonstrated in PSA assays 
containing both QD655 and QD705 AB conjugates. Our results provide important information 
concerning the development of QD-based FRET immunoassays for multiplexed clinical 
diagnostics because the AB-conjugation method we developed is applicable to any commercially 
available amino-functionalized QDs, which exist in many other colors than the three used in 
this study.  
The second study focuses on a novel QD functionalization and bioconjugation approach, which 
yielded stable compact QDs and highly luminescent QD–AB conjugates for improved Tb-QD 
TR-FRET immunoassay against PSA. These QDs were synthesized by the INAC-SyMMES 
laboratory, CEA Grenoble. Based on the results of the first study involving QDs with thick 
polymer coating that showed the possibility of detecting sub-nanomolar range of PSA, the 
design of compact QDs would allow overcoming the major limitations for developing QD-FRET 
immunoassays with LODs competitive to commercial kits which are: (i) insufficient colloidal 
stability of compact QDs in biological media, (ii) thick QD surface coatings (e.g., PEG, polymer, 
or lipid coatings that protect the inorganic QD from the biological environment and render 
them hydrosoluble), and (iii) insufficient AB-conjugation strategies for QDs with thinner 
organic capping. For this purpose aqueous phase transfer of InPZnS/ZnSe/ZnS QDs emitting at 
530 nm (QD530) and of commercial hydrophobic (Life Technologies) CdSe-based QDs emitting 
at 605 and 705 nm (QD605 and QD705 respectively) was achieved by ligand exchange with 
zwitterionic penicillamine (Pen) and post-functionalization was carried-out to produce 
maleimide-activated QDs using a Mal1 bifunctional ligand containing a lipoic acid anchoring 
function and a maleimide functional group space by three PEG moieties for conjugation with 
free sulfhydryl containing groups of F(ab). We also show for the first time another post-
functionalization strategy which involved direct coupling ABs (IgGs, F(ab’)2 and F(ab)) on the 
surface of the colloidal compact QD705 (highest sensitivity) without any crosslinkers to further 
reduce the distance of energy transfer between Tb-donor and QD-acceptor. TEM analysis was 
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performed on the QDs to confirm their size and dispersibility while Fourier transform infrared 
(FTIR) spectra and gel-agarose proved the successful functionalization and conjugation with 
Mal1 and F(ab) respectively. For these Tb-QD FRET-pairs, large R0 were calculated revealing 
the highest R0 for QD705 and small changes in the photophysical properties of the QDs at 
different stages of phase transfer, post-functionalization with Mal1 and upon conjugation to 
F(ab) were observed. In this study only full photophysical characterization of the direct 
conjugation of IgGs to QD705 was performed due to low collected volume samples from the 
direct conjugation of F(ab’)2 and F(ab). FRET-assays against PSA in serum-based samples, 
using QDs conjugated to F(ab) through Mal1, corresponding to the Tb-QD605/705 systems 
allowed quantification of the LOD, while the Tb-QD530 assay yielded a very low FRET signal 
most probably related to the lower R0 (6.1 nm), which could not be used to calculate a LOD. Tb-
QD705 assay using the direct conjugation of ABs to the QD’s surface provided even better 
sensitivities than when using Mal1. Our LODs of the two Tb–QD FRET immunoassays (using 
605 nm and 705 nm emitting QDs) are not only well below the clinical cut-off value of PSA (4 
ng/mL), but the utilization of the compact QD–AB conjugates also provided a 6.2 and 25 fold 
sensitivity improvement compared to the same commercially available QDs that were 
purchased with a standard PEG/polymer-based coating used in the first study. These highly 
sensitive and homogeneous Tb-to-QD FRET immunoassays are suitable for any other 
biomarker against which two specific ABs exist. Our results show that the compact QD–AB 
conjugates have a large potential for improving diagnostic applications, and given the 
multiplexing capability of Tb–QD FRET, we are confident that these small nanoparticle–AB 
fluorescent probes will become important players in clinical in vitro diagnostics.  
In the third study we attempt to detect CEA, NSE and TPSA from a single serum-based 
sample. The importance of detecting several biomarkers lies within the fact that a single 
biomarker does not contain sufficient information in order to make a clear diagnosis about a 
disease and the combination of different biomarkers increases the content of information about 
the state or type of cancer. CEA and NSE are among the tumor markers where their levels are 
monitored in combination with other tumor markers to get a clear diagnosis of small-cell lung 
cancer (SCLC) and/or non-small-cell lung cancer (NSCLC) and TPSA (sum of free PSA and PSA 
bound to proteins) which is a tumor marker for prostate cancer. As FRET is highly distance 
dependent, the choice of F(ab’)2 conjugation to QDs would result in a shorter separation 
distance between the QDs and Tb in sandwich immunoassays, hence higher FRET efficiencies 
and sensitivities than when using IgGs. Furthermore, the small size of the F(ab’)2 together with 
its 2 binding sites for more binding opportunity, would be beneficial to the increasing 
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biomarker sizes (32 kDa to 180 kDa) in the FRET immunoassays. Photophysical 
characterizations of the FRET-pairs (Tb-donor and QD-acceptor) were performed and the 
labeling ratio of Tb per AB and QD per AB were estimated by UV/Vis absorption spectroscopy. 
As the first study suggested that for different clinical cut-off values QD705 should be used for 
the biomarker with the lowest cut-off and QD605 for the one with the highest cut-off, 
antibodies against CEA, NSE and TPSA have been conjugated to eBioscience QDs eQD650, 
eQD605 and Life Technologies QDs iQD705 respectively. Our multiplexed homogeneous Tb-QD 
FRET immunoassay has been able to simultaneously detect 3 differently sized tumor markers 
from a single serum sample of CEA (180 kDa), NSE (95 kDa) and PSA (32 kDa) using Tb and 
QD probes conjugated to their respective monoclonal antibodies conferring no biological 
crosstalk. Taking advantage of the narrow and Gaussian emission spectra of the QDs and the 
well separated Tb emission bands together with the appropriate optical bandpass filters, 
allowed negligible optical crosstalk. Therefore no matrix correction was necessary to determine 
the tumor markers concentration. LODs calculated in 50 µL volume samples were all below the 
clinical cut-off levels of the tumor markers, where higher LODs we observed for the triplexed 
format as compared to the singleplex format except for TPSA. The contamination of the 
eQD605/650 detection channels from the 3 times more Tb signal resulted in an increase in LOD 
whereas virtually no Tb emission can be detected in the iQD705 detection channel. A “worst-
case scenario” assay was performed where we challenged our immunoassay with a combination 
of high and low target concentrations. Overall, CEA and TPSA could be detected with high 
precision with minor deviations from known concentrations except for NSE which presented an 
underestimation in its concentrations in a specific range of concentration with a combination of 
high and low concentrations of CEA and low concentrations of TPSA. Detection limits of the 
tumor markers in the sub-nanomolar range (few ng/mL) within a complex environment as in 
serum and containing 9 different biomolecules proves the immediate applicability to diagnostic 
applications for sensitive multiplexed measurements. 
The forth study comprised the investigation of new generation of fluorophores, known as 
upconversion nanoparticles (UCNPs). Upconversion is a process where low energy light (near-
infrared (NIR) or infrared (IR)) is converted to higher energies (ultraviolet or visible) by means 
of multiple absorptions or energy transfers in a non-linear process [27,28]. This property 
(among others) allow them to possess great potential for imaging and biodetection assays in 
both in vitro and in vivo applications [27]. Similar to lanthanide complexes, lanthanide-doped 
UCNPs possess very narrow emission bands in the visible wavelength region allowing them to 
function as energy donors with an assortment of acceptors in FRET-based biosensing. Three 
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types of UCNPs were analyzed in this thesis so as to choose the best candidate as FRET-donor. 
Core and core/shell UCNPs were synthesized by our collaborators from Institut National de la 
Recherche Scientifique (INRS), Québec Canada, which were NaGdF4:Er3+,Yb3+ (core-doped), 
NaGdF4:Er3+,Yb3+/NaGdF4 (core-doped/shell) and NaGdF4/NaGdF4:Er3+,Yb3+ (core/shell-doped). 
These UCNPs were rendered ligand-free and surface functionalization with amino-PEG-COOH 
was performed through electrostatic interaction in order to generate functional groups on the 
surface of UCNPs for possible biomolecule attachment. TEM measurements of the UCNPs 
showed rather spherical particles and XRD patterns showed that they are highly crystalline 
and comparison with the reference pattern revealed a hexagonal - structure of NaGdF4. FTIR 
spectra confirmed presence of the amino-PEG-COOH polymer on the surface of the UCNPs. 
DLS measurements showed that the three types of PEGylated-UCNPs were not at all stable in 
various buffers including physiological buffers where aggregation was observed. Hence, 
optimized surface functionalization strategies should be envisaged in order to produce good 
dispersibility in buffers as conjugation to biomolecules often requires using buffers of different 
pH. Upconversion emission in the visible range of the electromagnetic spectrum was observed 
for core-doped, core-doped/shell and core/shell-doped nanoparticles upon excitation at 980 nm. 
Green emissions occurred at the following transition states: (2H11/2, 4S3/2)  4I15/2 and red 
emission from 4F9/2   4I15/2. As compared to the core/shell UCNPs, the lifetime of the core-doped 
nanoparticles are smaller and can be attributed to surface-quenching effect of Er3+ ions at the 
core surface by high vibrational energy modes of OH groups from the surrounding solvent. 
Growing a shell around the doped-core, greatly suppresses surface-quenching effects as the 
shell brings a better protection between the core and the surrounding environment. The 
core/shell-doped nanoparticles showed unexpected long luminescent lifetimes as compared to 
the core-doped/shell nanoparticles, favoring them to be suitable FRET-donors as the presence of 
Er3+ ions on the surface would result in efficient FRET to an acceptor molecule in close 
distance.      
After this introduction, a theoretical background on biomarkers (protein tumor markers in this 
thesis), FRET, lanthanides and quantum dots will be presented as well as their application as 
FRET-donors and FRET-acceptors. Four experimental studies will follow in a paper-style with 
an introduction, materials and method, results and discussion, and a conclusion. A summary 
addressing the results obtained from the experimental studies will be discussed and an outlook 
on future research. Appendix and bibliography follow at the end of the thesis. 
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2. Background 
 
2.1 Biomarkers 
Interaction of chemicals with biological systems is recognized by the analysis of tissues and 
body fluids for chemicals, metabolites of chemicals, enzymes and other biological substances. 
These substances known as biomarkers, short for “biological markers”, have been defined in 
1988 by the National Institutes of Health Biomarkers Definitions Working Group as “a 
characteristic that is objectively measured and evaluated as an indicator of normal biological 
processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention”  
[29–31]. Biomarkers which can also reflect the entire spectrum of a disease from its early to 
terminal stage, play therefore a vital role in understanding the prediction, cause, diagnosis, 
progression, regression, or outcome of disease treatments [32]. Biomarkers can be classified 
into the following categories: 1) predisposition, 2) diagnostic, 3) prognostic and 4) predictive 
biomarkers. Predisposition biomarkers give an increased probability of developing a health 
disorder based on someone’s genetic family history, whereas diagnostic biomarkers confirm 
whether or not a patient has a certain disease. Prognostic biomarkers, on the other hand, 
indicate how a health disorder will evolve after primary diagnosis and treatment of a disease, 
thus predicting recurrence. Predictive biomarkers help to foretell which specific treatment 
would be beneficial to a patient [33,34]. Examples of biomarkers can include everything from 
the recording of blood pressure, electrocardiogram, imaging tests to more complex laboratory 
tests from blood, urine or tissues [29,35]. One type of biomarker which is secreted in tissues, 
blood, and other body fluids are tumor biomarkers (or tumor markers) that are produced by 
cancer or by other cells of the body in response to cancer or certain benign conditions [36]. Most 
tumor markers are secreted by normal cells as well as by cancer cells but in the case of 
cancerous conditions, these markers are produced in higher levels. Therefore, the early 
diagnosis of tumor markers is crucial at such stage as they offer the high probability of 
successful treatment. These tumor markers include a large variety of molecules such as 
peptides, proteins, DNA, micro-RNA, metabolites and circulating tumor cells among others 
[35,37–40].  
Normal cells in the body age and die, and are replaced by new cells in a controlled and orderly 
manner. When this routine breaks down, cancer begins. Cancer is the malignant growth or 
tumor resulting from an uncontrolled abnormal division of cells which can invade neighborhood 
tissues and also spread to other parts of the body [40,41]. A tumor is said to be benign when the 
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tumor cells clustered in a single mass stays in one spot of the body. A complete cure is usually 
achieved by surgical removal of the mass. In the case of malignant tumors, their cells break off 
from the cancer and have the ability to invade and destroy surrounding healthy tissues by 
moving throughout the body using the bloodstream or lymphatic vessels, forming secondary 
tumors, or metastases at different sites in the body (Figure 2.1). This process called metastasis 
is a very severe condition that is hard to eradicate [42]. Among the large variety of tumor 
markers, circulating tumor cells (CTC) and protein markers could be measured to detect cancer 
activity in the body from a simple blood sample. CTC detection, a relatively new technique for 
early metastasis detection has been able to provide independent prognostic information and 
has shown a direct correlation of its presence in the blood of tumor patient with poor survival 
rate of patients suffering from metastatic prostate, breast, and colon cancers [43–45]. In 
comparison to ca. 5×106 white blood cells and ca. 5×109 red blood cells per mL of blood, the 
typical concentration of CTC (1 CTC in 1 mL) of blood is extremely low. To date the only 
method, Food and Drug Administration (FDA) approved, for the enumeration of CTC that has 
been cleared for clinical use in breast, colorectal and prostate cancer patients, is the 
CellSearchTM CTC Test by Veridex [45–49]. Protein tumor markers are specific proteins often 
produced by cancer tumors that can serve as a marker for a cancer. These protein tumor 
markers are predominantly found in blood and sometimes in urine [40]. In this thesis, we will 
focus exclusively in the detection of cancer protein markers (or tumor markers/biomarkers).                             
 
Figure 2.1. Representation of malignant cancer propagation. The tumors grow by creating their own 
blood vessels to get the necessary supply to keep them from surviving and getting bigger. Metastasis 
occurs when the cancer cells spreads through the bloodstream or lymphatic system to other parts of the 
body forming tumor somewhere else [50].  
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Cancer protein biomarkers are among the commonly used biomarkers for cancer detection as 
they can be used for early cancer detection, determine whether a particular treatment is 
working and/or to detect recurrence or progression during follow-up after treatment [40]. 
Despite their usefulness, no tumor marker could be identified to date to be sensitive or specific 
enough to be used on its own to screen for cancer. In most cases, tumor markers are used in 
combination with imaging, biopsy and associated clinicopathological information before a 
clinical decision is made. For example, carcinoembryonic antigen (CEA) which is used to detect 
colon cancer recurrence is produced only in 70-80 % of colon cancer cases and elevated levels of 
CEA are present only in 25 % of cases that are limited to the colon [51]. Although many 
strategies exist for new biomarker discoveries, among which we find, gene-expression profiling, 
peptidomics, cancer-biomarker-family approach, secreted protein approach, cancer researchers 
are turning to proteomics which is a strategic technology for the development and discovery of 
new protein biomarkers [41,52,53]. Mass-spectrometry-based methods of proteomic analysis, 
through its improved and including more-advanced technology, enables increased throughput 
and more reliable data for new protein biomarker profiling [52]. As the majority of current drug 
targets are proteins, most of the biomarkers used in clinical studies are based on proteomic 
applications as studying protein-protein interactions can be an innovative and an efficient way 
to find novel cancer biomarkers [54,55]. Furthermore, the majority of licensed tests available 
for disease detection are protein-based assays [56]. We can however note that even though an 
enormous number of publications on tumor biomarkers have been published in these recent 
years, only a handful have entered clinical use due to the absence of a clearly defined validation 
pathway for advancing a newly discovered biomarker into the clinic. The five phases of 
biomarker developments, which are preclinical exploratory studies, assay development and 
validation, retrospective longitudinal clinical repository studies, prospective screening and 
randomized control trials, should therefore undergo rigorous and effective validation for 
adoption in clinical practice [52,57]. Table 2.1 lists some of the protein tumor markers FDA-
approved which are currently used in clinical practice [58].              
Protein biomarkers are often interrogated and quantified by the immunoassay method (further 
explained in section 2.5), which depends on the reaction of an antibody and an antigen. 
Detection of the amount of antigen present in a sample is achieved by detection of the antibody-
antigen (immuno) complex [10,59]. In order to quantify the signal from the immuno-complex, 
there exists a wide range of labels such as radioisotopes, enzymes, and fluorophores. Among the 
widely used heterogeneous enzyme-linked immunosorbent assay (ELISA), many other 
immunoassay methods are applied in pharmaceutical analysis such a radio-, fluoro-, and 
chemiluminescence-immunoassays [59]. They will be discussed in section 2.5. 
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2.2 Antibodies  
  
 
Figure 2.2. Structure of the 5 classes of antibodies based on number of Y units and type of heavy chain 
[www.sigma-aldrich.com].  
Antibodies are glycoproteins belonging to the “immunoglobulin supergene family” that are 
produced in response to an invading substance in the body. IgG, IgM, IgA, IgD, and IgE 
(Figure 2.2) are the five classes of immunoglobulin in most higher mammals and they differ in 
size, charge, amino acid composition, and carbohydrate content. Antibodies exist as one or more 
copies of a Y-shaped molecule with each Y-shape consisting of four polypeptide chains: two 
identical heavy chains which are linked to each other by disulfide bonds and two identical light 
chains where each light chain is linked to a heavy chain by disulfide bonds. The light chain has 
two domains namely variable (VL) and constant (CL). The heavy chain is composed of four 
domains, which consists of one variable (VH) and three constant (CH1, CH2 and CH3). The Y-
shaped unit of the antibody can be divided into three fragments: two identical fragments which 
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contain the antigen-binding activity (F(ab) fragments) and another fragment that contains no 
antigen-binding activity called Fc fragment short for Fragment cristillizable. The structure of 
the Y-shape of an antibody is represented in Figure 2.2 top left. IgGs with an approximate 
molecular weight of 150 kDa, consist of one Y-shape unit and are the most abundant class of 
antibodies in blood, totaling up to 80 % of the total serum antibodies [10,60–62]. IgGs are also 
found in plasma which is a mixture of serum with clotting factors and fibrin. Measurement of 
antibodies is usually done in serum as compared to plasma because serum lacks clotting factors 
and large fibrinogen proteins, hence more specific detection of antibodies [63]. IgGs are almost 
exclusively used in immunoassays and can be covalently modified to accommodate labels (see 
section 2.4.3) [10]. Antigens are substances (e.g foreign proteins) that the body is trying to 
eliminate by provoking an immune response [64]. Antibodies specific to the antigen can be 
generated by vaccinating animals with the antigen of interest through the process called 
immunization [10]. Two distinct processes by which antigens are recognized in the body are by 
1) B cells and their surface antibodies and 2) by the T cell receptor on T cells [65]. Antibodies 
produced by B cells due the presence of an antigen can bind specifically to a small site on the 
antigen called an epitope. The antibodies produced can be polyclonal or monoclonal. A 
polyclonal antibody has the ability to recognize multiple epitopes on an antigen while a 
monoclonal antibody is restricted to only one epitope. The antigen-antibody binding reaction is 
reversible and follows the basic principles of thermodynamic for any reversible biomolecular 
interaction. At equilibrium: 
 
𝐾𝑒𝑞 =
𝑘𝑎
𝑘𝑑
=
[𝑎𝑛𝑡𝑖𝑏𝑜𝑑𝑦 − 𝑎𝑛𝑡𝑖𝑔𝑒𝑛 𝑐𝑜𝑚𝑝𝑙𝑒𝑥]
[𝑎𝑛𝑡𝑖𝑏𝑜𝑑𝑦] × [𝑎𝑛𝑡𝑖𝑔𝑒𝑛]
 (2.1) 
where   Keq is the equilibrium constant and is equal to the ratio between the association (ka) and        
dissociation (kd) rate constants; 
 [antibody-antigen complex] is the molar concentration of the antibody and antigen   
complex; 
          [antibody] and [antigen] are the molar concentrations of the reactants.  
 
 
Keq cannot be determined for polyclonal antibodies due to their heterogenic binding properties 
with their antigens. Factors affecting the antibody-antigen reaction include temperature, pH, 
and ionic strength of the solvent [10,66].  
 
In this thesis, we will use serum-based homogeneous fluoroimmunoassays in a sandwich 
format where monoclonal antibodies (IgGs) labelled with fluorophores bind to specific epitopes 
of the tumor marker. The antigens (tumor markers) used in this thesis are carcinoembryonic 
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antigen (CEA), neuron-specific enolase (NSE) and total prostate specific antigen (TPSA)          
(cf Table 2.1, highlighted in red). CEA is a glycoprotein with an approximate molecular weight 
of 180 kDa and is essentially secreted and excreted by digestive tract glandular cancers (colon, 
rectum, pancreas, stomach) and their metastases can be found in the lung, breast, bladder, 
ovary, and thyroid. CEA is mainly assayed in the field of colorectal cancers but when its level is 
related to metastatic propagation in breast and lung, its variation can be a useful indicator 
when monitoring patient response to therapy [67]. NSE is a glycolytic enzyme with a molecular 
weight that is approximately 95 kDa and is normally present in neurons, peripheral nerve 
tissues and neuroendocrinal tissues, and also in cells of the amine precursor uptake 
decarboxylation (APUD) system. NSE is not a specific tumor marker and was found to be 
frequently overexpressed in patients with small cell lung carcinoma (SCLC) and 
neuroblastoma. Its clinical use is in the follow up and therapy control for neuroblastoma and 
SCLC, and includes differential diagnosis for SCLC [68–70]. PSA is a glycoprotein of the 
kallikrein group with an approximate molecular weight of 32 kDa and is found almost 
exclusively in the prostate. PSA plays a major role in the liquefaction of seminal fluid and 
circulates simultaneously in two forms in serum: free PSA (fPSA) and complexed PSA (TPSA, 
which is the sum of fPSA and PSA complexed to anti-proteases). Increased concentrations of 
TPSA can result in men with malignant as well as benign prostatic diseases such as 
hyperplasia or prostatitis. To improve specificity it has been reported that the two forms of PSA 
can be measured where a low ratio of fPSA to TPSA is an indication of malignant prostatic 
diseases. Free PSA testing has mostly been used as additional test along with TPSA, 
particularly in men who have already undergone a negative prostate biopsy and have a PSA 
that remains elevated [71,72]. As soon as prostate cancer has been diagnosed, TPSA assays are 
used to establish the cancer stage, the tumor response after therapy for early detection of any 
relapse.   
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Table 2.1. Modified list of protein tumor markers, FDA-approved, currently used in clinical practice [58]. 
Biomarker Clinical use Cancer type Specimen 
Year first 
approved or 
cleared 
Pro2PSA 
Discriminating cancer 
from benign disease 
Prostate Serum 2012 
ROMA (HE4 
CA-125) 
Prediction of 
malignancy 
Ovarian Serum 2011 
OVA1 (multiple 
proteins) 
Prediction of 
malignancy 
Ovarian Serum 2009 
AFP-L3% 
Risk assessment for 
development of 
disease 
Hepatocellular Serum 2005 
Circulating Tumor 
Cells (EpCAM, CD45, 
cytokeratins 8, 18+, 
19+) 
Prediction of cancer 
progression and 
survival 
Breast Whole blood 2005 
c-Kit 
Detection of tumors, 
aid in selection of 
patients 
Gastrointestinal stromal 
tumors 
FFPE tissue 2004 
CA19-9 
Monitoring disease 
status 
Pancreatic 
Serum, 
plasma 
2002 
CA-125 
Monitoring disease 
progression, response 
to therapy 
Ovarian 
Serum, 
plasma 
1997 
Free PSA 
Discriminating cancer 
from benign disease 
Prostate Serum 1997 
Alpha-fetoprotein 
(AFP) 
Management of 
cancer 
Testicular 
Serum, 
plasma, 
amniotic fluid 
1992 
Neuron-specific 
Enolase (NSE) 
Aid in management 
and prognosis 
Small cell lung cancer, 
neuroblastoma 
Serum 1987 
Total PSA 
Prostate cancer 
diagnosis and 
monitoring 
Prostate Serum 1986 
Carcino-embryonic 
antigen (CEA) 
Aid in management 
and prognosis 
Colon,rectum,stomach, 
lungs 
Serum, 
plasma 
1985 
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2.3 Lanthanides 
2.3.1 Introduction 
Lanthanides (Ln) are a series of 15 metal elements, which are listed separately at the bottom of 
the periodic table and are also referred as the f-block elements. The name comes from 
lanthanum, which is the first element of this series and lutetium being the last element. The 
Ln series with scandium and yttrium are called rare earth elements as they were once thought 
to be present in small quantity in the Earth’s crust. Today we actually know that these 
elements are not actually rare in terms of abundance. Yttrium is among the 30 most abundant 
elements with thulium and lutetium 100 times more abundant than gold in the Earth’s crust. 
Rare earth elements were originally discovered in 1787 in the form of a mineral called Ytterbite 
which came from a quarry in the village of Ytterby in Sweden. The mineral was studied by the 
Finnish chemist Johan Gadolin and in 1794 found that it contained an oxide that he named 
yttria. From yttria, the pure element yttrium was obtained and later revealed to contain 
several lanthanide elements. The discovery of lanthanides took a long time period since the 
extraction of cerium (Ce) from its mineral cerite in 1803 and the last Ln element to be 
discovered was promethium (Pr) in 1938, more than 100 years later. Similarity in their 
chemical properties, particularly in their oxidation states, is responsible for such delay in their 
discovery. This can be explained by the electronic configuration of the Ln ions [73,74].  
Ln in the electronic ground state are characterized by the progressive filling of their 4f orbitals 
and share the electronic configuration of xenon. Xenon has an electronic configuration of 1s² 2s2 
2p6 3s² 3p6 4s² 3d10 4p6 5s² 4d10 5p6 and is abbreviated as [Xe]. The lowest energy orbitals are 
filled first with electrons and follow the sequence: 
1s2s2p3s3p4s3d4p5s4d5p6s4f5d6p7s5f6d7p8s 
Ln have the general electronic configuration [Xe] 4fn 6s2 with the exception of lanthanum (La), 
Ce, gadolinium (Gd) and lutetium (Lu) for which the ground electronic configuration is [Xe] 4fn 
5d1 6s2, with n=0 for La and n ranging from 1 to 14 for the rest of the Ln elements. In the case 
of Ln3+ ions where the +3 oxidation state is the most stable for all lanthanide cations in aqueous 
solutions, the filling of electrons is perfectly regular from 4f1 to 4f14 [75,76]. Through these 
specific electronic configurations, Ln show similar physical and chemical properties, such as in 
their oxidation states, and ionic radii [75]. Ln3+ ions possess magnetic properties arising from 
unpaired 4f electrons and are said to be paramagnetic in nature with the exception of La3+ and 
Lu3+, which are diamagnetic due to the cancellation of the opposite spins of the electrons as a 
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result of pairing [77]. The particularities of Ln elements result in the shielding of 4f orbitals by 
the filled 5p6 6s2 sub-shells allowing for very weak perturbations of the spectroscopic and 
magnetic properties of Ln ions by the surrounding microenvironment. Additionally, this 
shielding effect causes the interaction between Ln ions (the Ln ion being the central ion) with 
ligands to form complexes to be electrostatic in nature rather than covalent. The coordination of 
ligands to a central Ln3+ ion will depend on the steric demand of the ligand and the strength of 
electrostatic interaction between the Ln3+ ions and the ligand [14,74,78]. The coordination 
number in aqueous solution is usually in the range of 8 to 10 depending on their ionic radii. 
Another important feature of the Ln is the lanthanide contraction which leads to a smooth 
decrease of ionic radii of the ions with increasing charge density. This contraction arises 
because of the poor shielding ability of the inner 4f orbitals to the nuclear charge, thus the 
nucleus charge contracting and stabilizing the outer 5p, 5d and 6s orbitals. All these 
phenomena contribute to the similarities in chemical and physical properties of lanthanides 
[14,74,75].   
2.3.2 Lanthanide chelates 
2.3.2.1 Luminescence of lanthanide ions 
The luminescence of Ln3+ ions is related to its forbidden parity intra-shell 4f-4f transitions 
within their partially filled 4f orbitals. The electronic energy levels generated by the 4fn 
configuration are determined in order of importance (selection rule), by the Coulombic 
interaction and the spin-orbit coupling between the f orbital electrons. The mutual repulsion of 
electrons represented by the Coulombic interaction generates the total spin angular momentum 
(S), and the total orbital angular momentum (L), with the spin-orbit coupling defining the total 
angular momentum (J) of the f electrons.  
 
Figure 2.3. Simplified representation of the electronic transition within the 4f orbitals governed by the 
selection rules of spin (S), orbital (L) and total angular momentum (J) [79].  
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L, S and J are the quantum numbers that define a particular energy level and the distribution 
of the 4f electrons. The electronic levels generated by the 4fn configuration and characterized by 
the aforementioned quantum numbers S, L and J, can further be split by weak ligand field 
effects as shown in Figure 2.3 [79,80]. 
The transitions can be described by the Russell-Saunders coupling scheme and denoted as 
(2S+1)LJ, with (2S+1) the spin-multiplicity and L=0,1,2,3,4,5,6,7,8 designated in spectroscopy by 
the letters S, P, D, F, G, H, I, K, L respectively. Figure 2.4 represents the ground and excited 
state energy levels of the Ln3+ ions, where radiative transition between the energy levels occurs 
to give rise to luminescent lanthanide ions. As it can be observed for Gd3+, the large energy gap 
without intermediate energy states between 8S7/2 and 6P7/2, results in radiation at shorter 
wavelength in UV. A consequence of the shielding of the 4f orbitals is that the f-f emission lines 
exhibit narrow line-like emission bands and cover the entire spectrum from UV (Gd3+) to visible 
(for e.g., Pr3+, Sm3+, Eu3+, Tb3+) and NIR (Pr3+, Nd3+, Er3+, Yb3+) with the exception of La3+, Lu3+ 
[14,81,82].   
 
Figure 2.4. Ground and excited energy levels of Ln3+ ions where transitions results in f-f narrow line-
like emission bands except for La3+ and Lu3+ [83].  
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Other consequences of the parity forbidden 4f transition dictated by the spin and Laporte rule 
are their extremely long luminescent lifetimes (an asset for bioassays) and very low direct 
absorption of photons by the Ln3+ ions causing the absorption cross-sections of the f-f 
transitions to have very low molar absorption coefficients (typically < 3 M-1 cm-1) [76]. Actually 
luminescence of Ln3+ ions exhibit fluorescence (transitions which occur without change of 
electron spin from singlet excited state), phosphorescence (transitions which occur with a 
change of electron spin from triplet excited state) or, often both. Direct excitation using intense 
light sources are needed to populate the excited states of the Ln3+ ions and therefore limit their 
practical usage. One way to circumvent this limitation is by chelating the Ln3+ ions to some 
ligands which acts as a light-harvesting antenna that can further transfer its excitation energy 
to the Ln ion followed by emission of characteristic line-like luminescence [78,81]. This 
“antenna effect” or “luminescence sensitization” was first discovered by Weissman in 1942, 
when he observed an increased photoluminescence of Eu3+ in the presence of some UV 
absorbing organic aromatic ligands [84]. Another way of enhancing luminescence of lanthanide 
ions is by doping of Ln3+ ions (one being a sensitizer – light absorber - and another being an 
activator – light emitter) in a crystal lattice structure which serves as a host material. As 
suggested in 1966 by F. Auzel, energy transfer can take place between neighboring Ln3+ ions by 
a sequential two-step absorption process where a sensitizer is excited by  two (or more) low-
energy photons and energy is transferred non-radiatively to an activator resulting in higher-
energy photon emission, known as upconversion emission [80]. Photon upconversion was also 
demonstrated by Hyppänen et al. in an Er3+ complex which was chelated with an organic dye 
serving as an efficient NIR photon-harvesting antenna and upon excitation at 808 nm, 
upconversion energy transfer occurred between the antenna and the Er3+ ion. This resulted in a 
sequential two-step excitation of the Er3+ ion followed by the characteristic Er emission [85].  
2.3.2.2 Antenna effect on lanthanide complexes 
During the past two decades, a large variety of multidentate ligands have been synthesized and 
used as antennas to complex Ln3+ ions. Luminescence of Ln3+ ions in such complexes is a three 
step process where 1) photons are absorbed by the ligands coordinated to the Ln3+ ion, 2) energy 
is transferred onto one or several excited states of the Ln3+ ion and 3) light is emitted. These 
processes are quite intricate as they involve several energy migration mechanisms such as 
Dexter type and dipole-dipole or dipole-multipole (Förster) type [76,81]. The main energy 
migration paths imply permissible Laporte and spin rules, and are often modelled in terms of a 
simplified energy flow from ligand singlet state  ligand triplet state  Ln3+ excited state 
followed by Ln3+ ion centered emission. Figure 2.5 represents A) a simplified Jablonski 
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diagram for the antenna effect and B) the electronic transitions from excited 5DJ state to 7FJ 
ground state of europium (Eu) and terbium (Tb) complexes. Light is absorbed (h*) by the 
surrounding ligand and reaches a short-lived first singlet excited state (S0  S1), and is 
generally assumed to first undergo intersystem crossing to longer-lived triplet excited state   
(S1  T1) followed by population of Ln3+ excited states through energy transfer from T1 state of 
the ligand and finally characteristic radiative emission (h) of the centered lanthanide ion after 
suitable internal conversion. A large energy gap, often called ligand-induced Stokes shift, 
should exist between ligand absorption and lanthanide emission in order to prevent back 
energy transfer which results in low quantum yields and short, temperature-dependent 
lifetimes [78,81,86]. Figure 2.6 represents the Tb complex (Lumi4-Tb) based on                         
2-hydroxyisophthalamide ligands we used in this thesis bearing NHS functional groups for 
biomolecules’ coupling with the ligand having a molar absorption coefficient of ca.              
26000 M-1 cm-1 at 340 nm [87]. Examples of other ligands and lanthanide complexes are found 
in these selected references [14,74,75,81,83,86–88]. 
 
 
Figure 2.5. Simplified Jablonski diagram of the antenna effect. (A) h* is absorbed by the antenna 
which goes to the singlet excited state S1. S1 undergoes intersystem crossing to triplet excited state T1 
and populates the Ln3+ excited states. Finally characteristic radiative emission (h) of the centered 
lanthanide ion after suitable internal conversion occurs. (B) Commonly observed emission wavelengths of 
Eu (red) and Tb (green) complexes from the 5DJ excited state to 7FJ ground state [86].   
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The overall quantum yield, 𝑄𝐿𝑛
𝐿 , of a lanthanide complex is given by Equation 2.2:  
 𝑄𝐿𝑛
𝐿 =
𝐼𝐿𝑛(𝐸)
𝐼𝐿(𝐴)
=  𝑠𝑒𝑛𝑠 𝑄𝐿𝑛
𝐿𝑛 (2.2) 
where 𝐼𝐿𝑛(𝐸) is the number of photons emitted by the Ln metal ion; 
 𝐼𝐿(𝐴) is the number of photons absorbed by the ligand; 
 𝑄𝐿𝑛
𝐿𝑛 is the intrinsic quantum yield of the Ln metal ion when excitation has been 
 carried-out directly on the 4f excited state; 
 𝑠𝑒𝑛𝑠 represents the sensitization efficiency. 
  
Based on Equation 2.2, enhancing the overall quantum yield of lanthanide complexes requires 
tuning the following two parameters: 𝑠𝑒𝑛𝑠 and 𝑄𝐿𝑛
𝐿𝑛. The sensitization efficiency can be 
determined experimentally if both overall and intrinsic quantum yields are known, but 𝑠𝑒𝑛𝑠 is 
generally more difficult to calculate. 𝑄𝐿𝑛
𝐿𝑛 can be improved by considering the energy gap 
between the lowest lying excited state of the Ln ion and the highest sublevel of its ground 
multiplet. A small energy gap will result in non-radiative deactivation processes for example, 
through vibrational quenching by high O-H energy vibrations. The overall quantum yield can 
be further improved using antennas which have a high energy gap between the triplet excited 
state of the ligand and the lowest emitting levels of the Ln3+ ions, at least 2500 cm-1 difference. 
A low energy gap will limit the overall quantum yield due to thermal deactivation caused by 
back energy transfer and quenching effects to the triplet state. The ligand should be 
multidentate, have a high absorption coefficient, possess kinetic and thermodynamic stability, 
be biocompatible with activated functional groups for biolabeling, and be able to shield the 
lanthanide ion from its surrounding environment. Coordination with water molecules quenches 
the long lifetime of the Ln3+ through non-radiative vibrational energy transfer to the O-H 
oscillator [14,75,81]. 
 
Figure 2.6. Cage-like structure of the ligand for photon harvesting of the Lumi4-Tb complex used in this 
thesis and provided by Lumiphore Inc. (Berkeley, CA, USA) based on 2-hydroxyisophthalamide ligands. 
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2.3.3 Upconversion nanoparticles 
Luminescence of lanthanide chelates in most cases relies on energy downconversion where 
excitation usually occurs in the UV and luminescence generated at lower energies. In biological 
applications, excitation in the UV/Vis is generally accompanied by strong scattering and 
absorption in tissues, and is limited to penetration depths. Furthermore, sample 
autofluorescence causes low signal-to-noise ratio (SNR) and prolonged illumination at these 
excitation wavelengths may cause cell death and damage to the biomolecules being 
investigated [89]. Due to the long luminescence lifetimes of lanthanides, time-gated 
measurements can be performed to increase the SNR. An alternative to circumvent UV/Vis 
excitation of lanthanide chelates is by using upconversion nanoparticles (UCNPs) in which 
optically active Ln3+ ions are doped in an optically inactive inorganic crystal lattice structure 
that serves as a host material. Upconversion refers to non-linear optical processes capable of 
converting low energy excitation photons into high energy emission (anti-Stokes shift). 
Lanthanide ions-doped UCNPs offer the unique property of being able to emit visible/NIR light 
followed by excitation with a NIR laser. NIR excitation allows detection of signals with the 
significant minimization of background autofluorescence and scattered excitation light, and 
provides deeper and non-invasive penetration of photons in the tissue due to their NIR 
transparency (also known as the biological window). The measurement of upconversion 
luminescence in the red and downconversion luminescence in the NIR region also provides high 
sensitivity detection in the “second transparent biological window”. Even if a single Ln3+ ion 
allows upconversion emission, the low absorption cross-section results in weak emission and by 
co-doping with a different Ln3+ ion, upconversion efficiency is enhanced. In the latter, one Ln 
ion acts as a sensitizer that absorbs light and the other Ln ion is an activator responsible for 
upconversion emission [89–91]. 
Upconversion processes can be roughly divided into three classes: 1) excited state absorption 
(ESA), 2) energy transfer upconversion (ETU), and 3) photon avalanche (PA). These 
upconversion mechanisms involve sequential absorption of two or more photons resulting in the 
population of highly excited long-lived metastable energy states from which upconversion 
emission occurs and are represented in Figure 2.7. For ESA, at least two photons of sufficient 
energy are sequentially absorbed by the emitting ions to reach the emitting level            
(Figure 2.7 (a)). ETU is similar to ETA as they both employ sequential absorption of photons 
to populate the metastable excited states of the emitting ion but in ETU the excitation is 
performed by energy transfer to the neighboring ions where both ions are in the excited states 
and energy is transferred non-radiatively to the emitting ion leading to emission of light at a 
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shorter wavelength (Figure 2.7 (b)). In PA (Figure 2.7 (c)) , a pump intensity above a certain 
threshold value is required that will populate the level E1 by non-resonant weak ground state 
absorption, followed by the population of visible emitting E2 energy level by resonant ESA. 
Cross-relaxation energy transfer between a neighboring ion in its ground state and the excited 
ion occurs, resulting in building up of population in the excited state E1 from which a resonant 
absorption occurs to a higher level E2 to further initiate cross-relaxation and exponentially 
increase level E2 population by ESA, thus causing an upconversion emission as an avalanche 
process [90,92].           
 
Figure 2.7. UC mechanisms for lanthanide-doped crystals. (a) excited state absorption, (b) energy 
transfer upconversion, and (c) photon avalanche. The dashed-dotted arrows respresent photon excitation, 
dashed arrows correspond energy transfer and full arrows are radiative emission upconversion [90]. 
Ln-doped UCNPs that follow the ETU mechanism usually consist of a host lattice, sensitizers 
and activators. Yb3+ is often used as the sensitizer due to its larger absorption cross-section in 
the NIR (980 nm) region, only one large energy gap of ca. 10000 cm-1 and long luminescence 
lifetimes of about 1 ms. Upon 980 nm excitation, Yb3+ can effectively transfer its energy to 
activator ions such as Er3+, Tm3+, Pr3+, or Ho3+ by ETU which usually requires one activator in 
the presence of two or three Yb3+ ions. Nd3+ can also be used as a sensitizer when excited at its 
absorption maximum around 800 nm for Er3+ or Tm3+ activators. Shen et al. [93] showed that 
following excitation of Nd3+ at 800 nm initiated the energy transfer cascade to nearby Yb3+ ions 
(Yb3+ ions serves as a bridging sensitizer) that in turn activated Er3+ or Tm3+ following 
upconversion emission. Anti-Stokes emission efficiency of ETU is greatly dependent on the 
distance between the ions, which is related to their concentration. Upconversion enhancement 
can be obtained by varying dopant concentration but great care should be taken to avoid non-
radiative quenching such as concentration quenching, which results from concentration 
dependent cross-relaxation processes. For the case of Yb3+, a relatively high doping 
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concentration of 20%-30% is used for efficient energy transfer to neighboring ions and less than 
2% doping rate of activators such Er3+, Tm3+ and Ho3+ are required to avoid concentration 
quenching. In the work of Shen et al. Nd3+ was doped only up to 1% [89,94,95]. Figure 2.8 
represents the upconversion processes involving Yb3+ when excited by a 980 nm diode laser and 
Nd3+ when excited at 800 nm.  
The choice of the host lattice that accommodates the sensitizers and activators is essential for 
upconversion emission efficiency as they should have low phonon energies, bearing 
homogeneous doping, high chemical stability and show low non-radiative energy losses. Low 
phonon energies guarantee low non-radiative and multiphonon losses with enhanced 
luminescent lifetimes. Host lattice of chlorides, bromides and iodides having low phonon 
energies of ca. 144, 172 and 260 cm-1 are more appropriate than fluorides (ca. 355 cm-1) or 
oxides (ca. 600 cm-1) for upconversion emission. However, upconversion may at times require 
phonon assistance. Fluoride-based lattices such as LaF4, NaYF4, NaGdF4 (a start for bi-modal 
analysis), and BaYF4 have been used as host lattices in lots of studies and NaYF4  was 
acknowledged to provide the most efficient host lattice for upconversion visible emissions and 
long lifetimes [89,92,95]. Crystal symmetry has also an impact on upconversion efficiency and 
hexagonal -phase nanocrystals (-NaYF4) provided better upconversion emissions than cubic 
-phase nanocrystals (-NaYF4) [89,95].  
 
Figure 2.8. A simplified energy upconversion mechanism with (a) diode laser excitation of Yb3+ at 980 
nm followed by energy transfer to neighboring Tm3+ or Er3+, (b) diode laser excitation of Nd3+ at 800 nm 
followed by energy transfer to Yb3+ acting as a bridge for population of excited states of either Er3+ or 
Tm3+ [95]. 
 
26 
 
Many preparation techniques of UCNPs have been reported in the literature, including 
coprecipitation, thermal decomposition, solvothermal synthesis, and high-temperature 
coprecipitation. These synthesis techniques are usually carried out in organic solvents but 
synthesis in aqueous media can also be performed by hydrothermal synthesis, and sol-gel 
processes. Wet-chemical approaches such as thermal decomposition and hydrothermal / 
solvothermal allow controlled, narrow sized distribution and dispersibility of the upconversion 
nanocrystals. After synthesis, depending on the route taken, UCNPs can be rendered 
hydrophilic by ligand exchange or by obtaining ligand-free UCNPs. The surface can be further 
functionalized to accommodate reactive functional groups such as NHS, maleimide, NH2, and 
COOH for binding of biomolecules on the surface of UCNPs [96–99]. It is also important to 
confirm that surface modification did not have any negative impact on the upconversion 
efficiency and colloidal stability is retained for the UCNPs. Luminescent properties of 
lanthanide-doped UCNPs are known to be affected by the size of the nanocrystallites. The 
surface to volume ratio increases as the inverse of the NPs diameter (1/D), and as the size is 
decreased to reach nanometric scales (in order to be compatible with the infinitely small 
biological world), there is a high percentage of optically active dopant ions that are distributed 
on the surface of the nanoparticle. Despite the shielding of the f electrons, it is known that 
lanthanide ions are affected by surface defects, surface ligands and are quenched by water 
molecules, thus causing a drop in the overall upconversion efficiency. Arppe et al. studied the 
influence of water on the upconversion luminescence intensity and decay of bare and silanized 
NaYF4:Yb3+,Er3+ and NaYF4:Yb3+,Tm3+ UCNPs in H2O and D2O. They found out that the main 
quenching mechanism was a result of multiphonon deactivation of the Yb3+ sensitizer ion 
caused by OH-vibrations on the surface of the UCNPs instead of non-radiative relaxation of the 
activators (Er3+, Tm3+) and the silica shell around the UCNPs did not provide much protection 
against the quenching effect of water. Hence better surface passivation is necessary in order to 
eliminate most of the quenching effects and enhance the upconversion luminescence [100]. 
UCNPs possess generally quantum yields ranging from 0.1% to 1% [101], energy loss and 
surface quenching effects can be greatly minimized by coating the UCNPs with a uniform shell 
which can be active (doped with Ln3+ ions) or inactive to reduce non-radiative decays causing an 
increase in quantum yields. Many studies reported a several fold enhancement of the anti-
Stokes emission by growing a shell around the UCNPs [102–108]. Vetrone et al. demonstrated 
that core/shell strategies also cause a change in the energy distribution in the nanoparticle. 
They synthesized core-only, active-core/inert-shell and active-core/active-shell UCNPs, and 
observed an enhancement of the upconversion emission yield of ca. 3 in the green and ca. 10 in 
the red when comparing active-core/active-shell to active-core/inert-shell respectively. A 
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comparison with active-core/active-shell and core-only showed a more intense factor of ca. 13 
and 20 for the green and red emissions respectively. By increasing Yb3+ concentration in 
relation to Er3+ ions there was enhanced population of the red emitting state 4F9/2 and 
concentration quenching was reduced due to spatial separation of the ions by placing them in 
either the core or the shell [107]. 
2.3.4 Applications of lanthanides 
Lanthanide luminescence is implicated in a wide variety of technologies ranging from 
photovoltaics, optical imaging to biomedical and sensing areas. The NIR luminescence of the 
Nd3+, Yb3+ and Er3+ are used as optical signal amplifier in telecommunication network and Nd3+ 
has since a long time been used in laser systems such as the Nd:YAG laser with its main 
emission wavelength at 1064 nm. Ln ions emitting in the visible region when coupled to 
suitable antennas can be used in various lighting applications such as LEDs, security inks and 
bioprobes [75]. Lanthanide complexes and UCNPs have found their place as labels on biological 
compounds, in bioanalytical detection and in luminescence microscopy. Due to their unique 
photophysical properties such as microsecond to millisecond lifetimes and characteristic narrow 
emission bands and large Stokes shift / anti-Stokes shift, they provide a higher SNR as 
compared to organic dyes or QDs. Visible emitting Ln complexes are widely used in bioassays 
and microscopy while NIR emitting Ln complexes are becoming good candidates for optical 
microscopy and time-resolved imaging as their emission is in the 650-1350 nm region where 
light penetration in tissues is maximum with minimum autofluorescence and scattering.  When 
used in fluorescence-based bioassays or microscopy imaging, Ln complexes allows the 
suppression of short-lived sample autofluorescence and light scattering when combined with 
pulsed excitation and time-gating. The introduction of a delay with is typically in the range of 
10-100 µs after UV pulsed excitation, allows acquiring the PL signal of the Ln complexes 
background-free during a detector integration time of for e.g. 100-1000 µs [109]. The use of 
UCNPs in biomedical applications are of growing interest as the emission of upconversion light 
under 980 nm or 800 nm excitation falls in the so-called biological window resulting in an 
increased transparency of biological tissue towards NIR light as compared to UV or visible light 
excitation. Penetration of light with UV in the tissue is of a few µm to 1 mm whereas NIR 
radiation penetrates deeper several millimeters to centimeters with minimal photodamage. 
Detection of UCNPs can therefore be performed sensitively in steady-state or time-resolved 
mode with high SNR [110,111]. Figure 2.9, (left) represents the absorption spectrum of a 
human skin where three biological windows are defined and (right) a comparison of the 
penetration depth in tissue when exposed to 800 nm and 980 nm radiation.    
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Figure 2.9. (Left) Absorption spectrum of human skin where the 1st biological window is observed in the 
range ca. 650 nm - 950 nm; sensitive spectral range for in vivo imaging found in the 2nd biological window 
ranging from 1 to 1.35 µm and a 3rd biological window between 1.5 and 1.8 µm [110]. (Right) Comparison 
of penetration depth in tissue upon excitation at 800 nm and 980 nm [94]. 
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2.4 Quantum dots 
2.4.1 Introduction 
Quantum dots (QDs) are highly stable and brightly luminescent inorganic nanoparticles 
composed of semiconductor materials from II-VI (CdS, CdSe, CdTe, ZnO, ZnS), III-V (GaAs, 
GaN, GaP, InAs, InP), or IV-VI (PbS, PbSe) groups of the periodic table, and are also composed 
of their alloys (CdSeS, CdSeTe, InGaAs, etc.), or core/shell structures of these materials. QDs 
are roughly spherical in shape and sizes of these semiconductor nanocrystals range between ca. 
1 – 10 nm. Quantum mechanical behavior is observed due to their small nanometric sizes 
where their fluorescence is directly related to the sizes of the QDs resulting in a blue color shift 
in the emitted light as the size decreases. QDs have extensively been used for biological 
applications after two seminal studies in 1998 reported the potential of colloidal CdSe/ZnS 
core/shell as fluorescent labels for cellular imaging [112,113]. The most popular QD 
fluorophores for biological applications are composed of CdS, CdSe, and CdTe overcoated with a 
layer of ZnS is because of their already established chemistry and conjugation strategies 
[109,114,115]. However, due to the high toxicity of these heavy metals, QDs made of alternative 
materials have to be developed for e.g. indium phosphide (InP) which is one of the most 
promising compounds as a result of its low intrinsic toxicity [116]. Compared to conventional 
fluorophores, such as organic dyes or fluorescent proteins, which have narrow excitation 
spectra, small Stokes shifts, broad fluorescence band and more prone to photobleaching, QDs 
present several technical advantages, such as photostability, high brightness, and size-tunable 
absorption and narrow emission wavelengths. These unique properties of QDs have attracted 
more and more attention in biotechnology and medical applications where they have become 
important fluorescent probes for in vitro and in vivo bioimaging and clinical diagnostics 
research [117]. Figure 2.10 represents the spectral range of emission for the most widely 
studied types of semiconductor nanocrystals.   
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Figure 2.10. Spectral range of the photoluminescent emission for the most widely studied types of 
semiconductor nanocrystals [118]. 
2.4.2 Optical properties of QDs 
Quantum dots possess electronic properties that are intermediate between those of bulk 
semiconductors and discrete molecules. Semiconductors are electronically characterized by 
having a filled valence band separated from the empty conduction band by an energy bandgap 
of ca. 0.5 to 3.5 eV (where 1 eV = 1.602 × 10-19 J) [119]. When a bulk semiconductor is excited by 
photons of energy h > bandgap, an electron is promoted into the quasi-continuum conduction 
band leaving in the valence band a positively charged hole with the average separation 
distance between the electron and hole referred to as the exciton Bohr radius and electron-hole 
pair regarded as an exciton. When an exciton is created and that the size of the bulk 
semiconductor approaches the exciton Bohr radius, the density of electronic states is not 
enough to form complete band structures and quantization of the energy levels is observed at 
the band edges. The physical dimensions of the particle therefore confine the exciton as in a 
particle-in-box problem forcing the electron-hole pair to be closely together thus increasing the 
exciton binding energy. This phenomenon known as the quantum confinement has a direct 
effect on the boundaries of the bandgap (Figure 2.11) where the relative positions of the 
highest occupied state and lowest unoccupied state equivalent in 1) bulk semiconductor: top of 
valence band and bottom of conduction band, and 2) molecular dyes: highest occupied molecular 
orbital (HOMO) and lowest unoccupied molecular orbital (LUMO)) are controlled by the size of 
the QD. The magnitude of this energy spacing is inversely proportional to the number of atoms 
in the semiconductor nanocrystal. Due to the quantum confinement effect, there is an increase 
in the inter-bandgap energy as the size of the QD decreases, meaning that for a QD composed 
of the same material the emission frequency (from UV to NIR range for some QDs), which 
results from the radiative recombination of an exciton, is size dependent. The smaller the QD 
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the more blue shifted will be its photoluminescence (PL). Another characteristic of QDs is their 
narrow and symmetrical emission, which approximates a Gaussian profile and depends on the 
quality and size distribution of the QDs. High quality and monodisperse QDs yield emission 
profiles with FWHM which are typically in the range of 25-35 nm [109,119,120]. The broad 
absorption spectra are caused by an increase absorption probability at shorter wavelengths, 
which has the advantage of being able to excite different QDs with a single light source. QDs 
generally have multi-exponential lifetimes and absorption coefficients in the range of             
105 – 106 M-1.cm-1 that increase with shorter excitation wavelengths and larger nanocrystal 
sizes. It has also been reported of QD’s two-photon absorption cross-sections that are about two 
orders of magnitude larger than the best organic dyes [109,121]. In an aqueous environment for 
biological applications core nanocrystals suffer from surface defects and cause the formation of 
temporary trap states for the electron or hole preventing their radiative recombination and 
resulting in blinking at the single-molecule level and low quantum yield. A shell of a higher 
bandgap can be coated around the core which helps confine the exciton to the core of the 
nanocrystal therefore minimizing trap states, improving quantum yield, preventing leeching of 
the core materials and protecting the core from oxidation and other chemical reactions from its 
surrounding environment. Core/shell QDs are especially required in biological applications.  
Figure 2.11. (Left) Quantization of the energy level as a result of the quantum confinement effect in a 
QD. Eg represent the bandgaps energies, Em the radiative emission of a photon upon recombination of 
electron (e-) and hole (h+). Energy levels are color coded: The smaller the QD the more blue shifted will be 
its photoluminescence. Continuous conduction band (CB) and valence band (VB) of bulk semiconductor 
shown as comparison. (Right) Diagrams illustrating that the electronic structure of a QD is intermediate 
between a bulk semiconductor and a molecule [109]. 
2.4.3 Biofunctionalization 
QDs need to be exceptionally water-soluble, biocompatible, highly luminescent and 
monodisperse for use in biological applications. Synthesis of QDs can be carried-out using the 
top-down method or the bottom-up approach. In the top-down method the semiconductor 
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material is thinned to form QDs using the following processing methods: molecular beam 
epitaxy, ion implantation, e-beam lithography, and X-ray lithography. Synthesis of QDs via the 
bottom-up approach consists of preparing colloidal QDs by self-assembly in a solution following 
a chemical reduction [122]. The most common technique to yield high quality colloidal QDs is 
by the bottom-up approach where monodisperse QDs are synthesized in non-polar organic 
solvents by pyrolysis of organometallic precursors in the presence of hydrophobic coordinating 
ligands. The size of the QDs can be tuned by changing temperature, pH, or growth time. QDs 
have also been directly synthesized in aqueous solutions yielding immediate hydrophilic QDs 
for bio-applications but have so far not been equivalent as those prepared in hot organic solvent 
[123]. A schematic generic synthesis of a typical CdSe/ZnS core/shell QDs is presented in 
Scheme 2.1.  
 
Scheme 2.1. Typical synthesis of colloidal CdSe/ZnS core/shell QDs. (a) Cadmium presursor is generally 
dimethyl cadmium or cadmium oxide and selenium precursor is usually trioctylphosphine selenide 
(TOPSe). The growth time determines the size of the QDs and the solution is cooled to stop the reaction 
growth of the nanocrystals. (b) A solution of bis(trimethylsiyl)sulfide and either dimethyl or diethyl zinc 
is added to the core nanocrystals and heated at different temperatures between 100-150°C to slowly grow 
the ZnS shell around the core CdSe [109].  
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The resulting QDs prepared in organic solvents are hydrophobic in nature and need to be 
rendered water soluble for further bio-use, which can be done by different strategies of surface 
modifications such as ligand exchange, or encapsulation. Ligand exchange involves the 
substitution of hydrophobic ligands present on the QDs’ surface with bifunctional ligands that 
have the ability to anchor on the QDs at one end, generally through thiol based molecules, and 
on the other end provide solubility with a hydrophilic end group, which can be carboxylates, 
amines or PEGs. Small hydrodynamic diameters can be obtained using this method but yield 
usually a lower quantum yield as the surface state is modified [117,123]. It has been reported 
that ligand exchange using PEGylated-dihydrolipoic acid (PEG-DHLA) ligands produced small 
hydrodynamic sized QDs with low non-specific binding, high quantum yield and the ability of 
incorporating reactive functional groups for bioconjugation [124]. Recently, ligand exchange 
with zwitterionic penicillamine resulted in compact QDs with small hydrodynamic diameters 
and colloidal stability for at least two years, which could further be functionalized with reactive 
bearing functional groups for biomolecule attachment [125]. Encapsulation does not modify the 
QDs surface as assembly with amphiphilic molecules, such as polymers or phospholipids, are 
driven by the hydrophobic interactions, which intercalate within the alkyl chains terminated by 
the native ligands while the hydrophilic part (which can incorporated functional reactive 
groups towards biomolecules) faces outwards and interact with the aqueous environment [126]. 
The encapsulation method with polymer coating is known to provide QDs with high stability in 
aqueous solutions and retaining their optical properties as compared to ligand exchange 
method, but also yield QDs with large hydrodynamic diameter, which is not optimal for FRET 
applications.  
Once QDs have been rendered water soluble they can be further bio-functionalized with 
proteins, peptides, nucleic acids or any other biomolecules for their use in biological 
applications. When conducting bioconjugation, several parameters such as retaining activity of 
biomolecule, functionality of the QD, orientation of the biomolecule and reproducible and stable 
bioconjugation, should be carefully considered [115]. Different approaches for labeling of 
biomolecules on QD surfaces can be separated into chemistry- and biology inspired techniques. 
Biology inspired techniques include labeling based on receptor-ligand (biotin/avidin), 
fluorescent proteins, enzymatic (SNAPTM, HALOTM-tag, etc.), non-natural amino acids, and 
peptide recognition (tetracysteine, polyhistidine, etc.). Chemistry inspired techniques include 
non-covalent (electrostatic, encapsulation) and covalent attachment (amine reactive, cysteine 
reactive, ketone/aldehydes, tyrosine, tryptophan, clycloaddition reactions, etc.). Covalent 
attachment of biomolecules to their probes is the most popular and traditional group of 
chemistries used to date. For protein labeling, four major functional groups have been 
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identified as primary amines (-NH2), carboxyls (-COOH), sulfhydryls (-SH) and carbonyls (-
CHO), which can be targeted by a number of chemical reactive groups. Figure 2.12 illustrates 
the bioconjugation and surface coating strategies that can be performed on a QD [117], and 
Table 2.2 summarizes some of the functional groups and their representative reaction 
mechanism for bioconjugation [127,128]. DNA and peptides can be directly synthesized with 
site-specific amine or thiol groups for subsequent bioconjugation with QDs [127]. Polyhistidine 
tags affixed to biomolecules spontaneously coordinate via metal-affinity interactions directly to 
the QDs surface [120]. In this thesis, we mainly targeted free thiol groups and primary amines 
using maleimide reactive groups and succinimidyl ester (NHS) respectively, and involved 
crosslinking using heterobifunctional crosslinkers (heterobifunctional crosslinkers possess 
different reactive groups at either end of a short spacer arm). 
 
Figure 2.12. Illustration of selected bioconjugation (left, BOI stands for biomolecule of interest) and 
surface coating (right) strategies. Left side represents mostly covalent and receptor-ligand labeling 
strategies and right side (i,ii) represents encapsulation with amphiphilic polymers and (iii-v) hydrophobic 
ligand exchange to hydrophilic ligands take advantage of the thiol-affinity to anchor on the ZnS shell of 
the QD [117]. 
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2.5 Immunoassays 
Immunoassays can be considered to provide a sophisticated biochemical toolbox to 
quantitatively, selectively and sensitively detect an analyte (antigen), a recognition that 
depends on the reaction of an antigen and an antibody. These assets of immunoassays come 
from three important properties of antibodies which are 1) their enormous diversity of antibody 
paratopes to bind to an exceptionally wide range of natural and synthetic chemicals, 
biomolecules, cells and viruses; 2) the specificity of each antibody for the substance they bind 
to; and 3) the binding strength between an antibody and its target allowing precise and 
accurate detection of the target even at low concentrations in biological fluids. Immunoassays 
can be classified into heterogeneous or homogeneous assays and require signal-generating 
labels such as radioactive isotopes, enzymes, fluorescent probes, chemiluminescent substances, 
metals and metal chelates, for detection [10]. Heterogeneous and homogeneous assays can be 
performed in either competitive or immunometric (non-competitive) design. Competitive 
immunoassays are preferred when the target analytes are small molecules with the binding to 
only one antibody. The analyte is marked with a suitable signal-generation label and the exact 
concentration of analyte and antibodies should be known parameters. During reaction of 
analyte and antibody, competition reaction arises between unlabeled analyte and labeled 
analyte to a limited amount of antibody sites. The measured signal of the label is indirectly 
proportional to the concentration of the analyte in the sample. Immunometric designed 
immunoassays (also known as two-site or sandwich immunoassays) are usually used for large 
molecules (analytes) which possess several recognition epitopes and where two antibodies can 
bind to different locations on the molecule. One antibody has the role to capture an analyte and 
the other antibody is labeled and used for detection upon biological reaction. The measured 
signal from the labeled antibody in the form of antibody-antigen-antibody complex is in this 
case directly proportional to the concentration of the analyte in the sample. As signal-
generating labels we can find: iodine 125 is the commonly used radioisotope with a half-life of 
60 days and less commonly employed radioactive atoms are tritium (3H) with a half-life of 12.26 
years, and carbon 14 (14C) with a half-life of ca. 5730 years according to the National Institute 
of Standards and Technology (NIST). Labeled antigen allows the bound or free fractions to be 
estimated in a competitive assay, whilst labeled antibody in a sandwich assay allows the 
detection of the bound analyte. In enzyme immunoassays, the label is an enzyme which is 
marked on either antigen or antibody and can be carried out in competitive or non-competitive 
formats by analyzing the enzyme’s catalytic properties. Alkaline phosphatase and HRP (a 44 
kDa glycosylated hemoprotein) are the two frequently used enzymes in immunoassays. 
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Following immuno-reaction between antibody and antigen, the enzyme activity is monitored by 
observing color, fluorescence or luminescence, and chemiluminescence generation from a 
“neutral” substrate. The recorded signal is then correlated to the antigen’s concentration. 
Fluorescent probes such as organic dyes, quantum dots or metal chelates can be directly labeled 
on the immunoanalytical reagents through functional reactive groups and used in a competitive 
or immunometric format. During antibody-antigen reaction and upon excitation of the 
fluorophores by an external light source, fluorescence or luminescence signals are generated 
and the signal intensity directly correlates with the antigen’s concentration. Time-resolved 
fluorescence immunoassays using metal chelates have the advantage of overcoming 
background interference by measuring in a time-window after pulsed excitation. This technique 
will be discussed in the next section. Chemiluminescent immunoassays do not require external 
light excitation to emit photons for detection. They rather depend on chemiluminescent 
compounds as labels such as acridinium esters/sulphonamides, and isoluminol, where light is 
emitted during a chemical reaction using an alkaline solution of hydrogen peroxide as an 
oxidizing agent [10,59]. 
To establish the relationship between the response (in our case luminescent signal from FRET) 
and concentration of the measured analyte in an immunoassay, a calibration curve needs to be 
constructed. Known concentrations of the samples are necessary and these specific samples are 
called calibrators or standards. The calibrators can come in a high known concentration and 
are diluted to different lower concentrations covering the desired range of measurements. A 
calibration curve is thus obtained and fitted to the responses of the calibrators, which is used to 
determine the limit of detection of the system and estimation of unknown sample 
concentrations. Unknown sample concentrations are usually assayed together with the 
calibrators and the concentration of the unknown samples are directly read and estimated on 
the linear fitted calibration curve due to the proportionality of the signal strength to the 
concentration of the analyte. The important parameters which characterize an immunoassay 
are the dynamic and linear range of detection, followed by the limit of detection (LOD) and 
sensitivity. Dynamic range corresponds to the maximum range where an accurate 
measurement can be made and ranges between the limit of quantification (LOQ) and limit of 
linearity (LOL). LOQ is defined as the concentration of the analyte that can be calculated with 
a high degree of confidence and LOL is the concentration of the analyte that deviates 5% from 
linearity. LOD is the minimum concentration that can be detected at a known confidence limit 
and can be calculated using Equation 2.3. The 3×SD is equivalent to 99.7% confidence limit. 
The slope of the calibration curve determines the sensitivity of the immunoassay. 
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 𝐿𝑂𝐷 =
3 × 𝑆𝐷
𝑠𝑙𝑜𝑝𝑒
 (2.3) 
where SD corresponds to the standard deviation from a set of samples; 
 3 × SD is equivalent to 99.7% confidence limit; 
 slope determines the sensitivity of the immunoassay. 
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2.6 Förster resonance energy transfer 
2.6.1 Introduction 
Förster resonance energy transfer (FRET), reabsorption, complex formation, and collision 
quenching are among the main mechanisms where excitation energy can be transferred from a 
donor molecule to an acceptor molecule. To differentiate between these transfer mechanisms, 
we can approximate a donor as a group of electrical oscillators close together that produce an 
electric field in the space around the donor. The space around the donor can be divided into four 
concentric zones (Figure 2.13) named as the contact or Dexter zone, the near zone or near 
field, the intermediate zone, and the far zone or far-field/radiation zone. Complex formation 
and collision quenching require molecular contact to occur which happen when an acceptor is in 
the Dexter zone (0 - 1 nm) of the donor. Reabsorption, where an emitted photon by a donor gets 
absorbed by an acceptor, occurs in the radiation zone of the donor which spans from 1 µm to 
infinity. FRET happens only in the near zone which is approximately around 1 – 20 nm of the 
donor where the ideal dipole approximation can be applied. The ideal dipole approximation is 
valid in the near field when the distance separating the donor and acceptor is much larger than 
the radius of the donor and acceptor. As a result the electromagnetic interaction between the 
donor and acceptor is a dipole-dipole interaction, and all interactions due to higher multipoles 
can be ignored [129]. As verified and supported by a number of publications and citations, 
FRET appears to be among the most popular and important tools in biology and biochemistry. 
FRET is a non-radiative process involving an excited donor molecule and an acceptor molecule 
in its fundamental ground state. During this process, energy is transferred non-radiatively 
from the excited donor molecule to an acceptor molecule in close proximity. As a result, the 
fluorescence intensity (and decay time) of the donor decreases and the fluorescence intensity (or 
decay time) of the acceptor increases provided the acceptor is fluorescent. The rate of energy 
transfer is strongly distance dependent between the two molecules. Based on its intrinsic 
sensitivity to small variations in molecular distance and orientation, scientists were able to 
apply FRET as an optical technique to gain information in molecular conformation with 
nanometer resolution, structure elucidation, measuring of intermolecular/intramolecular 
interactions, and in in vivo/in vitro diagnostics [6,130,131]. In this chapter, FRET theory is 
mainly extracted from references [6,129,132].   
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Figure 2.13. Space around a donor fluorophore visualized as a group of electrical oscillators, divided into 
four zones: contact zone, near field, intermediate zone and far-field [129].      
2.6.2 FRET theory 
The theory behind resonance energy transfer was developed by Theodor Förster back in the 
40’s from his knowledge of classical [133] and quantum [134] theory. In honor of his 
contribution, the effect was named after him. Förster was able to link theory and experiment by 
explaining the relationship between spectral overlap, energy transfer, and proximity, thereby 
showing the inverse proportionality to the sixth power of the distance between two molecules to 
FRET efficiency [129]. FRET is the non-radiative energy transfer between a donor molecule (D) 
in the excited state to an acceptor molecule (A) in the ground state, which are in close 
proximity, and is based on the approximation that dipole-dipole coupling can be represented by 
Coulombic coupling. The donor must be a fluorophore and the acceptor should be able to absorb 
light at the emission wavelength(s) of the donor but does not necessarily have to remit photons. 
In order for energy transfer to take place, the resonance condition must be fulfilled. When the 
donor or acceptor molecule is treated as a group of coupled electrical oscillators, the oscillators 
in the donor will oscillate and generate their own electromagnetic field as a result of the donor 
oscillators being in an external electromagnetic field caused by light exciting the donor. Often, 
the acceptor oscillators will not respond to the external electromagnetic field, but may be 
sensitive to the electric field from the donor oscillators. The resonance phenomenon appears 
when the acceptor oscillators sensitive to the donor oscillators’ electric field, oscillate in phase 
with the donor oscillators at a distance. With the sharing of this electric field, in other words 
when the donor and acceptor share the same electronic transitions, resonance energy transfer 
occurs. These electronic transitions are presented in a simplified Jablonski diagram in    
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Figure 2.14 (left) showing the basic principle of FRET. In spectroscopic terms, there should be 
a spectral overlap between the donor emission and the acceptor absorption spectra            
(Figure 2.14 right).  
The degree of spectral overlap, the quantum yield of the donor, the relative transition dipoles 
orientation of the donor and acceptor, and the distance between the donor and acceptor 
molecules, directly affect the rate of energy transfer. The rate of energy transfer (or FRET 
transfer rate), 𝑘𝐹𝑅𝐸𝑇, is given by Equation 2.4 and we can observe a strong distance 
dependency which is proportional to r-6.  
 
𝑘𝐹𝑅𝐸𝑇 =
1
𝜏𝐷
(
𝑅0
𝑟
)
6
 (2.4) 
where 𝜏𝐷 is the excited-state lifetime of the donor in absence of the acceptor; 
 𝑅0 is the Förster distance representing a transfer efficiency of 50 %; 
 r is the donor-to-acceptor distance.    
    
 
Figure 2.14. (Left) Simplified Jablonski diagram representing the energy levels of the donor (D) and 
acceptor (A) molecules. The donor is brought to an excited state (D*) from an electronic ground state (D) 
by light excitation (h), followed by inner relaxation (dotted arrows) to an excited electronic ground state 
and finally to the ground state by radiative decay (kD), non-radiative decay (kD-NR) or FRET (kFRET, 
dashed lines referring to possible resonant transitions). FRET (horizontal lines with dots on each end) 
occurs when the energy levels of D* and A are in resonance. After FRET, the acceptor is in an excited 
state (A*), followed by radiative decay (kA) and non-radiative decay (kA-NR) to its ground state. (Right) 
Spectral overlap (grey) between the donor emission (blue) and the acceptor absorption (A). The integral 
of this overlap is calculated using Equation 2.6.           
From Equation 2.4, 𝑅0 expressed in nm, which is characteristic to a donor-acceptor pair, can 
be calculated at equilibrium where the FRET efficiency (𝜂𝐹𝑅𝐸𝑇) = 50%, giving rise to    
Equation 2.5 which encompasses several crucial variables including the overlap integral J().  
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𝑅0 = (
9(𝑙𝑛10) 𝜅2 𝛷𝐷
128 𝜋5 𝑁𝐴 𝑛
4 
 𝐽())
1
6
 (2.5) 
where  𝜅2 is the orientation factor describing the relative orientation of the transition dipoles of 
 the donor and acceptor. Usually assumed to be 2/3;  
 𝛷𝐷 is the quantum yield of the donor in absence of energy transfer (ie, the no. of photons 
 emitted / no. of photons absorbed);  
 𝑁𝐴 is Avogadro’s number (6.023 × 1023 mol-1); 
 n is the refractive index of the medium. Assumed to be ~1.4 for biomolecules in aqueous 
 media; 
 J() is the spectral overlap between the donor emission and acceptor absorption profiles. 
 
The overlap integral (Equation 2.6), J() expressed in M-1.cm-1.nm4, is an important variable of 
Equation 2.5 as it describes the degree of spectral overlap (resonance) between the donor 
emission and acceptor absorption. The donor emission and acceptor absorption spectra are 
obtained through spectroscopic measurements by recording the spectra every 0.5 or 1.0 nm. 
Same wavelength steps are recommended for acquiring both spectra. It is important to note 
that because of 4 in Equation 2.6, the peak of the overlap curve will always be at a larger 
wavelength than where the donor emission and acceptor extinction coefficient intersect. 
Overlap integral function will not correspond exactly to the spectral overlap curve and 
calculation of 𝑅0 from J() will thus lead to an approximation.   
 
𝐽() = ∫ 𝐼?̅?() 𝐴() 
4 𝑑 (2.6) 
where 𝐼?̅? is dimensionless and represents the area normalized emission spectrum of the donor; 
 𝐴()  is the molar extinction coefficient spectrum of the acceptor; 
  is the wavelength range of the spectral overlap in nm.   
 
The orientation factor,  𝜅2, describes the relative orientation of the transition dipoles in space of 
the donor and acceptor. In Equation 2.7, 𝜃𝐷𝐴 is the angle between the donor and acceptor 
transition moments and is defined by Equation 2.8. 𝜃𝐷 and 𝜃𝐴 are the angles between the 
donor and acceptor transition dipole moments and the donor-acceptor connecting vector r, and 
𝜙 is the azimuth between the planes (MD, r) and (MA, r). Figure 2. illustrates the angles 
involved in the definition of  𝜅2 and the different values of  𝜅2.      
 𝜅2 = (𝑐𝑜𝑠𝜃𝐷𝐴 − 3𝑐𝑜𝑠𝜃𝐷 𝑐𝑜𝑠𝜃𝐴)
2 (2.7) 
 𝑐𝑜𝑠𝜃𝐷𝐴 = sin 𝜃𝐷 sin 𝜃𝐴 𝑐𝑜𝑠𝜙 +  𝑐𝑜𝑠𝜃𝐷𝑐𝑜𝑠𝜃𝐴  (2.8) 
 
Kappa square,  𝜅2, can range from 0 to 4 depending on the relative orientation of donor and 
acceptor transition dipole moments. A value of 0 corresponds to perpendicular transition 
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moments, collinear transition moments results when  𝜅2 = 4 and  𝜅2= 1 for transition moments 
that are parallel (Figure 2.15 right). We assume an average  𝜅2 = 2/3 when the orientations of 
the donor and acceptor transition dipole moments randomize within the lifetime of the excited 
state (dynamic averaging regime). In other words when the donor and acceptor molecules 
undergo fast isotropic motion all orientations are equally probable and the dynamic isotropic 
average of  𝜅2 = 2/3. However, we can also assume static averaging regime when the rates of 
rotation are small compared to the rate of donor decay in the presence of the acceptor. In this 
case,  𝜅2 can take values ranging between 0 and 2/3.  In most biological FRET experiments the 
orientation factor is assumed to be 2/3 and since the sixth root is taken to calculate 𝑅0, an error 
not exceeding 35 % results.  
 
Figure 2.15. (Left) , 𝜽𝑫𝑨 is the angle between the donor and acceptor transition moments and is given by 
Equation 6. 𝜽𝑫 and 𝜽𝑨 are the angles between the donor and acceptor transition dipole moments and the 
donor-acceptor connecting vector r, and 𝝓 is the azimuth between the planes (MD, r) and (MA, r). (Right) 
Values which  𝜿𝟐 can take depending on the orientation of the donor and acceptor transition dipoles 
[132].  
The efficiency of energy transfer (or FRET efficiency) denoted as 𝜂𝐹𝑅𝐸𝑇, can be calculated by 
using the FRET transfer rate and the decay time 𝜏𝐷 of the donor. The faster the transfer rate as 
compared to the decay rate, the more efficient will be the energy transfer. First part of 
Equation 2.9 shows the relationship of FRET transfer rate to the total decay rate of the donor 
in presence of an acceptor. Substituting Equation 2.4 into 𝜅𝐹𝑅𝐸𝑇, we obtain the right side of 
Equation 2.9 which shows that FRET efficiency is greatly dependent as sixth power of the 
distance between the donor and acceptor molecules. Determination of r using 𝜂𝐹𝑅𝐸𝑇 and 𝑅0, 
allows FRET to be used as a spectroscopic molecular ruler. As it can be observed in          
Figure 2.16, due to this sixth power dependency, FRET efficiency is mostly sensitive in the 
region 0.5𝑅0  𝑅0  2.0𝑅0 with a sharp efficiency at r = 𝑅0 (high dynamic range).    
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𝜂𝐹𝑅𝐸𝑇 =  
𝜅𝐹𝑅𝐸𝑇
𝐷
−1 +  𝜅𝐹𝑅𝐸𝑇
=  
𝑅0
6
𝑅0
6  +  𝑟6
 (2.9) 
where r is the distance separating the donor and acceptor 
 
Figure 2.16. FRET efficiency 𝛈𝐅𝐑𝐄𝐓 variation as a function of the donor-acceptor distance (r) shows the 
sixth power dependency and a measurable range of the FRET efficiency between 0.5𝐑𝟎 and 2.0𝐑𝟎 with a 
steep curve around 𝐑𝟎 [135]. 
FRET efficiency can also be calculated using intensities and lifetimes of the donor in absence 
and presence of an acceptor (Equation 2.10). During FRET process, quenching of donor 
intensity and lifetime occur causing 𝐼𝐷𝐴 < 𝐼𝐷 and 𝐷𝐴 < 𝐷 hence leading to efficiency values 
between 0 and 1. 
 
𝜂𝐹𝑅𝐸𝑇 = 1 − 
𝐼𝐷𝐴
𝐼𝐷
= 1 − 
𝐷𝐴
𝐷
  (2.10) 
where 𝐼𝐷 is the fluorescence intensity of the donor in absence of the acceptor; 
 𝐼𝐷𝐴 is the fluorescence intensity of the donor in presence of the acceptor; 
 𝐷 is the donor decay time in absence of the acceptor;   
      𝐷𝐴 is the donor decay time in presence of the acceptor. 
 
2.6.3 FRET applications 
The ability of FRET to detect near field interaction between two molecules at the nanometer 
scale enables numerous applications for the study of molecular dynamics in biophysics and in 
molecular biology. Some examples include monitoring of protein-protein / protein-DNA 
interactions, receptor/ligand interactions, and protein conformational changes. Recently, more 
and more FRET-based biosensors are being developed for use in the medical field as a simple, 
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rapid, and sensitive transduction mechanism [130,136]. FRET is not restricted to the biological 
field and can also be used as the basis for pH and cation sensors [6].  FRET happens when a 
donor and acceptor fluorophore are in close proximity and the examples mentioned earlier 
allow doing so. FRET can be triggered upon attachment of a donor fluorophore and an acceptor 
fluorophore to a single protein, and due to environmental constraints the protein is forced to 
alter its conformation thus bringing donor and acceptor close together [136]. In the case of 
monitoring of cellular dynamics, donor and acceptor fluorophore are labelled to a molecule at 
close positions to continuously observe FRET. Upon cleavage by a cellular process on the 
binding site of one of the fluorophores, they are separated and FRET decreases [137]. Single-
molecule FRET (sm-FRET) is another FRET technique that allows the sensitive detection at 
the single-molecule level. Compared to an ensemble of measurements that provide average 
FRET data of a whole population of molecules, sm-FRET gives conformational changes in a 
single biomolecule or association/dissociation dynamics in a single complex of interacting 
partners [138]. Biosensors using FRET as a signal transduction mechanism are gaining 
popularity in the medical field such as in medical diagnostics, prognostics and personalized 
medicine based on their improved sensitivity, specificity and performance. Biomolecules target 
of interest include proteins, metabolites, drugs, toxins, nucleic acids, human cells, microbes, 
and other pathogens such as viruses, parasites and are often found in blood, urine, saliva, urine 
and other bodily fluids [130,139]. Conjugation/labeling of donor and acceptor fluorophores to 
biomolecules such as on antibodies, proteins and peptides, nucleic acids, and aptamers, results 
in measurable FRET signals when the donor and acceptor are brought close together during 
sensing/recognition process [130]. pH probes based on FRET are optical sensors for pH 
determination, for e.g. in intracellular pH sensing and imaging, and have the advantages of 
being non-invasive, can be miniaturized to the nanoscale level and are shielded from electrical 
or magnetic field interferences as compared to pH sensors based on electrodes. One method of 
designing a highly sensitive FRET-based pH probe is by using a europium chelate which is 
coupled to a fluorescent near-infrared emitting pH indicator via a dodecyl spacer, resulting in a 
FRET system that is sensitive to pH changes covering a dynamic range of pH from 9 to 3 [140]. 
There exist a tremendous amount of fluorophores which can be used as donor and acceptor 
(FRET-pairs) and great care should be taken while choosing the appropriate FRET-pairs for the 
successful design of the experiments. Among the most often used fluorophores we can find 
organic dyes, fluorescent proteins, lanthanide chelates (terbium/europium complexes), quantum 
dots, and carbon nanomaterials. These materials may function as FRET donor and/or acceptors 
depending on the experimental design [9].   
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2.6.3.1 FRET-based immunoassays 
A competitive homogeneous FRET-based assay was first demonstrated by Ullman et al. in 1976 
by labeling fluorescein (donor dye) to an antigen and an antibody with rhodamine         
(acceptor dye) [141] and since then, FRET-based immunoassays have been greatly improved. 
Immunoassays based on FRET using fluorescent labels provide high selectivity and sensitivity 
by measuring the donor quenched luminescence or sensitized acceptor emission when the 
FRET-pairs are brought in close proximity due to biological recognition from large or small 
analytes (antigens) with their corresponding antibodies. Other sensing and recognition 
molecules include polymers, carbohydrates, nucleic acids, and aptamers [130]. FRET is a 
spectroscopic tool that allows measuring distances in the 1-20 nm range; hence FRET-pairs 
having large 𝑅0  should be wisely selected in order to achieve sufficient energy transfer for 
sensitive detection of biomolecules especially when large analytes are involved. As discussed in 
section 2.2, proteins contain a wide range of functional groups, and there exists many 
donor/acceptor probes modified with reactive functional groups for bioconjugation. The probes’ 
position and stoichiometry should also be considered when designing FRET experiments in 
order to be consistent in terms of reproducibility [9]. Even though sandwich assays are the 
conventional format for antigen detection, the relatively large immuno-complex can be an 
inconvenient from a FRET perspective bringing decreased energy transfer efficiency, hence 
sensitivity of the immunoassay is impacted. By using “non-traditional” FRET materials 
(“traditional” materials being organic dyes) such as colloidal QDs or lanthanide complexes, 
unique labeling strategies, or using fragmented antibodies, have been reported to improve 
energy transfer efficiency. QDs known for their high quantum yields have been used in 
combination with an Alexa Fluor dye to improve 𝑅0 for the sensitive detection of estrogen 
receptor  using monoclonal IgGs in a sandwich assay format [142]. Sub-nanomolar 
concentrations of prostate-specific antigen [25] and alpha-fetoprotein [143] were detected using  
FRET combinations of QDs and lanthanide complexes. QDs and a terbium complex in a 
homogeneous sandwich format has been recently designed for the duplexed measurement of 
EGFR/HER2 from a single sample using nanobodies and antibodies with sub-nanomolar 
detection limits [144]. Multiplexed sensitive detection, without any amplification steps, of 
micro-RNA using terbium complexes to QDs FRET was also reported [145]. Oligonucleotide 
antibody-labeling system has also been used to detect several target analyte types also in a 
homogeneous sandwich assay. Short complementary oligonucleotides (single-stranded DNA, 
ssDNA) were labeled with either a donor or an acceptor which were in turn conjugated to 
specific antibodies. Addition of the target analyte and binding of the antibodies to the epitopes 
of the target resulted in hybridization of the two ssDNA due to their close proximity [146,147].      
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2.6.3.2 Lanthanides as FRET-donor 
LLCs and UCNPs make ideal FRET-donors due to their unique photophysical properties. In 
1993, Mathis presented for the first time the use of LLCs as energy donors in a homogeneous 
FRET immunoassay [148] and since then terbium- and europium-based LLCs have been used 
greatly as FRET-donors. With extremely narrow emission bands of LLCs and UCNPs it is fairly 
easy to discriminate their luminescence from other PL signals and they are relatively less 
prone to photobleaching as compared to organic fluorescent dyes. Depending on the designed 
FRET experiments, luminescent acceptor fluorophores such as fluorescent proteins, organic 
dyes, and QDs can be paired with LLCs as donor in order to achieve large Förster distance, R0, 
(ca. 11 nm for a Tb-QD FRET-pair [125]) [149]. However, UCNPs-QD (or any suitable acceptor) 
FRET-pairs yield smaller Förster distance due to the low quantum yield of UCNPs as compared 
to LLCs (R0 < 5 nm). Lanthanide ions possess long luminescence lifetime of up to a few 
millisecond and when paired with traditional acceptor fluorophores which have generally very 
short nanosecond range lifetimes, a detector gating after pulsed excitation can efficiently 
suppress nanosecond to microsecond lifetimes of directly excited acceptors and sample 
autofluorescence, hence improving measurement accuracy and SNR. Furthermore, due to large 
difference in donor and acceptor excite-state decay times, 𝐷𝐴 =  𝐴𝐷 in the case the acceptor is 
excited by FRET via the donor. This particularity provides the same decay time analysis on the 
quenched donor and sensitized acceptor and also allows detection of sensitized emission of the 
acceptor caused by FRET. Two lanthanide ions that have been commonly used in LLCs are 
terbium and europium as a result of their strong luminescence in the visible range and 
detection with standard spectroscopy and microscopy equipment [149,150]. These Eu and Tb 
complexes have been employed in several FRET experiments for conformational changes study, 
biological binding events, DNA hybridization, and as spectroscopic ruler [149–151]. Spectral 
multiplexing is possible with LLCs as a result of their narrow and well-separated emission 
bands, and multiplexed detection of tumor markers or micro-RNA using Tb complexes as donor 
with organic dyes or QDs as acceptors in a homogeneous TR-immunoassay have been 
successfully demonstrated [11,144,145,152]. LLCs had a major impact on homogeneous and 
heterogeneous time-resolved immunoassays for biomarker detection. In commercially available 
assays we find dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) from 
PerkinElmer which is a heterogeneous TR-assay based on luminescence of europium, 
samarium and terbium chelates [153]. Among the TR-homogeneous assays we find HTRF 
(homogeneous time-resolved fluorescence) from Cisbio [154], TRACE (time-resolved amplified 
cryptate emission) from B.R.A.H.M.S and Cezanne [155], LANCE (lanthanide chelate 
excitation) from PerkinElmer [156], and LanthaScreen from ThermoFisher Scientific [157]. 
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Today, HTRF and TRACE are the routinely used technologies in medical diagnosis and high-
throughput-screening applications for the detection of different biomarkers [149]. 
UCNPs donors in most cases are coupled to organic dyes as acceptors for biosensing. UCNPs-
based DNA sensor was firstly designed by Zhang et al. in 2006 using DNA hybridization with a 
complementary DNA labeled with dye TAMRA as FRET-acceptor for the detection of target 
DNA [158]. Zhu et al. in 2014, developed a novel aptasensor for the detection of lysozyme and 
DNA based on FRET between NaYF4:Yb3+,Er3+ UCNPs as donor and a dye labeled aptamer as 
acceptor which provided nM detection limit [159]. UCNPs coupling with QDs have also been 
reported where UCNP-to-QD FRET was successfully designed for biosensing [13]. Doughan et 
al. in 2015 developed a paper-based FRET nucleic acid hybridization assay where core/shell 
UCNPs were immobilized on a paper substrate and then conjugated to ssDNA, which was 
complementary to one part of the target ssDNA. Formation of UCNP-QD FRET pairs occurred 
when solutions containing QD-ssDNA and target DNA were added on the paper substrate. 
Upon NIR excitation, Tm3+ transferred non-radiative energy to the QDs and QD PL could be 
observed due to FRET. The test was able to detect three different ssDNAs with fmol detection 
limits [160]. Another FRET bioassay involving UCNPs and QDs were designed by Mattsson et 
al. in 2016 where they used UCNP-streptavidin-biotin-QD recognition as a biological model 
system. Such model system allowed the quantification of biotin in a competitive replacement 
assay and upon 980 nm excitation, QD PL could be detected due to FRET from Er3+ ions to QDs 
having a maximum emission at 605 nm. The detected QD PL intensity was relatively low due 
to the relatively large distance between Er3+ donors and QD acceptors and low PL quantum 
yields of UCNPs but could nevertheless return very sensitive measurements of biotin in the nM 
range due to no sample autofluorescence or no PL from direct excitation of QDs at 980 nm 
[161]. Another attractive system which has great potential for sensing and imaging 
applications was reported by Lahtinen et al. in 2015, where they used NIR excitation to 
generate long-luminescence of an Eu3+-chelate (which is normally excited in UV to 
luminescence) by using Tm3+-doped UCNPs as donors which have their emission in the UV 
range. The functionality of the pair was demonstrated in a homogeneous back-titration assay 
for biotin and upon excitation at 980 nm, Tm3+ ions could transfer their energy by resonance 
energy transfer to the neighboring excited singlet state of the Eu3+ chelate antenna which 
further populated the excited energy levels of Eu3+ after intersystem crossing to the triplet 
state of the antenna. Relaxation of the excited energy levels of Eu3+ was accompanied by 
characteristic emission wavelengths of the metal ion [162]. Monitoring of pH inside cells is 
crucial as an abnormal acidic pH is usually assigned to cellular dysfunctions such as cancer 
[163]. Optical pH sensors combining UCNPs and pH-sensitive dyes represent a good alternative 
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to available pH-sensitive sensors (which are prone to photobleaching and background 
autofluorescence) for sensing and imaging of pH in biological applications. Meier et al. 
demonstrated an easy-to-fabricate pH sensor film consisting of NaYF4:Er3+,Yb3+ upconversion 
phosphors (UCP) and pH indicator neutral red (absorbing at the UCP’s green emission) 
incorporated in a hydrogel matrix. The red emission of the UCP is unaffected by the pH 
indicator and was used as a reference signal for ratiometric measurements. A hand-held digital 
camera based on a CMOS chip containing red-green-blue channels was utilized as a simple 
spectrometer for recording the green and red peak of the UCP. Upon 980 nm excitation of the 
pH sensor film, ratiometric measurement of the red to the green channel data allowed 
measuring pH in the range of 5 – 8.5, background-free, which enabled the sensor to be applied 
in strong scattering and highly autofluorescent samples such as milk and human serum. 
Maximum sensitivity with this pH sensor was observed in the pH range of 6.0 to 7.5 with a 
resolution of 0.06 pH units [164]. Arppe et al. developed a much more sensitive nanoprobe for 
sensing and imaging of intracellular pH compared to common luminescent pH indicators, with 
a dynamic pH-range of 2.5 to 7.2, and a resolution of 0.3 pH units. Their pH nanosensor was 
based on the upconversion resonance energy transfer between an aminosilane-coated 
NaYF4:Yb3+,Er3+ UCNPs and a fluorescent NHS red pH-dependent dye. Upon conjugation of 
both probes and excitation at 980 nm, ratiometric measurement could be performed by 
determining the ratio of the green upconversion emission and the sensitized emission of the 
indicator, which increased with decreasing pH. They also demonstrated the applicability of 
their pH nanosensor as a probe for ratiometric pH imaging in HeLa cells using a confocal 
fluorescence microscope [165].    
2.6.3.3 QDs as FRET-donor/acceptor 
The unique photophysical properties of QDs make them ideal FRET donors and when paired 
with appropriate donors make them excellent FRET acceptors. As FRET donors, their emission 
can be size (or composition) fine-tuned due to the confinement effect and hence optimize the 
spectral overlap and FRET efficiency with an acceptor, for e.g.  an inorganic dye, yielding larger 
Förster distance. Their narrow emission spectra allow minimizing the optical crosstalk in both 
acceptor and donor PL detection channels. Furthermore, QDs have broad absorption 
wavelength range and excitation wavelength can be chosen in order to avoid direct excitation of 
the acceptor. Different QDs can be excited at a single wavelength and their narrow PL emission 
which can be more readily deconvoluted, make them serious candidates for multiplexing. QDs 
are suitable acceptors only for a very few donor molecules. Considering that PL decay times of 
QDs (>10 ns) are usually longer than that of most organic dyes (< 5ns) and in a FRET 
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experiment upon light excitation when they are in close proximity, there will be only a very 
small population of QDs, which remain in the ground state for accepting non-radiative energy 
from a short-lived donor dye. This FRET configuration shows that QDs as acceptors are limited 
to donors having long-lived decay times (> µs) [120].  
Potential donors having long luminescent lifetimes are lanthanide based complexes or UCNPs. 
When used as donors to QD acceptors, upon pulsed excitation both donor and acceptor will be 
excited and due to their large decay time difference the majority of the lanthanide donors will 
remain in the excited state longer than the nanosecond short-lived QDs which have already 
decayed to their ground state thus enabling FRET if they are close to one another. Some 
applications of lanthanide as donors and QDs as acceptors for FRET have already been 
discussed in section 2.6.3.2. 
      
2.6.4 Measurement techniques 
Once suitable FRET-pairs have been selected with known photophysical properties and 𝑅0 
determined, detection of luminescence intensities from donor and acceptor probes during FRET 
can be measured by steady-state and/or time-resolved spectroscopy [6,135]. It should also be 
noted that the photophysical characterization of the FRET-pairs are also performed using 
steady-state and time-resolved measurements. Steady-state measurements are performed by 
continuous excitation (generally with a xenon arc lamp) at a fixed wavelength and recording of 
the emission intensities of the FRET-pairs as a function of wavelength. Full emission spectra 
measurement is achieved by scanning over the wavelength range of their emission spectra 
using usually monochromators and detection with a photomultiplier tube (PMT) in selected 
wavelength steps. The smaller the wavelength steps, the more resolute the emission profile. 
Emission (also applies to excitation) spectra need spectral correction in order to obtain the 
“true” emission profiles of a sample. The raw spectra are affected by the output of the excitation 
source, monochromator efficiency and spectral response from the detector. The corrected 
spectra are obtained by using calibration files that are unique for each spectrometer, 
monochromator, and detector which are usually built in the acquisition software by the 
manufacturer. From the corrected spectra, we can extract donor only intensities (ID), acceptor 
only intensities (IA), donor in presence of acceptor intensities (IDA) and acceptor in presence of 
donor intensities (IAD). In order to yield quantitative information, the individual spectra of the 
donor only and acceptor only (Figure 2.17 (a)) should be deconvoluted (separated)           
(Figure 2.17 (c-d)) from the FRET spectra (Figure 2.17 (b)), which can be performed by using 
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a fitting procedure by identifying the proportional contribution of the donor and acceptor to the 
donor-acceptor spectrum during FRET.  In this way we obtain correct values for ID, IA, IDA, and 
IAD, which can be substituted in Equation 2.10 for FRET efficiency and hence determination of 
distances from Equation 2.9. For spectrally well separated emission, we can use the peak 
values of ID, IA, IDA, and IAD for FRET parameters calculation [135].  
 
Figure 2.17. Representative steady-state FRET experiments involving dyes. (a) Peak normalized 
absorption (dotted) and emission (continuous) spectra of  donor and acceptor. (b) Emission spectra of 
different mixtures of donor-acceptor during FRET. Excitation of donor at 420 nm. Luminescence of donor 
is quenched by acceptor and luminescence of acceptor is sensitized in presence of donor as indicated by 
the arrows. (c) represents the deconvoluted spectra of the donor in presence of the acceptor and (d) the 
deconvoluted spectra of the acceptor in presence of the donor [135]. 
Time-resolved measurements are performed to measure luminescence decay-times or 
lifetimes of a fluorophore and represent the average time for a molecule to remain in an excited 
state before emission of a photon. Time-domain and frequency-domain measurements are the 
two dominant methods employed in time-resolved luminescence spectroscopy. After presenting 
both methods for lifetime determination and the techniques involved for photon counting 
involved in this thesis, time-resolved FRET (TR-FRET) will be presented. In time-domain 
measurements, time-dependent intensities are measured following short pulsed excitation of 
light. The pulse width should be very short and depending on the lifetime of the sample 
excitation pulse can be in nanosecond range for lasers and up to microsecond range for flash 
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lamps. Single or multiple luminescence decay times i are determined by exponential fitting of 
the photoluminescence decay curves based on Equation 2.11:        
 𝐼 =  ∑ 𝐴𝑖𝑒
−
𝑡
𝑖
𝑖
 (2.11) 
where I is the luminescence intensity;  
Ai is the amplitude for different i; 
 i is the different decay times. 
When luminescence decay is multi-exponential, each decay time is weighted by the 
corresponding fractional intensity or amplitudes and are referred as intensity-averaged or 
amplitude-average lifetime respectively. Depending on the phenomenon under study, intensity-
average lifetime (<>Int, Equation 2.12) is used for the calculation of an average collisional 
quenching constant, whereas amplitude-average lifetime (<>Amp, Equation 2.13) is used for 
the calculation of FRET efficiency in FRET experiments. 
 <  >𝐼𝑛𝑡 =  
∑ 𝐴𝑖𝑖
2
∑ 𝐴𝑖𝑖
 (2.12) 
 
 <  >𝐴𝑚𝑝 =  
∑ 𝐴𝑖𝑖
∑ 𝐴𝑖
 (2.13) 
 
Frequency-domain method relies on the excitation of a sample with intensity-modulated 
light, which is typically a sine-wave modulation, at a frequency 𝑓. The light emitted from the 
sample follows the modulation frequency, which is defined as =

2𝜋
 , with  being the angular 
modulation frequency, but with a time delay usually called phase shift or phase angle and 
partially demodulated with respect to the excitation. Suppose the sample is excited by an 
intensity–modulated light source, 𝐼 =  𝐼𝑎𝑣(𝑒𝑥) + 𝐼𝑝(𝑒𝑥) cos(𝑡), then the emitted light will be 
𝐼 =  𝐼𝑎𝑣(𝑒𝑚) +  𝐼𝑝(𝑒𝑚) cos(𝑡 − 𝜙); where Iav(ex) and Iav(em) are the average intensity of 
excitation and emission, respectively. Ip(ex) and Ip(em) are the amplitude or peak of the 
intensity oscillations of excitation and emission, respectively, and ϕ the phase shift. The 
demodulation is expressed as modulation ratio M =  
𝐼𝑝(𝑒𝑚)
𝐼𝑎𝑣(𝑒𝑚)
𝐼𝑝(𝑒𝑥)
𝐼𝑎𝑣(𝑒𝑥)
 , and both ϕ and M characterize the 
harmonic response of the fluorophore which can be used to calculate single or multiple 
lifetimes. The mathematical relation between phase shift, modulation ratio and lifetimes are 
defined by Equations 2.14 and 2.15 with 𝛼𝑖 being the pre-exponential factors (or amplitudes): 
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𝜙 =  tan−1 (
∑ (𝛼𝑖𝜔𝜏𝑖
2) (1 +  𝜔2𝜏𝑖
2)⁄𝑖
∑ (𝛼𝑖𝜏𝑖) (1 +  𝜔
2𝜏𝑖
2)⁄𝑖
) 
(2.14) 
 
 
 
𝑀 =  √
[(∑ (𝛼𝑖𝜔𝜏𝑖
2) (1 +  𝜔2𝜏𝑖
2)⁄𝑖
2
+  ∑ (𝛼𝑖𝜏𝑖) (1 +  𝜔
2𝜏𝑖
2)⁄𝑖
2
 )]
(∑ 𝛼𝑖𝜏𝑖𝑖 )
2
 (2.15) 
Response curves (decay curves) generated for the time-domain and frequency-domain are fitted 
using the least-square method by varying the fitting parameters Ai, 𝛼𝑖 and 𝑖 in         
Equations 2.11-2.15 until a best fit is obtained between the experimental data and the 
mathematical fit values. In the case of short lifetimes (in the nanosecond range), a 
deconvolution of the instrument response function (IRF) to the measured fluorescence decay 
curve is necessary in time-domain measurements in order to extract the “true” lifetime of the 
sample whilst no deconvolution is necessary for frequency-domain measurements as the data 
are directly analyzed in the frequency domain [6,132,135]. IRF depends on the shape of the 
excitation pulse and the instrumentation used to detect the pulse. The IRF is recorded under 
the same measuring conditions as the fluorescence decay curve by using a scattering solution 
such as Ludox which is a colloidal silica solution or water [6,132]. The measured IRF is thus 
the convolution of the response from the detector, the electronic response time of the 
acquisition system and the laser pulse duration. Similarly, the acquired fluorescence decay 
curve is the convolution of the real exponential decay with the IRF. A deconvolution process is 
then performed using the least-square method in order to obtain the best fit to the model decay 
and then comparing the fit to the experimental decay curve hence extracting the “true” 
lifetimes of the sample. It should be noted that the term “deconvolution” is not mathematically 
exact in this context as the fitting procedure used by most fitting programs is achieved using 
iterative reconvolution with least-square analysis [6,166]. The model for performing the multi-
exponential fits with reconvolution is given by Equation 2.16:  
 𝐼(𝑡) =  ∫ 𝐼𝑅𝐹(𝑡′) ∑ 𝐴𝑖𝑒
−
𝑡−𝑡′
𝑖 𝑑𝑡′
𝑖
𝑡
−∞
 (2.16) 
where t’ is the fitting starting point               
Figure 2.18 and Figure 2.19 show the measurement of decay curves in the time-domain and 
frequency-domain. A “deconvolution” is needed in time-domain in order to extract the lifetimes 
of the fluorophore whereas in frequency-domain no deconvolution is necessary.  
Measurements of lifetime in the frequency domain are compatible with tunable continuous-
wave excitation sources and lifetimes in the ps range can be rapidly determined. In time-
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domain, the decay curves are acquired by excitation with pulsed sources such as pulsed diode 
lasers. Depending on the lifetime of the fluorophore, the photons arriving at the detector can be 
counted by several techniques such as steady-state photon counting, gated photon counting, 
multichannel scalers (MCS), and time correlated single photon counting (TCSPC) [167]. In this 
thesis we chose to use the time-domain method for temporal characterization of the FRET-pairs 
using MCS and TCSPC as counting techniques.  
 
Figure 2.18. (Black) Multi-exponential decay curve of a QD sample emitting at 605 nm when excited by 
a pulsed laser at 405 nm. (Red) Instrument response function (IRF) measured at excitation wavelength 
of 405 nm. "Deconvolution" of the 2 curves resulted in a typical lifetime of QDs with <>amp = 4.8 ns. 
 
Figure 2.19. Frequency domain measurements for the determination of luminescence lifetimes. In this 
simulated graph, the sample is excited at an intensity modulated frequency of 80 MHz (black curve). The 
emission profile is displayed in grey and calculation of ϕ and M gives an average lifetime of 2 ns [135].  
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Multichannel Scalers (MCS) are able to count several photons per signal period. All incoming 
photons are counted within subsequent time intervals and stored in channels of a fast data 
memory. Each sequence or sweep is started in the memory by a trigger pulse and is 
synchronized with the period of the optical signal. A waveform is generated as a result of the 
numerous photons arriving at the photomultiplier tube (PMT) and the waveform of repetitive 
emitted signals can therefore be accumulated over many signal periods to improve data quality. 
A histogram of counts as a function of time is constructed (Figure 2.20). MCS however are not 
fast enough to record fluorescence lifetimes which are in the ns range due to its channel width 
but are excellent solution for long luminescence lifetime measurements in the microsecond to 
second range [168]. We will use this counting technique for TR-FRET experiments and 
characterization of our donor, which is a lanthanide complex of Tb. Figure 2.20 represents the 
principle of a multichannel scaler.  
 
Figure 2.20. Principle of a multichannel scaler where several photons per signal period are recorded and 
the direct accumulation of the photons in high speed memory allows the creation of a histogram of counts 
versus time  [167]. 
Time correlated single photon counting (TCSPC) is another counting technique for the 
counting of single photons per excitation pulse. The probability of detecting one photon at time 
t after pulsed excitation is directly proportional to the fluorescence intensity at that time. The 
generation of a single photon or an empty cycle is a completely random process and is described 
in terms of probabilities (Figure 2.21). This counting technique can be compared to a 
stopwatch where the reference for the timing (start time) is the excitation pulse and when a 
single photon is detected (stop time) by a single photon sensitive PMT (or by micro channel 
plate detector; single photon avalanche diode detector), this photon count is stored in one 
memory cell of the TCSPC electronics card for one corresponding time bin. The recording of 
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numerous single photons after timing is performed over a large number of exciting pulses and a 
histogram of counts versus time is constructed (Figure 2.22). Figure 2.21 represents the 
timing technique for recording a single photon per excitation pulse.   
 
Figure 2.21. Analogy to a stopwatch with start/stop times, which represents the timing technique for 
recording a single photon per excitation pulse. Laser pulse triggers a start condition, and generation with 
detection of a photon per laser pulse produce the stop condition [169].  
 
Figure 2.22. A histogram of counts in function of time is created when sufficient counts have been 
collected and is used for lifetime analysis [169]. 
In order to build a histogram based on single photon counting, the average count rate at the 
detector must be in the range between 1 to 5% of the excitation rate, if not more than one 
photon can occur during one excitation cycle and the detector will record the first photon but 
will miss the following ones due to most of single photon counting detectors and TCSPC 
electronics have a “dead-time” after recording a photon. This “dead-time” usually lasts pico to 
nanoseconds where no events can be processed and a pileup effect would appear if more than 
one photon is generated in one excitation cycle which would distort the counting statistics, 
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thereby leading to an over-representation of early photons in the histogram and causing the 
decay times to be shorter [168,169]. This pileup effect is represented in Figure 2.23. For 
TCSPC measurements we used a compact single photon sensitive PMA Hybrid -40 detector, 
based on a fast hybrid photomultiplier tube, from PicoQuant with a spectral response ranging 
between 300-720 nm and a dead-time of typically 600 ps.   
 
Figure 2.23. (Left) Representation of the pileup effects with the occurrence of more than one photon per 
excitation rate and dead time of the detector and TCSPC electronics. (Right) Distortion of the decay 
curves due to the pileup effect causing shorter decay than it actually is [169]. 
TCSPC makes use of high repetition signal rates and with their time bin in the ps range, 
fluorescence lifetimes can be measured in the nanosecond range. We will use this technique to 
measure the lifetimes of the acceptor molecules which are quantum dots.  
2.6.5 Time-resolved FRET   
The development of fluorescence FRET assays with time-resolved measurements provided 
great improvement in normal fluorescence immunoassays. Time-resolved measurements were 
made possible in FRET assays due to the utilization of rare-earth lanthanides as FRET-donors 
with long-lived emission decay times which are usually of the order of millisecond as compared 
to traditional donor dyes which have nanosecond fluorescence lifetimes. When engaged in TR-
FRET after a short pulsed excitation, the excited long-lived donor will transfer energy non-
radiatively to a short-lived acceptor in close proximity, resulting in donor lifetime quenching 
and a long-lived fluorescence (sensitization) of the acceptor. The signals can be integrated for a 
period of time by applying a time-gated window after pulsed excitation, hence measuring 
fluorescence associated only with the emission of the donor and only from the acceptor that 
participated in FRET. This time-gated window can be varied depending on the experiment in 
order to optimize the signal-to-noise ratio. In an assay involving biomolecules and complex 
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matrix like serum, TR-FRET significantly allows performing highly sensitive detection of the 
analyte as by delaying the time (ca. between 50-150 µs) between light excitation and 
fluorescence measurement, we are able to eliminate any short-lived autofluorescence from the 
biological media/samples and from directly excited acceptor molecules not participating in 
FRET. Figure 2.24 shows the principle of time-gated FRET detection after pulsed excitation. 
Furthermore, the ratiometric format (FRET-ratio), by analyzing the time-gated 
photoluminescence (PL) intensities of the FRET-pairs in presence of FRET at two different 
wavelengths, can be very advantageous for analytical applications as they offer an 
instantaneous suppression of sample and excitation source fluctuations. The FRET-ratio is 
proportional to the concentration of the analyte. In our TR-FRET immunoassays, we will use a 
lanthanide complex of terbium (Tb) as FRET-donor with a decay time of ca. 2.6 ms and 
quantum dots as FRET-acceptor with lifetimes ranging from 6 to 90 ns. The time-gated PL 
intensities obtained from 100 flashes for Tb (ITG(Tb)) and QDs (ITG(QD) when engaged in FRET 
were used to calculate the FRET-ratio (Equation 2.18) using a temporal detection window of 
800 µs after a time delay of 100 µs after pulsed excitation. In this particular FRET case with 
𝜂𝐹𝑅𝐸𝑇 < 90 %, the quenched PL lifetime of the Tb donor is still much longer than the 
fluorescence lifetime of the QDs, and therefore the decay time of the donor in presence of the 
acceptor and the lifetime of the acceptor in presence of the donor are equal (𝐷𝐴 =  𝐴𝐷) 
[10,135,170]. Equation 2.10 can then be written as Equation 2.17: 
 𝜂𝐹𝑅𝐸𝑇 = 1 −  
𝐷𝐴
𝐷
= 1 −  
𝐴𝐷
𝐷
 (2.17) 
    
 𝐹𝑅𝐸𝑇 − 𝑟𝑎𝑡𝑖𝑜 =  
𝐼𝑇𝐺(𝑄𝐷)100−900 µ𝑠
𝐼𝑇𝐺(𝑇𝑏)100−900 µ𝑠
 (2.18) 
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Figure 2.24. Principle of time-gated FRET detection. PL intensity after pulsed excitation is plotted as a 
function of time (logarithmic scale). FRET quenching of Ln donor results in a reduced decay time (green 
dots) and FRET sensitization of the QD acceptor results in an increased decay time (red dots), which 
equals the one of FRET-quenched Ln PL (0.5 ms in this example). Time-gated detection allows for 
measuring both PL signals (Ln and QD) in two spectrally separated detection channels (green and red) to 
completely suppress autofluorescence background and QD PL from direct light excitation. Decay time (τ) 
and FRET-efficiency (EFRET) values were arbitrarily chosen but are representative values for Ln-to-QD 
FRET [13]. 
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3. Terbium to commercial QDs FRET immunoassays 
for PSA detection 
S. Bhuckory, O. Lefebvre, X. Qiu, K. D. Wegner, and N. Hildebrandt. Evaluating quantum dot performance in 
homogeneous FRET immunoassays for prostate specific antigen. Sensors 2016, 16(2), 197. 
3.1 Introduction 
Over the last two decades QDs have become one of the most attractive nanomaterials for 
fluorescence-based biosensing [23,24]. Despite the advantages mentioned in section 2.4, QDs 
have still not become standard fluorophores for diagnostic applications. Toxicity issues have 
been largely resolved by the application of appropriate surface coatings so that their 
application in in vitro diagnostics is not hampered by that issue. However, one of the main 
problems remains a widely applicable, reproducible and stable bioconjugation that allows a full 
exploitation of both the photophysical advantages of the QDs and the complete functionality of 
the biological recognition molecule. In particular for homogeneous immunoassays (in which two 
different fluorescently labeled primary antibodies bind to a biomarker of interest to induce a 
close proximity between the antibodies and a concomitant FRET between their respective 
fluorophores) the relatively large dimensions of the biological recognition system that contains 
antibodies, biomarkers, and a QD nanoparticle have limited the application of QDs [10]. One 
possibility to overcome the large distances in homogeneous FRET immunoassays and to provide 
at the same time high sensitivity and multiplexing capability is the use of luminescent terbium 
complexes as FRET donors for QD acceptors (section 2.6.3.2 & 2.6.3.3, respectively). 
Oligonucleotide-based hybridization assays for the detection of DNA or RNA have the 
advantage that the hybridization strategy allows the design of shorter donor-acceptor distances 
and recent results have demonstrated the sensitive and multiplexed detection of different 
microRNAs using Tb-to-dye and Tb-to-QD FRET [145,152]. As the binding sites of antibodies to 
their antigens are well-defined and the Y-shaped IgG antibodies have a length of ca. 10 nm, the 
design of efficient FRET systems using QDs is significantly more difficult. To date, Tb-to-dye 
FRET immunoassays have been demonstrated for the multiplexed detection of up to five 
different tumor markers [11], but the application of Tb-to-QD FRET has so far been limited to 
the detection of single antigens using self-synthesized QDs for the detection of                   
alpha-fetoprotein (AFP) and carcinoembryonic antigen (CEA) in buffered solution [143,171] or 
commercial QD-antibody conjugation kits (eFluor nanocrystal antibody conjugation kits, 
Affymetrix/eBioscience, which are unfortunately not available anymore) for the detection of 
prostate specific antigen (PSA) or the epidermal growth factor receptor (EGFR) [25,172]. 
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Probably the most frequently applied types of QDs are Qdots from Life Technologies, but so far 
only one study showed their use in Tb-to-QD FRET immunoassays for the detection of CEA 
[150]. Within that study only a single QD color was used and the QD-antibody conjugates were 
prepared by a costly custom labeling performed at the Invitrogen laboratories. 
In this contribution, we demonstrate the general applicability of multicolor Tb-to-QD FRET 
immunoassays using standard in-stock Qdot ITK amino PEG QDs (Life Technologies) with PL 
maxima at 605, 655, and 705 nm, respectively, and a commercial Lumi4-Tb complex 
(Lumiphore). We have developed a standard procedure of conjugating these QDs via           
sulfo-EMCS crosslinkers to sulfhydryl groups of F(ab) antibodies (ABs) and show the successful 
application of these different QD-AB conjugates in homogeneous Tb-to-QD FRET assays 
against PSA. We also present a detailed photophysical analysis of the QD-AB and Tb-AB 
bioconjugates and their FRET properties and show that the Tb-QD FRET-pair with the largest 
Förster distance and the lowest Tb PL background (Qdot705) also provides the highest 
sensitivity (lowest limit of detection) compared to the FRET-pairs using Qdot655 (second best) 
and Qdot605. Multiplexing capability was shown by a duplexed detection of PSA using the Tb-
Qdot655 and Tb-Qdot705 FRET-pairs. Our results will be of high importance for the 
development of QD-FRET acceptor-based immunoassays against different biomarkers 
(Chapter 5). 
 
3.2 Materials and Methods 
3.2.1 Materials 
Qdot® ITK™ amino PEG 605, 655, and 705 (QD605, QD655, and QD705) were purchased from 
Life Technologies/Thermo Fisher Scientific and possess amine-derivatized polyethylene glycol 
(PEG) ligands covalently attached to the amphiphilic coating rendering them water soluble and 
compatible for the attachment of biomolecules. The reactive amino groups of the ligand allow 
for the attachment of biomolecules via N-hydroxysuccinimide (NHS) ester conjugation. The 
NHS-activated terbium complex Lumi4-Tb was kindly provided by Lumiphore in lyophilized 
form. Prostate specific antigen (PSA) and monoclonal primary antibodies against PSA (IgGs 
“PSR222” and “PSS233”) were provided by Cezanne/Thermo Fisher (Nîmes, France). IgGs were 
fragmented to F(ab) using a Pierce™ Mouse IgG F(ab′) F(ab′)2 preparation kit and following the 
instructions provided by the supplier (Thermo Fisher Scientific) and the SDS-PAGE of the 
fragmentation is shown in Appendix 8.2.3. Bovine calf serum was provided by 
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Cezanne/Thermo Fisher Scientific. Sulfo-EMCS (a water-soluble heterobifunctional amine-to-
sulfhydryl cross-linker that contains NHS ester on one end and a maleimide reactive group on 
the other end) used to transform the amino-reactive QDs into maleimide-reactive QDs was 
purchased from Sigma-Aldrich. Bovine serum albumin (BSA), Tris(hydroxylmethyl)-
aminomethane (TRIS/Cl), sodium tetraborate (borate), phosphate buffer saline (PBS) and 
Tris(2-carboxyethyl)phosphine (TCEP) were also purchased from Sigma-Aldrich.  
3.2.2 Methods 
3.2.2.1 Tb-AB conjugation 
Lumi4-Tb-NHS was reacted in molar excess to available primary amines of the IgG (“PSR222”) 
antibodies by mixing both solutions in carbonate buffer (pH 9). The mixtures were incubated 
for 2 h at room temperature while rotating at 30 rpm using an ELMI Intelli-Mixer. The IgG-Tb 
conjugates (Figure 3.1) were purified and washed 4 times with 100 mM TRIS/Cl pH 7.4 using 
50 kDa molecular weight cut-off (MWCO) spin columns from Millipore, to remove the unbound 
Tb-complex. The purified conjugate was stored at 4 °C. 
 
 
 
 
 
3.2.2.2 QD-AB conjugation 
Conjugation of F(ab) to the QDs was performed using sulfo-EMCS crosslinkers. To receive 
maleimide-reactive QDs a several-fold molar excess of sulfo-EMCS was mixed and incubated in 
1xPBS buffer (pH 7.4) with the QDs for 30 min at room temperature while rotating at 30 rpm 
using an Intelli-Mixer. Disulfide bonds (S-S) on the F(ab) were reduced to sulfhydryls (S-H) 
using 30 min of incubation (rotating at 30 rpm) with 5 mM of Tris(2-carboxyethyl)phosphine 
(TCEP) in 1x PBS buffer (pH 7.4). Maleimide-activated QDs and F(ab)-SH were purified using 
Zeba 7K desalting columns to remove excess cross-linkers and reducing agent, respectively. For 
the final F(ab)-QD conjugation step both desalted solutions were mixed and incubated for 4 h at 
room temperature in the dark while rotating at 30 rpm. Unbound F(ab) was separated from the 
conjugation mixture using a 100 kDa MWCO spin column from Millipore by washing four times 
Figure 3.1. Random labeling via NHS coupling of Lumi4Tb-NHS to available primary amines of 
PSR222 in carbonate buffer pH 9. 
Excess Tb-NHS 
Carbonate buffer pH 9.0 
2hr incubation . . . . . 
. . . . . 
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with 100 mM borate buffer (pH 8.4). Purified conjugates were centrifuged at 4000 g and 
supernatants were taken and stored at 4 °C. The QD-antibody conjugation procedure is 
presented in Scheme 3.1. 
 
Scheme 3.1. F(ab) conjugation of QD605, QD655, and QD705 was performed by transferring the amine-
reactive QDs to maleimide-reactive QDs (mal-QD) using a sulfo-EMCS crosslinker (left). IgG was 
fragmented to F(ab) using a commercial fragmentation kit. The available disulfides on the F(ab) were 
reduced to sulfhydryls, which allowed a conjugation to the mal-QDs. 
3.2.2.3 Photophysical characterization 
Absorption spectra were acquired using a Lambda 35 UV/Vis spectrophotometer from Perkin 
Elmer. Photoluminecence (PL) spectra and decay curves were recorded on a FluoTime 300 
lifetime fluorescence spectrometer from PicoQuant using as excitation sources a continuous-
wave Xe lamp for spectra acquisition, a Xe flash lamp (100 Hz repetition rate) for Tb decay 
curves, and a 405 nm diode laser (Edinburgh Instruments) for QD decay curves. Tb-conjugates 
and QD-conjugates were measured in 100 mM TRIS/Cl buffer (pH 7.4) and 100 mM borate 
buffer (pH 8.4) respectively.  
3.2.2.4 FRET characterization and immunoassays 
The Förster distances (R0, distance at which FRET efficiency is 50%) of the different Tb-QD 
FRET-pairs were calculated using Equations 2.5 and 2.6. All homogeneous Tb-QD FRET 
immunoassays were measured on a modified KRYPTOR Compact Plus (Cezanne/Thermo 
Fisher) clinical fluorescence plate reader. Time-gated PL intensities of the Tb donor (donor 
detection channel ChD) and the QD acceptors (accepter detection channel ChA) were collected 
simultaneously in a time window from 100 to 900 µs after pulsed excitation using an integrated 
nitrogen laser operating at 20 Hz. Spectral separation in the detection channels was performed 
by optical bandpass filters: 494 ± 10 nm (Semrock) for Tb, 607 ± 4 nm (Delta) for QD605, 660 ± 
6.5 nm (Semrock) for QD655 and 707 ± 8 nm (Semrock) for QD705 . The time-gated PL 
intensities from ChD (ITG(Tb)) and ChA (ITG(QD)) were used to calculate a time-gated       
FRET-ratio by Equation 2.18.  
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Within all immunoassays the Tb-AB and QD-AB were dissolved in 10 mM TRIS/Cl buffer     
(pH 7.4) containing 0.5% BSA and their concentrations were kept constant (3 nM) while the 
antigen (PSA) concentrations were increased. This induced an increase in Tb-to-QD FRET-
pairs with increasing PSA concentration and lead to a typical FRET immunoassay calibration 
curve for which the FRET signal increased with biomarker concentration. 
 
3.3 Results and discussion 
In a previous study (using eBioscience QD-AB conjugation kits) we showed that sulfhydryl-
based conjugation to maleimide-reactive QDs led to functional QD-AB conjugates that could be 
successfully used in homogeneous immunoassays [25,172]. Because the eBioscience QD-AB-
conjugation kits are unfortunately not sold anymore and maleimide-reactive QDs are not sold 
by Life Technologies either, we transferred the amine-reactive QDs into a maleimide-reactive 
form using a sulfo-EMCS crosslinker (NHS-to-maleimide). The maleimide-reactive QDs could 
then be conjugated with F(ab) antibody fragments, which had shown to be advantageous for 
FRET immunoassays due to their smaller size and the higher amount of ABs per QD [25]. 
Nevertheless, IgGs were conjugated to QD705 using the same conjugated method as for F(ab) 
and tested in a FRET immunoassay against PSA but yielded no exploitable calibration curves 
for quantitative analysis due to the almost negligible FRET signal as it can be witnessed in 
Figure 3.2. 
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Figure 3.2. PSA immunoassay calibration curve for the detection of TPSA using Tb-QD705 IgG conjugates. 
Although a small increase in FRET-ratio is observable at higher concentration of TPSA, the data are not exploitable 
for statistical analysis due to the negligible FRET-ratio increase.  
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Another important aspect of our investigation was the performance evaluation of QDs with 
different PL emission wavelengths (QD605, QD655, and QD705). This evaluation is very 
important for their application as acceptors in FRET assays with Tb donors because the 
variations in shapes, sizes, spectral overlap (QD absorption with Tb emission), and PL 
wavelength range lead to differences in FRET and detection efficiencies, which can result in 
significant differences in sensitivity. Therefore a careful photophysical characterization and 
sensitivity evaluation within comparable immunoassays for the same antigen are indispensable 
for designing and optimizing such homogeneous FRET immunoassays, in particular for 
multiplexed detection with different QD colors. The following paragraphs will discuss the 
photophysical properties of the assay constituents (Tb and QD AB-conjugates) and show their 
performance in Tb-QD FRET immunoassays for the detection of PSA in low volume serum 
samples. 
3.3.1 Tb and QD AB conjugates and Tb-QD FRET-pairs 
Tb concentrations were calculated using Beer-Lambert’s law with a molar absorptivity 
(extinction coefficient) of 26,000 M−1·cm−1 at the absorption maximum of 340 nm. AB 
concentration was determined at 280 nm using a molar absorptivity of 210,000 M−1·cm−1. A 
labeling ratio of 6 Tb per PSR222 IgG was determined by linear combination of the respective 
absorbance spectra of Tb and AB to fit the spectrum of the Tb-AB conjugate Figure 3.3 A. 
Excitation of the Tb-AB conjugates in the absorption band of Tb (between ca. 300 and 400 nm) 
led to the typical Tb3+ PL spectrum (Figure 3.3 A) and a nearly mono-exponential PL decay 
with an average decay time of 2.6 ± 0.2 ms (Figure 3.3 B). 
 
Figure 3.3. Optical characterizations of Tb-AB conjugates. (A) Absorption spectrum (dotted line) of the 
Tb-AB conjugate, of which the Tb peak at 340 nm and the AB peak at 280 nm were used to calculate the 
Tb per AB labeling ratio. The PL spectrum (solid line) was acquired upon excitation in the Tb absorption 
band (365 ± 2 nm); (B) Pulsed (Xe flash lamp at 100 Hz) excitation (360 ± 2 nm) was used to measure the 
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PL decay at 490.0±0.5 nm. The slightly bi-exponential decay curve (τ1 = 0.4 ± 0.3 ms, τ2 = 2.70 ± 0.02 ms) 
gave an amplitude-averaged decay time of τ(Tb) = 2.6 ± 0.2 ms. 
QD concentrations were calculated using the QDs’ molar absorptivities at 405 nm    
(ε405(QD605) = 2.8 × 106 M−1·cm−1, ε405(QD655) = 5.7 × 106 M−1·cm−1, ε405(QD705) = 8.3 × 106 
M−1·cm−1). ABs per QD labeling ratios of 5 PSS233 F(ab) per QD605, 8 PSS233 F(ab) per 
QD655, and 6 PSS233 F(ab) per QD705 were determined by linear combination of the 
respective absorbance spectra of QDs and AB to fit the spectrum of the QD-AB conjugates 
(molar absorptivity of ABs used to calculate labeling ratios was ε280(ABs) = 70,000 M−1·cm−1). 
The different QD absorption and PL spectra as well as their PL decay curves are shown in 
Figure 3.4. 
The QD PL spectra were selected to fit in between (for QD605 and QD655) or beyond (for 
QD705) the Tb PL bands. This allows a detection of the QD PL with a low PL background of Tb. 
The PL decays of all QDs are multi-exponential with amplitude averaged decay times of         
6.3 ± 1.2 ns for QD605, 14.0 ± 0.9 ns for QD655, and 80.0 ± 3.0 ns for QD705. Due to the large 
difference in excited-state lifetimes of Tb and QD (ca. 50,000 times longer for Tb) the FRET-
quenched PL decay time of Tb equals the FRET-sensitized PL decay time of the QD [2,12]. 
Therefore time-gated FRET detection can be performed using the different QD PL wavelengths. 
The spectral overlap integrals (Equation (2.6)) and the Förster distances (Equation (2.5)) 
were calculated using the QD molar absorptivity spectra and the Tb PL spectrum. As expected 
from the spectral overlaps in Figure 3.4 A the Tb-QD705 FRET-pair provided the largest 
Förster distance (R0 = 11.2 ± 0.6 nm), followed by the Tb-QD655 FRET-pair (R0 = 10.5 ± 0.5 
nm), and the Tb-QD605 FRET-pair (R0 = 8.8 ± 0.4 nm). Considering that FRET should still be 
detectable at distances of up to ca. 2R0, all Tb-QD systems should be able to provide at least 
measurable QD-FRET sensitization within the [QD-AB]-PSA-[Tb-AB] binding system, even 
with the thick QD polymer coatings, which extend the QDs to diameters of ca. 16, 20, and 21 
nm for QD605, QD655 and QD705, respectively (as provided by the supplier). 
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Figure 3.4. Optical characterizations of QD-AB conjugates. (A) Absorption (dotted lines) and PL (solid 
lines) of QD605 (blue), QD655 (green) and QD705 (red). To show the spectral overlap between Tb 
emission and QD absorption and the differences in PL wavelengths also the Tb PL spectrum is shown 
(gray spectrum in the background). Förster distances were calculated as R0(QD605) = 8.8 ± 0.4 nm, 
R0(QD655) = 10.5 ± 0.5 nm, and R0(QD705) = 11.2 ± 0.6 nm; (B) Pulsed (405 nm diode laser at 1 MHz) 
excitation was used to measure the PL decay curves at the respective PL peaks of the QDs. The multi-
exponential decay curves (same colors as in (A) gave amplitude-averaged decay times of                
τ(QD605) = 6.3 ± 1.2 ns, τ(QD655) = 14.0 ± 0.9 ns, and τ(QD705) = 80.0 ± 3.0 ns. 
3.3.2 Homogeneous Time-Resolved FRET immunoassay 
To compare the performance of the different Tb-QD FRET-pairs for homogeneous 
immunoassays, fixed volumes of serum samples spiked with increasing concentrations of PSA 
(from 0.05 to 4.0 nM) were added to fixed volumes of assay solutions containing constant 
concentrations of Tb-AB and QD-AB conjugates. Both the time-gated Tb and QD PL intensities 
were measured and the FRET-ratio (Equation (2.18)) was plotted as a function of PSA 
concentration as shown in Figure 3.5. Although the FRET-ratio increases were relatively 
small (ca. 1.2, 1.3, and 3.5 from 0 to 4 nM PSA for Tb-QD605, Tb-QD655, and Tb-QD705, 
respectively) they were still very significant and the many different concentrations measured 
showed a clear increase of FRET ratio over PSA concentration, as expected for an assay 
calibration curve. Also the expected saturation becomes visible at PSA concentrations 
corresponding to those of the Tb-ABs (3 nM). The absolute values of the FRET-ratio are 
smallest for the Tb-QD705 pair, followed by Tb-QD605 and Tb-QD655. This was expected as 
the Tb PL background in the different QD detection channels follows a similar trend       
(QD705 < QD605 < QD655). The strongest relative increase is again measured for the            
Tb-QD705 FRET-pair, due the most efficient FRET. Tb-QD655 and Tb-QD605 have similar 
relative FRET-ratio increases although the Förster distance is smaller for QD605. In this case, 
the significantly smaller size of the QD605 compared to the QD655 compensates the smaller 
Förster distance. 
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To compare the sensitivity of the Tb-to-QD FRET pairs the limits of detection (LODs) were 
calculated using the calibration curves in Figure 3.5, the standard deviation of 30 
measurements of samples without any PSA (zero concentration) and Equation 2.3. All three 
FRET systems provide sub-nanomolar LODs and as expected from the previous performance 
results the Tb-to-QD705 FRET assay yields the lowest LOD. Although the relative increase of 
the Tb-QD605 and Tb-QD655 calibration curves is very similar, the QD655 system has an 
almost 6-fold lower LOD. This is caused by the larger relative errors of the time-gated PL 
intensities in the QD605 channel compared to the QD655 channel. The LODs for PSA (and also 
the conjugation ratios and Förster distances) are summarized in Table 3.1. Taking into 
account a clinical cut-off concentration of 4 ng/mL for PSA [173], QD655 and QD705 provide 
sufficiently low LODs, whereas the QD605 LOD is too high for clinically relevant PSA 
concentrations. Nevertheless, the comparison of LODs for the same biomarker (PSA) is highly 
important because the relative comparison provides an important guidance for the development 
of multiplexed diagnostic kits. As most biomarkers have different clinical cut-off values QD705 
should be used for the biomarker with the lowest cut-off and QD605 for the one with the 
highest cut-off. An important finding is that all Tb-QD FRET pairs provide LODs in a 
concentration range that is clinically relevant and that the 50 µL serum samples present 
clinically relevant solutions. Therefore our results present an important step toward the 
development of QD-based multiplexed homogeneous FRET immunoassays for their application 
in clinical diagnostics.  
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Figure 3.5. PSA immunoassay calibration curves of the different Tb-QD FRET systems using QD605 
(A); QD655 (B); and QD705 (C). Bottom abscissae give total PSA (TPSA) concentrations in nM, top 
abscissae give TPSA concentration in ng/mL. LODs were determined using the linear parts of the 
calibration curves (solid lines) and the standard deviation of the FRET-ratio at zero TPSA concentration 
(Equation (2.3)) 
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Table 3.1. Overview of Tb and QD AB conjugation ratios, Förster distances R0, and limits of detection 
(LOD) of PSA immunoassays using the three different FRET pairs. 
Donor-AB Tb/AB Acceptor-AB AB/QD R0 (nm) LOD (nM) LOD (ng/mL) 
Tb-IgG 6 ± 1 
QD605-F(ab) 5 ± 2 8.8 ± 0.4 0.71 ± 0.07 23 ± 2 
QD655-F(ab) 8 ± 3 10.5 ± 0.5 0.12 ± 0.01 3.7 ± 0.4 
QD705-F(ab) 6 ± 2 11.2 ± 0.6 0.06 ± 0.01 2.0 ± 0.3 
 
3.3.3 Duplexed Tb-to-QD FRET immunoassay 
In order to demonstrate the ability of multiplexed detection using different Tb-QD FRET-pairs 
we prepared a duplexed PSA immunoassay that contained the two QD-AB conjugates with the 
lowest LODs (Tb-QD655 and Tb-QD705). Conjugation ratios for these Tb and QD AB 
conjugates were 7 Tb per PSS233 IgG, 49 PSR222 F(ab) per QD655, and 48 PSR222 F(ab) per 
QD705. A high labeling ratio for these two QD-AB conjugates, as compared to those mentioned 
in Table 3.1, can be due to the larger molar excess of F(ab) that were conjugated to the QDs. 
The same experimental parameters and concentration of the QD-AB and Tb-AB conjugates 
were used as within the singleplex assays. However, for the duplexed assays the FRET ratios of 
both Tb-QD FRET-pairs were measured from the same samples for each PSA concentration. 
Figure 3.6 shows the assay calibration curves (relative FRET ratios as a function of PSA 
concentration) for both Tb-QD655 (green) and Tb-QD705 (red) FRET-pairs. These calibration 
curves show the same trends as the single Tb-QD FRET-pair assays in Figure 3.5, namely a 
linear increase of the FRET-ratios until ca. 3 nM PSA, after which the FRET-ratio levels off 
because of a saturation of Tb-AB conjugates (3 nM). These similar trends of the single and 
duplexed calibration curves demonstrate the capability of using our Tb-QD FRET 
immunoassays for multiplexed detection. 
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Figure 3.6. PSA immunoassay calibration curves for the detection of TPSA in a duplexed detection 
format using the Tb-QD655 (green) and Tb-QD705 (red) FRET-ratios measured from the same samples 
(for each concentration) that contained both QD655 and QD705 AB conjugates. 
 
3.4 Conclusions 
We have successfully tested the performance of three commercially available QDs – from Life 
Technologies – possessing a thick polymer PEG coating and surface amino functionalized in 
homogeneous FRET immunoassays. The development of a generic and easily applicable        
AB-conjugation method to the QDs yielded successful labeling with fragmented F(ab) ABs 
against PSA, which were used in combination with Lumi4-Tb-AB conjugates for Tb-to-QD 
FRET assays. All three Tb-to-QD FRET systems showed increasing time-gated FRET signals 
with increasing PSA concentrations and immunoassay calibration curves could be successfully 
recorded. The LODs for PSA in 50 µL serum samples were in the sub-nanomolar concentration 
range and below the clinical cut-off value of 4 ng/mL for the QD655 and QD705 based FRET-
pairs. Duplexing capability was demonstrated in PSA assays containing both QD655 and 
QD705 AB conjugates. Our results provide important information concerning the development 
of QD-based FRET immunoassays for multiplexed clinical diagnostics because the AB-
conjugation method is applicable to any commercially available amino-functionalized Qdot, 
which exist in many other colors than the three used in this study. Our results show a direct 
relation between the FRET parameters and the analytical performance of the FRET-pairs. The 
comparison of LODs for the same biomarker (PSA) is an important tool for a relative 
comparison of the FRET-pairs in order to adapt the FRET-probes to the required concentration 
range of different biomarkers in a multiplexed assay. Our proof-of-concepts for three-color     
 
72 
 
Tb-to-QD FRET and two-color duplexed Tb-to-QD FRET detection for biomarker immunoassays 
in serum samples present highly important steps toward the development of multiplexed QD-
based FRET immunoassay kits for clinical use.  
In reference to these results, the next two chapters will be consecrated to the influence of a 
compact surface coating of QDs (same core-shell QDs from Life Technologies used in this study) 
on the sensitivity of such FRET immunoassays and to the development of multiplexed assays 
against different biomarkers. 
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4. Terbium to compact QDs FRET immunoassay for 
PSA detection 
L. Mattera, S. Bhuckory, K.D. Wegner, X. Qiu, F. Agnese, C. Lincheneau, T. Senden, D. Djurado, L.J. 
Charbonnière, N. Hildebrandt, and P. Reiss. Compact quantum dot-antibody conjugates for FRET 
immunoassays with subnanomolar detection limits. Nanoscale 2016, 8, 11275-11283. 
S. Bhuckory, L. Mattera, K. D. Wegner, X. Qiu, Y-T. Wu, L. J. Charbonnière, P. Reiss, and N. Hildebrandt. 
Direct conjugation of antibodies to the ZnS shell of quantum dots for FRET immunoassays with low picomolar 
detection limits. Chemical Communications 2016, 52, 14423-14425. 
 
4.1 Introduction 
Involving QDs with thick polymer PEG coating and surface amino functionalized from Life 
Technologies, and sulfhydryl bioconjugation chemistry for Tb-to-QD FRET immunoassays 
reported in the previous chapter showed that it was possible to detect PSA in the sub-
nanomolar range. Therefore, the development of QD–AB conjugates with compact surface 
functionalization for aqueous phase transfer and high-performance photophysical properties for 
efficient FRET immunoassays in serum samples would present a milestone of the utmost 
importance for the integration of QDs into clinical in vitro diagnostics. They would allow 
overcoming the major limitations for developing QD-FRET immunoassays with LODs 
competitive to commercial kits which are: (i) insufficient colloidal stability of compact QDs in 
biological media, (ii) thick QD surface coatings (e.g., PEG, polymer, or lipid coatings that 
protect the inorganic QD from the biological environment and render them hydrosoluble), and 
(iii) insufficient AB-conjugation strategies for QDs with thinner organic capping. The latter two 
QD surface related aspects result in long FRET donor–acceptor distances and unfavorable 
binding conditions, respectively. This leads to lower sensitivities compared to conventional 
time-resolved (TR)-FRET immunoassays that use lanthanide donor and dye acceptor AB 
conjugates [174]. Here we present a novel QD functionalization and bioconjugation approach, 
which yielded stable compact QDs and highly luminescent QD–AB conjugates for improved TR-
FRET immunoassay. This work was jointly carried out with the INAC-SyMMES laboratory in 
CEA Grenoble, where they performed phase transfer of the QDs from organic to aqueous 
solvent and their characterization. Post-functionalization of the QDs with a bifunctional ligand 
was carried-out by both groups, and bioconjugation with fragmented antibodies as well as 
optical characterization and FRET immunoassays were done by our group.        
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Aqueous phase transfer of lab-synthesized (by INAC-SyMMES laboratory) InPZnS/ZnSe/ZnS 
QDs emitting at 530 nm and commercial CdSe/ZnS and CdSeTe/ZnS QDs (Life Technologies) 
emitting at 605 and 705 nm was achieved by surface ligand exchange with penicillamine (Pen). 
These wavelengths have been selected as they result in minimal interference with the emission 
of the Tb-complexes used as the FRET donor. Under optimized conditions, ligand exchange 
with Pen results in a very compact (∼1 nm) organic surface layer while preserving high PL 
quantum yields. The zwitterionic Pen also provides low non-specific binding with serum 
proteins and very high colloidal stability of several years in aqueous buffers. For sulfhydryl-
reactive QD–AB conjugation, we further functionalized the QD surface with a bifunctional 
ligand (Mal1) containing a lipoic acid anchoring function and a maleimide group, spaced by 
three poly(ethylene) glycol (PEG) moieties. The bidentate (reduced) lipoic acid function is able 
to substitute Pen molecules and provides excellent stability of the Mal1 ligand on the QD 
surface. Successful conjugation of the prepared QDs with fragmented antibodies F(ab), further 
reducing the size of the sandwich immunocomplexes, was characterized by optical spectroscopy, 
dynamic light scattering (DLS), agarose gel electrophoresis, and FTIR. These QD-AB 
conjugates will be further referred as QD-Mal1-AB. To demonstrate the advantages of the 
ultra-compact (hydrodynamic diameter <13 nm), stable, and strongly fluorescent QD–AB 
conjugates for clinical diagnostics, we performed Tb-to-QD FRET immunoassays for the 
detection of prostate specific antigen (PSA) in 50 μL serum samples on a commercially 
available clinical fluorescence plate reader (KRYPTOR). The FRET results being consistent 
with those obtained in Chapter 3, we further challenged our sulfhydryl conjugation strategy 
by showing for the first time the direct attachment of ABs (IgG, F(ab’)2, F(ab)), via free 
sulfhydryl groups, to the surface of the compact QDs (metal-affnity of thiols to zinc) emitting at 
705 nm (largest Ro, highest sensitivity) without using any linker or crosslinker. This would 
allow for more efficient FRET immunoassays due to the close proximity of the donor and 
acceptor molecules. The direct conjugation of the ABs to the QDs will be further referred as 
QD-d-AB conjugates, with “d” corresponding to direct conjugation. The achieved LODs down to 
0.8 ng/mL (Mal1 ligand conjugation) and 0.08 ng/mL (direct conjugation) are 2.5 fold and 25 
fold lower than the best Tb-to-QD PSA FRET immunoassays reported so far, which were 
performed under identical conditions but with the commercially available ITK-Qdots (Life 
Technologies) as reported in Chapter 3 [175]. The latter differ from our QDs only by their 
surface coating: a comparably thick organic layer composed of amphiphilic polymers, which 
yields QDs with hydrodynamic radii of more than 26 nm (without conjugated biomolecules) 
[151]. Our results are the first demonstration of using compact surface-ligand capped QDs for 
homogeneous FRET immunoassays that can outperform the commercial QD “gold standard” 
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and function under clinically relevant conditions (50 μL serum samples measured on a clinical 
plate reader). Comparing the 0.08 ng/mL LOD with the clinical cut-off level of PSA (4 ng/mL) 
[173] clearly shows the immediate applicability of the compact QD nanoprobes for PSA 
diagnostics. 
4.2 Materials and Methods 
4.2.1 Materials 
4.2.1.1 Chemicals 
D-Penicillamine, tetramethylammonium hydroxide (TMAOH), phosphate-buffered saline 
solution (10x PBS), 0.5 M tris(2-carboxyethyl)phosphine hydrochloride solution (TCEP), 
tris(hydroxymethyl)aminomethane (TRIS/Cl), bovine serum albumin (BSA), agarose powder, 
indium acetate (99.99%), myristic acid (>99%), tris(trimethylsilyl)phosphine (95%),                   
1-dodecanethiol (97%), and 1-octadecene (90%) were purchased from Sigma-Aldrich. Zinc 
stearate (90%) was acquired from Riedel de Haën. MAL-dPEG3-lipoic acid (Mal1) was 
purchased from Quanta Biodesign. QD CdSe/ZnS 605 and QD CdSeTe/ZnS 705 were purchased 
from Life Technologies/Thermo Fisher Scientific [176] while the NHS-activated terbium 
complex (Lumi4-Tb) was provided by Lumiphore in lyophilized form. Prostate specific antigen 
(PSA) and monoclonal primary antibodies against PSA (IgGs: “PSR222” and “PSS233”) were 
provided by Cezanne/Thermo Fisher. IgGs were fragmented to F(ab’)2 and F(ab) using a 
Pierce™ Mouse IgG F(ab′) F(ab′)2 preparation kit and following the instructions provided by the 
supplier (Thermo Fisher Scientific). SDS-PAGE of the fragmentation is shown in        
Appendix 8.2.3. Solvents were purchased from Aldrich, Fluka, and Acros, and used without 
further purification. All water solutions were prepared from ultrapure laboratory grade water 
(resistivity 18 MΩ cm) that was filtered and purified using a Millipore MilliQ cartridge system 
and autoclaved.  
4.2.1.2 Instruments 
Absorption and emission spectra were recorded on the following spectrometers: HP 8452A and 
Perkin Elmer Lambda 35 for UV-Vis absorption; Hitachi F-4500 fluorescence 
spectrophotometer equipped with a 150 W xenon lamp and an excitation monochromator as 
well as a PicoQuant Fluotime 300 for photoluminescence (PL). Decay curves were acquired on 
the Fluotime 300 and fitted using EasyTau (PicoQuant). The hydrodynamic diameter (by 
dynamic light scattering) and zeta potential of the NCs dispersed in water were measured 
using a Malvern Zetasizer (NanoZS). Fourier transform infrared (FTIR) spectra were taken on 
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a Perkin Elmer Paragon 500 spectrometer equipped with an attenuated total reflection (ATR) 
setup. Gel images were acquired using a Gel Doc XR system (Bio-Rad, Hercules, CA). HRTEM 
analyses were performed on a JEOL 3010 working at 300 kV, equipped with a LaB6 gun and a 
Gatan Orius SC 200 2k × 2k CCD camera. The homogeneous FRET immunoassays were 
measured on a modified “KRYPTOR compact plus” clinical fluorescence plate reader using 500 
detection bins of 2µs integration time from Cezanne/Thermo Fisher Scientific and a prototype 
fluorescence plate reader (developed during a joint project) from Edinburgh Instruments (EI) 
using 4000 bins of 2µs integration time for FRET decay curves. 
4.2.2 Methods 
4.2.2.1  InPZns/ZnSe/ZnS QD synthesis 
The synthesis of InPZnS/ZnSe/ZnS alloy core gradient shell nanocrystals is based on reported 
procedures [116,177]. All procedures except for nanocrystal purification have been carried out 
under an inert atmosphere. 
Preparation of precursor solutions 
For the preparation of the indium myristate (In(MA)3) stock solution (0.1 M), 1 mmol of 
anhydrous indium acetate was mixed with 3 mmol of myristic acid (MA) and 10 mL of              
1-octadecene (ODE) in a 50 mL three-neck flask equipped with a condenser. The mixture was 
heated to 100–120 °C for 1 h under vacuum until an optically clear solution was obtained. After 
backfilling the flask with Ar and cooling to room temperature, the turbid solution of indium 
myristate was stored in a glovebox. For the zinc oleate (Zn(OA)2) stock solution (0.4 M), 5 mmol 
of zinc acetate, 10 mmol of oleic acid (OA) and 9.35 mL of ODE were loaded into a 50 mL three-
neck flask and the same procedure as for the preparation of In(MA)3 was followed. The zinc 
stearate (Zn(St)2) stock solution (0.1 M) was prepared by heating 1 mmol of Zn(St)2 with 10 mL 
of ODE at 120 °C for 1 h. A 0.4 M TOPSe stock solution was prepared by the dissolution of        
2 mmol Se powder in 5 mL of trioctylphosphine (TOP) under stirring for 24 h. A TOPS stock 
solution was prepared with the same procedure using elemental sulfur. 
Synthesis of InPZnS alloy nanocrystals 
In a glovebox, 1 mL of the In(MA)3 stock solution (0.1 mmol In(MA)3), 1 mL of the Zn(St)2 stock 
solution (0.1 mmol), 0.1 mmol of 1-dodecanethiol (DDT) and 7.5 mL of ODE were added to a    
50 mL three-neck flask. Afterwards the flask was equipped with a condenser and connected to 
a Schlenk line. Next, the mixture was heated under vigorous stirring to 300 °C with a ramp of 
around 60 °C min−1 using a molten salt bath. When the temperature inside the flask reached 
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100 °C, 0.1 mmol of tris(trimethylsilyl)phosphine (P(TMS)3), diluted with 1 mL of ODE, were 
injected. During the heating, NC formation is visible by the color change of the reaction 
mixture to dark yellow/orange. After 30 min, the reaction mixture was cooled to below 220 °C to 
stop growth. 
Growth of a ZnSe/ZnS gradient shell 
For the ZnSe/ZnS gradient shell growth, a 10 fold excess of precursors was used with respect to 
the core synthesis, and a Se:S ratio of 0.2. Briefly, Zn(OA)2 (1 mmol, 2.5 mL of the 0.4 M stock 
solution) was added dropwise to the reactive mixture at 220 °C. This was followed by the 
successive injection of TOP-Se (0.2 mmol, 0.5 mL of the 0.4 M solution) and TOP-S (0.8 mmol, 2 
mL of the 0.4 M solution). The resulting mixture was heated to 300 °C within 10 minutes and 
then kept at this temperature for 20 min. After cooling down to room temperature, purification 
of the QDs was performed via three cycles of precipitation/redispersion. First, 10 mL of a 1 : 1 
(v/v) mixture of chloroform/methanol and 100 mL of acetone was added. Then the resulting 
suspension was centrifuged (8000 rpm for 5 minutes), the supernatant discarded and the 
obtained solid dispersed in 5 mL of chloroform. Finally, the QDs can be dispersed and stored in 
a variety of organic solvents, like hexane, toluene or chloroform. 
Purification before phase transfer 
Thorough purification of the initial QDs, enabling the complete removal of excess surface 
ligands or side-products is crucial for successful phase transfer. 1 mL of the InPZnS/ZnSe/ZnS 
QDs in chloroform was mixed with anhydrous ethanol (1 mL) and centrifuged at 10 000 rpm for 
2 minutes. The clear solution of supernatant was discarded and the precipitate was dispersed 
in 1 mL of chloroform. This cycle was repeated three times. For the commercial CdSe/ZnS-
based QDs in decane the solvent was changed to chloroform prior to phase transfer. 4 mL of a 
methanol/isopropanol (3 : 1 v : v) mixture were added to 1 mL of the QD colloidal solution and 
centrifuged for 2 min at 10 000 rpm. The supernatant was discarded and the resulting pellet 
dispersed in 1 mL of chloroform. 
Phase transfer 
A 0.2 M solution of penicillamine (containing 200 μL of 0.5 M TCEP) was prepared in 1 mL of 
degassed MilliQ water (18 MΩ cm). The pH was adjusted to 9 by drop-wise addition of 0.5 M 
TMAOH. 500 μL of the phase transfer solution was mixed with 1 mL of a 3–5 μM colloidal 
solution of QDs in chloroform. The biphasic mixture was stirred vigorously at ∼1400 rpm for    
2 h at room temperature. At the end of the transfer, affording QD–Pen, the biphasic mixture 
 
78 
 
results either in a clear separation of two phases or in an emulsion. In the latter case, the 
mixture is centrifuged at 5200 rpm for 1 min to obtain a clear phase separation. The QDs in the 
(upper) aqueous phase are separated from the (lower) organic phase. 
Purification and storage 
A NAP™-5-10,-25 size exclusion column (Sephadex™ G-25 DNA Grade from GE Healthcare) 
was vertically clamped and equilibrated according to the manufacturer's protocol. QDs in water 
were added and after being adsorbed on the gel bed, they were eluted using 1x PBS buffer and 
kept at 4 °C in the dark for storage. 
Post-functionalization 
Solutions of Mal1 (1 mL, 10 mM) and TCEP (0.046 mL, 0.5 M) in degassed water were added to 
a suspension of QD–Pen (0.5 mL, 5.2 μM in degassed water) and the pH was adjusted to 7.0 by 
dropwise addition of 0.5 M TMAOH. The mixture was vortexed at 800 rpm overnight at room 
temperature. The resulting fine suspension was purified by size exclusion chromatography with 
NAP™-10,-25 columns (Sephadex™ G-25 DNA Grade from GE Healthcare). The obtained    
QD-Mal1 were then concentrated under vacuum or by using a 30 kDa molecular weight cut-off 
(MWCO) spin column from Millipore, centrifuging at 4000g for 4 min with a final volume of  
400 μL. Storage at 4 °C in the dark.  
4.2.2.2  Preparation of Tb-AB conjugate 
The same conjugation protocol as described in Section 3.2.2.1 was applied to prepare the Tb-
IgG conjugate. 
4.2.2.3  Preparation of QD-AB conjugates 
IgGs were fragmented to F(ab’)2 and F(ab) using a Pierce™ Mouse IgG F(ab′) F(ab′)2 
preparation kit following the instructions provided by the supplier. QD-Mal1 were conjugated 
to F(ab) whilst QD-Pen (QD705) were conjugated to IgGs, F(ab’)2 and F(ab).  Prior to 
conjugation of the QDs to the ABs in a molar ratio of 1 : 20, disulfide bonds of the latter were 
reduced to sulfhydryls with 5 mM of TCEP in 1x PBS by mixing for 30 minutes at 30 rpm at 
room temperature (RT). Purification from excess TCEP was performed using Zeba 7K spin 
columns (Thermo Fisher Scientific) according to the manufacturer's protocol. The resulting 
purified ABs were then mixed with the QDs in 1× PBS and incubated for 4 hours while rotating 
at 30 rpm at RT. Conjugates were washed from unbound ABs 4 times with 1 mL 1× PBS pH 7.5 
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using a   100 kDa MWCO spin column from Millipore at 1000g. Supernatants were taken after 
a final centrifugation at 4000g for 5 minutes. 
4.2.2.4  QD photoluminescence quantum yields 
The absolute fluorescence QYs of the QDs were determined by comparison with a standard of 
known QY (freshly prepared solution of Fluorescein 548 in 0.1 M NaOH; QY = 93%, Rhodamine 
6G in ethanol; QY = 95% [178] or QD705 in chloroform; QY = 92% [176]). The QY was 
calculated with the following formula: 
 
Φ𝑁𝐶 =  Φ𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 (
𝑎𝑁𝐶
𝑎𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑
) (
𝑛𝑁𝐶2
𝑛𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑2
) (4.1) 
where Φ is the QY, a the gradient (slope) of the plot of the integrated fluorescence intensity vs. 
absorbance and n the refractive index of the solvent (1.375 for hexane, 1.446 for chloroform, 
1.333 for water and buffer and 1.360 for ethanol [178]). All spectra were corrected for the 
instrumental response with calibration curves furnished by the supplier and the estimated 
errors on QY are ±15% of the calculated values. Aliquots or purified samples of the QDs in 
hexane, chloroform or water were put into 1 cm quartz cuvettes and diluted until the 
absorbance at the excitation wavelength was around 0.1. At least four samples of different 
concentrations were prepared and measured for determining the slopes. Both the sample and 
the reference were excited at 460 nm for InP based QDs and at 480 nm for CdSe based QDs.  
4.2.2.5 Hydrodynamic size and dispersibility of QDs 
The hydrodynamic diameter of the water-soluble QDs was measured by dynamic light 
scattering (Malvern Zetasizer NanoZS). Multiple runs (>3) were performed and averaged, and 
the QDs in 1x PBS buffer were filtered (0.22 μm) prior to the measurements. The spectra have 
been corrected by the instrument software for viscosity (0.882 mPa s at 25 °C), absorption 
(0.01), solvent (water) refractive index (1.33) and material refractive index (assumed as 2.7 and 
2.45 for In- and Cd-based QDs, respectively [179]). The data were collected in automatic mode 
and expressed in number %. The zeta potential was measured using the same instrument 
under zeta potential settings.  
4.2.2.6 Gel electrophoresis 
A 1% gel was prepared in 25 mM Hepes buffer (pH 7.4) and poured in a 10.7 × 5.2 cm gel tray 
levelled in a gel caster (RunOne System). A comb (12 wells) was placed into the gel. The gel was 
allowed to cool down to room temperature and to solidify within at least 1 hour. The comb was 
removed and the gel was taken out of the casting device and placed into the electrophoresis 
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device which was filled with 25 mM Hepes buffer pH 7.4 until the whole gel was covered. The 
samples were mixed with about 20% of their volume with the loading buffer (30% glycerol in 25 
mM Hepes buffer with 0.3% Orange G) and carefully filled into the wells. The electrophoresis 
devices were run at a constant voltage of 100 V. After 5, 10, 15 and 30 min an image was taken 
placing the gel on a UV transilluminator (Gel Doc XR system, Bio-Rad). 
4.2.2.7 FRET immunoassays 
All FRET assays contained 50 µL of each AB-Tb and QD-AB conjugate (in 10 mM TRIS/HCl; 
0.5% BSA pH 7.4) at constant concentrations, to which 50 μL of serum with increasing 
concentrations of TPSA was added. The homogeneous FRET immunoassays were measured on 
a modified “KRYPTOR compact plus” clinical fluorescence plate reader from Cezanne/Thermo 
Fisher Scientific and the EI plate reader with a 20 Hz nitrogen laser as excitation source 
operating at 337.1 nm. The KRYPTOR simultaneously detects the time-gated PL intensities, in 
a time window from 0.1 ms to 0.9 ms, in the Tb donor and QD acceptor channels fitted with the 
appropriate bandpass filters. The same bandpass filters were fitted on the EI plate reader.     
 
4.3 Results and discussion 
4.3.1 Surface functionalization of the QDs  
Initially the strongly fluorescent InP-based or CdSe-based QDs were capped with hydrophobic 
organic surfactants rendering them soluble in non-polar media. Aqueous phase transfer is a 
critical step to make these QDs usable in biological studies. Two factors are of prime 
importance with regard to the phase transfer protocol: first, the procedure needs to guarantee a 
minimum loss of fluorescence quantum yield; second, it should provide high colloidal stability 
preventing the aggregation of QDs. Many literature protocols and commercial products rely on 
the encapsulation of the QDs with bulky amphiphilic polymers, which leads to hydrodynamic 
diameters in the range of 15–20 nm or more. Here, we focus on direct ligand exchange, which 
yields a much more compact surface coating beneficial for FRET applications. In the first step, 
the QDs were transferred from the organic to the aqueous phase by means of penicillamine 
(Pen), following a procedure we reported earlier [180]. It relies on the use of a biphasic mixture 
of QDs in chloroform and Pen in an aqueous solution of precisely controlled pH in the presence 
of the mild reducing agent TCEP. Basic pH is required for achieving the deprotonation of the 
Pen thiol group, which results in stronger binding to the surface of the different ZnS-coated 
QDs, while TCEP prevents Pen disulfide formation. Quantitative phase transfer was visible by 
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the mutual color change of both phases (Figure 4.1). In a second step, post-functionalization 
with the bifunctional ligand Mal1 was carried out under reduction of the disulfide group by 
means of TCEP (Scheme 4.1) [128].The bidentate lipoic acid group provides stronger binding 
to the QD surface than Pen molecules, facilitating introduction of Mal1 [124]. The short PEG 
chain improves hydrosolubility and adds a spacer, which makes the maleimide functions stick 
out of the Pen corona and hence easily available for subsequent antibody conjugation. The full 
structural and photophysical characterization of the Pen- and Mal1-functionalized QDs is 
presented below and in the next section. Though we succeeded in conjugating directly 
antibodies on the QD-Pen emitting at 705 nm surface, full photophysical characterizations of 
all the QD-d-AB conjugates were not possible due to the low concentration recovery after 
purification for QD-d-F(ab’)2. Absorption measurements were carried out in order to perform 
FRET immunoassays and only absorption and PL spectra of QD705-d-IgG will be shown.  
 
Figure 4.1. Yellow sample corresponds to QD530 and brown sample to QD705. Mutual colour change 
from (left) chloroform phase (bottom) to (right) aqueous phase (top). 
 
Scheme 4.1. Schematic representation of (a) the aqueous phase transfer of QDs with Pen, (b) post-
functionalization with Mal1.  
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Surface functionalization of the QDs with Pen and post-functionalization with Mal1 did not 
lead to significant modifications of the PL and UV-Vis spectra as shown in Figure 4.2. On the 
other hand, a decrease of the PL QY was observed, from 0.40 (QD530), 0.60 (QD605), and 0.92 
(QD705) in chloroform to 0.27, 0.30, and 0.66, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. PL and UV-vis (inset) spectra of (A) InPZnS/ZnSe/ZnS QD530, (B) CdSe/ZnS QD605, (C) 
CdSeTe/ZnS QD705, in chloroform (black), after functionalization with penicillamine (red) and with the 
bifunctional ligand Mal1 (blue) in 1× PBS buffer. No significant alteration of their spectra could be 
observed after surface functionalization and post-functionalization.  
4.3.2 Tb-AB and QD-AB conjugates 
Tb-AB conjugate 
NHS-functionalized Tb complexes (Lumi4-Tb) were directly labeled to available primary 
amines of anti-PSA IgG ABs (Tb–AB). A Tb per IgG (Table 4.2) conjugation ratio of 11 ± 3 was 
determined by UV-Vis absorption spectroscopy using the molar absorptivities of Lumi4-Tb 
(ε(340 nm) =    26 000 M−1 cm−1) and IgGs (ε(280 nm) = 210 000 M−1 cm−1) and Beer–Lambert's 
law (Figure 4.3 left). The comparison of Tb–AB with the unconjugated complex shows no 
A B 
C 
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Fragment antibody 
(Fab) 
alteration of the PL properties after AB-conjugation. Upon excitation at 365 nm the PL 
spectrum of Tb–AB shows the characteristic Tb emission lines and the obtained decay curve 
had an almost single exponential decay with an average PL lifetime of ca. 2.6 ms            
(Figure 4.3 right). 
 
Figure 4.3. Left: absorption (black line) and PL (green, excitation wavelength 365 nm) spectra of Tb–AB 
conjugate. Right: Tb–AB PL decay curve (490 ± 0.5 nm) upon pulsed excitation at 365 nm with a 
repetition rate of 100 Hz. Amplitude-averaged decay time: τ(Tb) = 2.6 ± 0.3 ms. 
QD-AB conjugates 
 
 
 
 
 
 
 
 
 
Scheme 4.2. (a) Indirect conjugation of QD-Mal1 to reduced F(ab) forming a covalent thio-ether bond, (b) 
direct conjugation to QD-pen surface with reduced F(ab) through metal affinity coordination of thiol on 
F(ab) to Zn2+ on QDs surface. 
The conjugation of ABs to the QDs was performed by two different methods: referred in this 
thesis as indirect conjugation and direct conjugation. F(ab) were indirectly conjugated to QD-
Mal1 through sulfhydryl chemistry [128,181]. IgG, F(ab’)2 and F(ab) were directly conjugated to 
A 
B 
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QD705-Pen (coming from a different batch of QD705-Pen) through metal affinity. The choice of 
direct conjugation of ABs to the QD-Pen emitting at 705 nm was based on the results obtained 
in Chapter 3 (largest R0, highest sensitivity). For both indirect and direct conjugation, the ABs 
prior to coupling with the QDs, were first activated through reduction of the S–S bond by TCEP 
( 
Scheme 4.2) as described in section 3.2.2.2 
The absorption and PL spectra of the three QD–Mal1-F(ab) conjugates are shown in        
Figure 4.4 A-D left. QD concentrations (Table 4.2) were determined using the molar 
absorptivities of ε450 nm(QD530) = 4.2 × 105 M−1 cm−1 (experimentally determined),                     
ε405 nm(QD605) = 2.8 × 106 M−1 cm−1 and ε405 nm(QD705) = 8.3 × 106 M−1 cm−1 (provided by the 
supplier) [176]. The estimation of the labeling ratio of AB/QDs could not be determined here 
due to the high background of the QD’s absorption at 280 nm interfering with the absorption of 
the ABs at this wavelength. The photophysical properties of the QDs were slightly altered by 
the F(ab) conjugation, as summarized in Table 4.1, compared to the Pen-capped QDs. A PL red 
shift of 4 nm could be detected for the CdSe-based QD605 and QD705, while a blue shift of 3 
nm was found for the InP-based QD530. Further experiments are needed to unequivocally 
elucidate the origin of these shifts; we tentatively ascribe them to the quantum confined Stark 
effect, induced by the change of the dielectric environment of the QDs upon conjugation with 
F(ab) [182]. On the other hand, no emission maxima shifts could be observed for the QD705-d-
IgG, although a slight broadening of the spectra towards the red spectrum resulted. We believe 
to have similar results upon direct conjugation with F(ab’)2 and F(ab) due to the same 
conjugation protocol. F(ab)-conjugation through Mal1 also led to changes in the PL lifetimes 
(Table 4.1) from 24 to 18 ns for QD530, from 4.6 to 10 ns for QD605, and from 79 to 41 ns for 
QD705 and direct conjugation of IgGs to QD705, from 93 ns to 84 ns. These changes are 
attributed to the generation or filling of electronic trap states acting as competing deexcitation 
channels upon AB attachment.  
Table 4.1. Optical characterization of QD-Mal1-F(ab) and QD-d-IgG conjugates were performed by 
excitation at 405 nm using as excitation sources a continuous-wave Xe lamp and a pulsed diode laser 
from Edinburgh Instruments for steady-state and time-resolved measurements respectively. *coming 
from a different batch of QD-Pen emitting at 705 nm 
Sample 
InPZnS/ZnSe/ZnS 
530 
CdSe/ZnS 605 CdSeTe/ZnS 705 
CdSeTe/ZnS 
705* 
-Pen -F(ab) -Pen -F(ab) -Pen -F(ab) -Pen -IgG 
Emission wavelength maxima 
(nm) 
505 ± 1 502±1 602±2 606±0.5 699±2.5 703±0.5 707±0.5 707±0.5 
Lifetime (ns) 24.3±6.1 17.7±2.8 4.6±0.4 10.4±1.1 79.4±20.8 40.7±6.4 93.0±9.6 83.6±8.1 
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Figure 4.4. Absorption and PL spectra (left) and PL decay curves (right) of (A-C) F(ab)-conjugated 
through Mal1 InPZnS/ZnSe/ZnS (QD530-Mal1-F(ab)), CdSe/ZnS (QD605-Mal1-F(ab)), CdSeTe/ZnS 
(QD705-Mal1-F(ab)) and (D) CdSeTe/ZnS (QD705-d-IgG) QDs in 1× PBS buffer. Amplitude-averaged PL 
lifetimes: τ(QD530-Mal1-F(ab)) = 17.7 ± 2.8 ns, τ(QD605-Mal1-F(ab)) = 10.4 ± 1.1 ns, τ(QD705-Mal1-
F(ab)) = 40.7 ± 6.4 ns and τ(QD705-d-IgG) = 83.6 ± 8.1 ns 
0 500 1000 1500 2000
1
10
100
1000
10000
P
L
. 
in
te
n
s
it
y
 (
c
o
u
n
ts
)
Time (ns)
0 200 400 600 800 1000
1
10
100
1000
10000
P
L
. 
in
te
n
s
it
y
 (
c
o
u
n
ts
)
Time (ns)
350 400 450 500 550 600 650 700
0.0
1.0x10
6
2.0x10
6
3.0x10
6
4.0x10
6
5.0x10
6
m
o
la
r 
a
b
s
o
rp
ti
v
it
y
 (M
-1
.c
m
-1
)
Wavelength (nm)
0.0
0.2
0.4
0.6
0.8
1.0
n
o
rm
. 
P
L
 i
n
te
n
s
it
y
0 100 200 300 400 500
1
10
100
1000
10000
P
L
. 
in
te
n
s
it
y
 (
c
o
u
n
ts
)
Time (ns)
350 400 450 500 550 600 650 700 750
0.0
5.0x10
6
1.0x10
7
1.5x10
7
2.0x10
7
m
o
la
r 
a
b
s
o
rp
ti
v
it
y
 (M
-1
.c
m
-1
)
Wavelength (nm)
0.0
0.2
0.4
0.6
0.8
1.0
n
o
rm
. 
P
L
 i
n
te
n
s
it
y
0 500 1000 1500 2000
1
10
100
1000
10000
P
L
. 
in
te
n
s
it
y
 (
c
o
u
n
ts
)
Time (ns)
350 400 450 500 550 600 650
0.0
5.0x10
5
1.0x10
6
1.5x10
6
2.0x10
6
2.5x10
6
3.0x10
6
m
o
la
r 
a
b
s
o
rp
ti
v
it
y
 (M
-1
.c
m
-1
)
Wavelength (nm)
0.0
0.2
0.4
0.6
0.8
1.0
n
o
rm
. 
P
L
 i
n
te
n
s
it
y
A 
B 
C 
D 
QD530-Mal1-F(ab) 
QD705-d-IgG 
QD705-Mal1-F(ab) 
QD605-Mal1-F(ab) 
350 400 450 500 550 600 650 700 750
0.0
5.0x10
6
1.0x10
7
1.5x10
7
2.0x10
7
m
o
la
r 
a
b
s
o
rp
ti
v
it
y
 (
M
-1
.c
m
-1
)
Wavelength (nm)
0.0
0.2
0.4
0.6
0.8
1.0
n
o
rm
. 
P
L
 I
n
te
n
s
it
y
 
86 
 
Table 4.2. Overview of concentration and labeling ratios of the FRET-pairs. 
Tb-AB [Tb] (µM) [AB] (µM) Tb/AB QD-AB [QD] (nM) 
Tb-IgG 2.6 27.6 11.0 ± 2 
QD530-Mal-F(ab) 480 
QD605-Mal-F(ab) 207 
QD705-Mal-F(ab) 120 
QD705-d-IgG 60 
QD705-d-F(ab’)2 11 
QD705-d-F(ab) 132 
 
Sizes and morphologies of the inorganic parts of the QDs were characterized using 
transmission electron microscopy (TEM), which revealed nearly monodisperse spherical 
(QD530 and QD605) and elongated (QD705) nanocrystals (Figure 4.5).  
 
 
Figure 4.5. TEM image of CdSe705- (left) InP-based QDs (middle) after post-functionalization with Mal1 
and CdSe605-based QDs after functionalization with Pen. 
The hydrodynamic diameters of the QDs were evaluated by dynamic light scattering (DLS) and 
are presented in Figure 4.6. These measurements confirmed the narrow size distribution 
observed with TEM and revealed small hydrodynamic diameters, which slightly increase with 
each functionalization step. As exemplified by QD705, introduction of the Mal1 ligand led to a 
size increase from 8 to 10 nm with respect to QD705-Pen, which was in the expected range for a 
 
87 
 
ligand with an approximate length of 3.0 nm. Conjugation with F(ab) led to a further increase 
to 13 nm as the total hydrodynamic diameter, which makes this QD–Mal1-AB conjugate one of 
the smallest AB-functionalized near-infrared (NIR) emitting nanoprobes ever reported.  
Table 4.3. Polydispersity index (PDI) and zeta potentials of QD-Pen and QD-Mal1. 
Sample PDI-Pen PDI-Mal1 Zeta potential-Pen (mV) Zeta potential–Mal1 (mV) 
QD530 0.33 0.58 -31 -24 
QD605 0.15 0.23 -33 -28 
QD705 0.08 0.23 -36 -24 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6. Size distribution of (A) QD530 (B) QD605 (C) QD705 after each functionalization step (Pen-
capping: green, Mal1-functionalization: red, and F(ab)-conjugations: blue) obtained by DLS 
measurements. The average hydrodynamic diameter d (nm) of each measurement is given in the legend. 
Zeta potential of both Pen-capped and Mal1-capped were measured in order to understand the 
state of the QDs surface and prediction of long term stability. The magnitude of zeta potential 
is therefore predictive of the QDs colloidal stability. Generally, zeta potential values greater 
than +25 mV or less than -25 mV result in high degrees of stability [183]. Zeta potential values 
(Table 4.3) of both Pen-capped and Mal1-capped QDs display values between -36 mV and -24 
mV, respectively, and together with low polydispersity indices, high colloidal stability is 
confirmed. The negative charge on the carboxylate group of the Pen ligands guarantees 
C 
A B QD530 
QD705 
QD605 
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stability by electrostatic repulsion between the QDs. After post-functionalization with Mal1, 
the zeta potential decreases due to the reduction of negatively charged Pen ligands on the QDs’ 
surface in favor of neutral Mal1 ligands. The short PEG moieties of Mal1 are expected to 
contribute in colloidal stability of the QDs in aqueous media.  
Colloidal stability of the QDs in water or relevant buffer solutions is of crucial importance for 
biological detection. The obtained Pen- and Mal1-functionalized QDs showed no sign of 
aggregation after storage of more than two years (Figure 4.7) at 4 °C in the dark in 1× PBS 
buffer (pH = 7.4), as confirmed by combined periodical DLS and UV-Vis measurements. After 
indirect F(ab) conjugation and direct AB conjugation the colloidal stability was determined to 
be at least 2 and 1 month respectively, which is the current limit of our measurements.  
 
Figure 4.7. Photographs of Pen-functionalized QD705 (1/4), QD605 (2/5) and QD530 (3/6) taken two 
years after aqueous phase transfer with Pen. 1-3 under room light, 4-6 under UV light. 
The photophysical and morphological characterization results show that our approach of using 
an optimized ligand exchange with Pen, followed by post-functionalization with Mal1, is an 
efficient and simple way of obtaining highly luminescent, stable, and compact QDs ready for 
further functionalization with small F(ab)s to yield very small fluorescent AB-nanoprobes. Gel 
electrophoresis (Figure 4.8) and FTIR (Figure 4.9) measurements further confirmed 
successful post-functionalization with Mal1 and F(ab) conjugation of the QDs. For all QDs, the 
bands on the agarose gel corresponding to the QD–Mal1-F(ab) conjugates were the most 
retarded due to the larger sizes of the QD–AB conjugates. FTIR spectra (Figure 4.9) clearly 
revealed, by comparison to the free, i.e. not QD-bound, molecules, peaks corresponding to the 
carbonyl stretch vibrations of the maleimide function in QD-Mal1 (Figure 4.9 left, green) 
centered around 1000 cm-1 and to the N–H stretch vibration of F(ab) in QD-Mal1-F(ab) centered 
around 3300 cm-1. In these characterizations all three types of QDs behaved in the same way, 
which was expected as they mainly differ in the inorganic core composition but all possess an 
identical ZnS outer shell and the same first ligand exchange procedure with Pen has been used. 
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Figure 4.8. Gel electrophoresis characterization of the sample InP530 (a, b), QD705 (c) and QD605 (d) at 
different stages of functionalization was carried out on 1% agarose gel in 25 mM Hepes buffer at 100 V 
on a RunOne System. Prior to gel electrophoresis, to each sample a solution corresponding to 20% of the 
sample volume and containing Orange G and 30% glycerol in 6% loading buffer was added. For 
visualization, the gel was placed on a UV transilluminator, and an image was captured with a Gel Doc 
XR system (Bio-Rad, Hercules, CA). In the case of InP-based QDs (a-b) the image shown here was 
acquired after 10 min while for the Cd-based QDs after 20 min. The label a, c and d refers to the sample 
functionalized with Pen and Mal1, while b refers to the sample functionalized with Mal1 and 
bioconjugated with F(ab). 
 
  
Figure 4.9. FTIR characterization showing the successful functionalization of the QDs with the Mal1 
ligand and subsequent conjugation of the fragmented antibody F(ab). Left: FTIR spectra of Mal1 (red), 
QDs functionalized with Pen (blue) and post-functionalized with Mal 1 (green); right: FTIR spectra of 
F(ab) and of CdSe/ZnS QD705 after F(ab) conjugation.  
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4.3.3 FRET immunoassays 
To demonstrate the functionality of the compact QD–AB conjugates, we performed 
homogeneous Tb-to-QD FRET immunoassays against PSA on the KRYPTOR compact plus 
clinical fluorescence plate reader (Cezanne/Thermo Fisher). PL intensities of Tb (ITb) and QDs 
(IQD) were acquired simultaneously in a time-gated detection window between 100 μs to 900 μs 
after pulsed excitation at 337 nm using a nitrogen laser operating at 20 Hz. Due to the 
extremely long PL lifetimes of Tb (ms) compared to QDs (ns), the time-gating allows efficient 
suppression of short-lived sample autofluorescence and direct excitation of the QDs. This allows 
for solely obtaining the pure FRET signals (FRET-quenched Tb PL and FRET-sensitized QD 
PL). Optical bandpass filters (Delta and Semrock) for the Tb donor and QD acceptor detection 
channels were (494 ± 10) nm for Tb and (522 ± 6) nm, (607 ± 4) nm, and (707 ± 8) nm for 
QD530, QD605 and QD705, respectively. The FRET-ratio was defined as Equation 2.18. 
Within all the FRET-assays the Tb–AB and QD–AB concentrations were kept constant. 
Concentrations of 3 nM Tb–AB with 3 nM QD605-Mal1-F(ab) or QD705-Mal1-F(ab), and 9 nM 
Tb–AB with 9 nM QD530-Mal1-F(ab) were used. For direct conjugation with the QDs, 3 nM Tb-
AB with 3 nM QD-d-IgG, QD-d-F(ab’)2 or QD-d-F(ab) were used. PSA concentrations, prepared 
in serum, ranged from 0.05 nM (for QD605 and QD705) or 0.1 nM (for QD530) to 9 nM and to 
24 nM for QD705-d-IgG/F(ab’)2. 50 μL of each AB-conjugate (Tb–AB and QD–AB) were mixed 
with 50 μL of serum for a total working volume of 150 μL. The immunoassay calibration curves 
(FRET-ratio over total PSA concentration) are presented in Figure 4.11. Assays A-C from 
Figure 4.11 showed a steep FRET-ratio increase with increasing PSA concentration up to ca. 2 
to 4 nM, which was expected due to the saturation of Tb–QD FRET complexes (in the 
concentration range of Tb–AB or QD–AB). Assays D-F from Figure 4.12 yielded even steeper 
FRET-ratio increase as compared to its QD-Mal1 conjugate counterpart indicating better 
sensitivity of these assays. It should be noted that the FRET-ratio increase was very small 
(only ca. 5% at the maximum) for the Tb–QD530 assay, which was most probably related to the 
lower Förster distance of Tb–QD530 (R0 = 6.1 nm) compared to the values of Tb–QD605 (R0 = 
7.7 nm) and Tb–QD705 (R0 = 11 nm). These findings can be understood by analyzing the 
overlap integrals of the different D–A pairs (Figure 4.10). Therefore, only the FRET systems 
B-C could be used for a quantitative evaluation of PSA immunoassays using QDs-Mal1  
(Figure 4.11 B and C). 
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Tb-to-QD-Mal1 immunoassays 
Calibration curves (A-C) over a concentration range of 0 to 9 nM (black squares) revealed a 
linear FRET-ratio increase, followed by saturation and a FRET-ratio decrease. This decrease is 
due to the so-called Hook-effect, describing the increase of the fraction of single fluorophore 
(Tb–AB–PSA and QD–AB–PSA) binding complexes compared to FRET (Tb–AB–PSA–QD–AB) 
binding complexes. Homogeneous FRET assays are usually designed for the detection of very 
low concentrations without any washing or separation steps. To access the very low 
concentration range, high signal-to-background ratios are required and therefore the Tb–AB 
concentrations are selected in a low nM range (in our case 3 nM) to keep the Tb PL background 
at a minimum intensity level. As a consequence, the dynamic detection range becomes 
relatively narrow (ca. 0.05 to 2 nM in our case). On the KRYPTOR clinical plate reader used in 
our study, this drawback is overcome by a kinetic sample detection and automated dilution of 
too highly concentrated samples,[25] which can increase the dynamic detection range by 
several orders of magnitude. A second calibration curve, with many more PSA concentrations 
in the linearly increasing parts of the assay curves (red circles), was used to determine the 
LODs (Table 4.5). The same method for determining the LODs as in the previous chapter was 
used.  
 
Figure 4.10. Overlap between QDs absorption spectra (QD530: green; QD605: red; QD705: brown)) and 
area-normalized Tb emission spectra (olive green). Förster distances: Tb-QD530 = 6.1 nm, Tb-QD605 = 
7.7 nm and Tb-QD705 = 11 nm. 
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Figure 4.11. Calibration curves for total PSA (TPSA) homogeneous FRET immunoassays using the (A) 
Tb–QD530-Mal1, (B) Tb–QD605-Mal1, and (C) Tb–QD705-Mal1 FRET pairs. Assays (B) and (C) could be 
used for quantitative analysis. Black data points (squares) were from a first set of experiments using 
PSA concentrations between 0 and 9 nM. Red data points were taken in a second set of experiments for a 
statistical analysis of LODs in the linearly increasing parts of the assay curves. The inset corresponds to 
the linear part used for LOD calculation.  
Tb-to-QD-d immunoassays  
The FRET calibration curves Tb-to-QD705 (Figure 4.12) (D) IgG, (E) F(ab’)2 and (F) F(ab)  
show a remarkable increase of the time-gated FRET-ratio with a linear detection range of ca. 1 
order of magnitude as compared to the calibration curves obtained when using the QD-Mal1 
conjugates. One reason could be of direct conjugation of the ABs on the surface of the QDs 
bringing the Tb donors closer to the QDs upon biological recognition of PSA, hence more 
efficient energy transfer. As  is directly proportional to r-6, Mal1 ligand, as observed by DLS, 
brings another ca. 3 nm before conjugation to F(ab), which greatly influences the energy 
transfer efficiency. The LODs were calculated using the linear increasing slope and are 
summarized in Table 4.5. Calibration curve (E) could not be used for quantitative analysis 
because of the low concentration of the QD-F(ab’)2 conjugate obtained and only a test assay (i.e 
one data point corresponding to a single concentration) could be performed. However, 
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comparison of the sensitivities of the calibration curves as summarized in (G), suggest 
comparable sensitivity of the F(ab’)2 to the IgG in the linear range (0 to 2 nM). So, we could 
expect similar LOD when using F(ab’)2. Furthermore, graph (G) shows that the highest 
sensitivity is obtained using F(ab).    
        
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12. Calibration curves using the direct conjugated QDs to ABs. Assays with Tb-to- (D) QD705-
d-IgG, (E) QD705-d-F(ab’)2 and (F) QD705-d-F(ab) FRET pairs. Calibration curves (D) and (F) could be 
used for LOD calculation while (E) correspond to a test assay. (G) Relative FRET-ratio curves of the 
FRET assays with the different ABs showing the highest sensitivity achieved using F(ab).  
PL FRET decay curves could be acquired for the Tb-to-QD705-d-IgG/F(ab) systems, revealing 
obvious FRET-sensitization in the QD channel and more obvious FRET-quenching for Tb-
QD705-d-F(ab) than for Tb-QD705-d-IgG. For the FRET-pairs involving IgGs, we mainly 
observe stable and unquenched Tb signals which can be attributed to long distance between 
donor and acceptor. Unbound Tb-IgG and the random labeling of Tb on the IgG (only close Tb 
near the IgG binding sites can participate in efficient energy transfer) in the FRET 
experiments also cause a high background of unquenched Tb signals thus making it difficult for 
an observable FRET quenching. As the Tb PL background is weaker in the acceptor channel, 
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FRET-sensitization can be observed more easily and allows a more precise fitting of the 
acceptor channel for distance determination between the FRET-pairs. Figure 4.13 represents 
the PL decays curves for the Tb-to-QD705-d-IgG/F(ab) where we can distinguish in the QD 
channel the appearance of new decay components in the µs range and higher PL intensities 
with increasing TPSA concentration as compared to the 0 nM black curve where only Tb-QD 
FRET-pairs (µs decay component from QD and long decay component from Tb originating from 
PL background in the QD detection channel) are present, which indicates sensitization of the 
QDs by FRET. The PL decay curves measured in the Tb channel reveal differences in FRET-
quenching when QD-IgG or QD-F(ab) was used. For the Tb-QD-d-IgG immunoassay, stable and 
undistinguishable FRET-quenching of Tb PL decay curves could be observed whereas the 
combination of QD-d-F(ab) and Tb-IgG showed a decrease of the Tb PL intensities with 
increasing TPSA concentration. These observations are direct evidence of non-radiative energy 
transfer from Tb to QD in the presence of TPSA (target) and use of F(ab) brings the FRET-pairs 
closer together where FRET-quenching of Tb and FRET-sensitization of QD could be observed. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13. PL decay curves of the IgG and Fab system. Top curves correspond to acceptor channel 
showing sensitization of QDs due to FRET and below (bottom curves) their respective Tb decay curves in 
the donor channel. 
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As it was mentioned before, both acceptor and donor channels contain signals from unquenched 
donor (Figure 4.13). Decay time fitting in the two channels of the Tb-to-QD FRET system to 
estimate the pure FRET decay time, for FRET efficiency and distance analysis, involves decay 
time correction of free Tb not participating in FRET. A detailed description of LLC-to-QD FRET 
decay time analysis of donor quenching and acceptor sensitization is available in reference 
[135]. The pure donor can be fitted with a double-exponential resulting in a short 𝐷1 and a long 
dominant decay time 𝐷2 with amplitude fractions 𝐷1 and 𝐷2 respectively. FRET-quenched 
donor and FRET-sensitized acceptor can be fitted with triple-exponential and quadruple-
exponential fit functions respectively. Due to sample autofluorescence and direct excitation of 
QDs in the short time range, and contribution of donor crosstalk within the QD channel in the 
long time range, a delay of around 10 - 50 µs can be applied to the fits to avoid such 
disturbances. Such fits with a delay in the starting point of the fit which is different from 𝑡0 are 
called tail fits and although they do not change the different single decay times, the single 
amplitudes Ai-FIT have to be corrected from 𝑡0 to the actual correct start at 0 to yield the correct 
amplitudes (Ai) of the complete decay function:  
 𝐼 =  𝐴𝑖−𝐹𝐼𝑇 . 𝑒
(−
𝑡−0

)
=  𝐴𝑖𝑒
(−
𝑡

)
→ 𝐴𝑖 = 𝐴𝑖−𝐹𝐼𝑇𝑒
(−
0

)
  (4.2) 
 
The FRET-quenched donor decay curves can be fitted with three exponents with amplitude 
fractions 𝐷𝐴∗1, 𝐷𝐴∗2 and 𝐷𝐴∗0 for decay times 𝐷𝐴1, 𝐷𝐴2 and 𝐷𝐴0 where 𝐷𝐴0 fixed to 2 to 
account the emission of the unquenched donor. Therefore, only 𝐷𝐴1 and 𝐷𝐴2 are used for 
estimation of FRET decay time and as such necessitates the redefinition of the amplitude 
fractions of these two decay times as follows: 
 𝐷𝐴1 =  
𝐷𝐴∗1
𝐷𝐴∗1 +  𝐷𝐴∗2
      and        𝐷𝐴2 =  
𝐷𝐴∗2
𝐷𝐴∗1 + 𝐷𝐴∗2
  (4.3) 
 
The unquenched donor has two decay time components 𝐷1 and 𝐷2, and 〈𝐷𝐴〉 should be 
corrected from the short 𝐷1 as it falls within the FRET decay time but fixing 𝐷1 by addition of 
an extra exponential fit will lead to inconsistent fit. Hence a correction factor 𝑧𝐷, which 
corresponds to the fraction of unquenched donors in the short time components, has to be 
involved and corresponds to the ratio of amplitude fractions of 𝐷2 and 𝐷𝐴0  multiplied by the 
amplitude fraction 𝐷1 :  
 𝑧𝐷 =  (
𝐷𝐴∗0
𝐷2
) .𝐷1  (4.4) 
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The average FRET-quenched decay can then be calculated using the redefined amplitudes 
(𝐷𝐴1 +  𝐷𝐴2 = 1 ) and 𝑧𝐷 with the Equation 4.3 and substituting 〈𝐷𝐴〉 in Equation 2.9 and 
Equation 2.10 results in estimation of FRET efficiency and distance between the FRET-pairs:  
 〈𝐷𝐴〉 =  
𝐷𝐴1 𝐷𝐴1+ 𝐷𝐴2 𝐷𝐴2− 𝑧𝐷 (𝐷𝐴1 + 𝐷𝐴2 )𝐷1 
𝐷𝐴1+ 𝐷𝐴2− 𝑧𝐷 (𝐷𝐴1 + 𝐷𝐴2 )
=
 𝐷𝐴1 𝐷𝐴1+ 𝐷𝐴2 𝐷𝐴2− 𝑧𝐷 𝐷1  
1− 𝑧𝐷
  (4.5) 
  
Fitting of the FRET-sensitized acceptor is performed by four exponential fit function where 
only the first three components (𝐴𝐷∗1, 𝐴𝐷∗2 and 𝐴𝐷∗3 for decay times 𝐴𝐷1, 𝐴𝐷2 and 𝐴𝐷3) are 
used to calculate the FRET decay time and the forth component 𝐴𝐷0 is fixed to account for free 
and unquenched donor. The amplitudes 𝐴𝐷∗𝑖 should therefore be corrected by the FRET rates 
𝑘𝐹𝑅𝐸𝑇𝑖 =  𝐴𝐷𝑖
−1 −  〈𝐷〉
−1 for i=1-3 which considers the FRET efficiency dependent excitation of the 
acceptors using Equation 4.6 and from the short component of the donor crosstalk in the 
acceptor channel by the correction factor 𝑧𝐴 (Equation 4.7): 
 𝐴𝐷𝑖 =  
𝐴𝐷∗𝑖/𝑘𝐹𝑅𝐸𝑇𝑖
(
𝐴𝐷∗1
/𝑘𝐹𝑅𝐸𝑇2) + (𝐴𝐷∗2/𝑘𝐹𝑅𝐸𝑇2) + 𝐴𝐷∗3/𝑘𝐹𝑅𝐸𝑇3
    (4.6) 
   
 𝑧𝐴 =  (
𝐴𝐷∗0
𝐷2
) .𝐷1   (4.7) 
The FRET-sensitized decay time can as a result of these corrections be calculated by   
Equation 4.8: 
 〈𝐴𝐷〉 = =
 𝐴𝐷1 𝐴𝐷1 + 𝐴𝐷2 𝐴𝐷2 −  𝑧𝐴 𝐴1  
1 −  𝑧𝐴
 (4.8) 
The average FRET-efficiency and distances can be calculated using 〈𝐴𝐷〉 in Equations 2.9 and 
2.17  
Following the above corrections to account for unquenched donor emission and therefore the 
determination of pure FRET from quenching and sensitization of the FRET-pairs from    
Figure 4.13, we find for the Tb-to-QD-d-IgG and Tb-to-QD-d-F(ab) immunoassay, a FRET-
efficiency (acceptor channel fitting) of 34 and 38 % with an estimated donor to acceptor distance 
of 12.3 and 11.9 nm respectively. The donor channel fitting for Tb-to-QD-d-IgG is not 
convenient as the Tb decay curves are all stable and no quenching could be observed resulting 
to an almost similar lifetime of Tb alone and Tb in presence of QD. Donor channel fitting for 
Tb-to-QD-d-Fab resulted in a FRET-efficiency of 47 % with an estimated donor to acceptor 
distance of 11.2 nm. The results are summarized in Table 4.4. The similar FRET-efficiencies of 
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the IgG and F(ab) Tb-to-QD FRET systems indicate that the average donor-acceptor distances 
are similar for both systems. Intuitively, this is surprising because a F(ab) fragment is 
significantly smaller than an IgG. However, this finding confirms previous results [144] and 
could be related to the orientation of the antibodies on the QDs’ surface and the flexibility of 
the antibodies. IgGs and F(ab) were conjugated via sulfhydryl groups to the surface of the QDs 
leading to less random orientation as compared to labeling via primary amino groups on lysine 
residues, hence allowing for similar orientation of IgG and F(ab) on the QD. From the distance-
point-of-view, there is no reason to favor IgG vs F(ab) but using F(ab) bring more Tb per QD 
causing a higher FRET-sensitization, hence higher sensitivity. On the other hand, the average 
donor-acceptor distances of ca. 12 nm are very large when taking into account the size of 
QD705 (ca. 10x5 nm in TEM – Figure 4.5, and ca. 9 nm in diameter in DLS – Figure 4.6) and 
the direct surface labeling approach. Further investigations are necessary to explain this 
relatively long distance.  
Table 4.4. FRET efficiencies and donor-acceptor distance calculated from the decay times of the acceptor 
sensitization. < 𝑫 > corresponds to the average lifetime of Tb in absence of QD and < 𝑨𝑫 > is the 
average lifetime of QD in presence of Tb 
FRET system 
𝐹𝑅𝐸𝑇   
(acceptor channel) 
D-A distance  
(acceptor channel) 
< 𝐷 > < 𝐴𝐷 > 
Tb-to-QD-d-IgG 34 % 12.3 nm 2.20 ms 1.45 ms 
Tb-to-QD-d-F(ab) 38 % 11.9 nm 2.19 ms 1.36 ms 
    
Table 4.5 summarizes the Förster distances and LODs obtained for the Tb–QD605 and Tb–
QD705 FRET pairs, as well as LOD values obtained for the same Tb-to-QD FRET 
immunoassays against PSA using the readily surface-coated (thick PEG/polymer coating) 
hydrophilic QD605 and QD705 from the same supplier (Life Technologies). Tb–QD assays with 
compact QDs provide LODs below the clinical cut-off value for PSA (4 ng/mL) [184], and these 
LODs are also 6.2 (Tb-QD605) and 25 (Tb-QD705) fold lower compared to the same assays 
using the larger commercial QDs. It should be noted that the FRET assays, performed on a 
clinical plate reader, use ratiometric time-gated PL detection, which is known to provide very 
low coefficients of variation [148]. The 6.2 and 25 fold improvements are therefore very 
significant, particularly when taking into account the very low and clinically relevant 
concentrations, and the results confirm the superior performance of our compact QD–AB 
conjugates for homogeneous FRET immunoassays using serum samples. 
 
98 
 
Table 4.5. Förster distances R0 and LODs of Tb-QD FRET immunoassays against PSA. Acceptor-AB 
with “Mal1” corresponds to indirect conjugation via Mal1 ligand. Acceptor-AB with “d” corresponds to 
direct conjugation on the QDs’ surface. 
Donor-
AB 
Acceptor-
AB 
R0 
(nm) 
LOD compact 
QDs         
(ng/mL) 
LOD* Qdot ITKTM 
amino PEG 
(ng/mL) 
Clinical cut-
off level of 
PSA 
Tb-IgG 
QD605-
Mal1-F(ab) 
7.7 3.7 23 
4 ng/mL 
Tb-IgG 
QD705-
Mal1-F(ab) 
11.0 0.8 2.0 
Tb-IgG 
QD705-d-
IgG 
11.0 0.3 -- 
Tb-IgG 
QD705-d-
F(ab’)2 
11.0 -- -- 
Tb-IgG 
QD705-d-
F(ab) 
11.0 0.08 2.0 
* From Chapter 3. Same Tb-QD FRET immunoassays against PSA, which used same 
commercial QDs but with a thick PEG/polymer coating.  
 
4.4 Conclusions 
In this study we presented a technique for the preparation of compact, highly luminescent, and 
colloidally stable QDs. These QDs were further used for the simple and functional conjugation 
with ABs via Mal1 ligand and directly on the surface of the compact QDs, yielding one of the 
smallest fluorescent AB-nanoparticle conjugates to be used for FRET reported to date. Aqueous 
phase transfer was achieved by ligand exchange with the zwitterionic penicillamine and post-
functionalization with Mal1 bifunctional ligand containing reactive maleimide functions 
allowed conjugation with free sulfhydryl containing groups of ABs. Another post-
functionalization strategy involved was the direct conjugation of ABs containing free sulfhydryl 
groups on the surface of the compact QDs. Although these bioconjugation strategies were 
demonstrated only with InPZnS/ZnSe/ZnS, CdSe/ZnS, and CdSeTe/ZnS core/shell QDs and 
F(ab) antibodies via Mal1 and direct attachment of ABs on CdSeTe/ZnS core/Shell QDs, they 
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should be applicable to any kind of nanoparticle containing surface atoms with binding affinity 
for thiolate ligands and biomolecules containing sulfhydryl groups (e.g., on available cysteines). 
The immediate applicability of the compact QD–AB conjugates to biosensing was demonstrated 
in homogeneous FRET immunoassays against PSA, using Tb–ABs as FRET donors and the 
QD–ABs as FRET acceptors, both coupled by an immunological sandwich complex between the 
two ABs and the PSA biomarker. Detection of PSA in 50 μL serum samples with subnanomolar 
(2 pM = 0.08 ng/mL) detection limits showed the clinically relevant concentration range, over 
which these FRET immunoassays can be applied. Not only were the LODs of two Tb–QD FRET 
immunoassays (using 605 nm and 705 nm emitting QDs) well below the clinical cut-off value of 
PSA (4 ng/mL), the utilization of the compact QD–AB conjugates also provided a 6.2 and 25 fold 
sensitivity improvement compared to the same commercially available QDs that were 
purchased with a standard PEG/polymer-based coating. These highly sensitive and 
homogeneous Tb-to-QD FRET immunoassays are suitable for any other biomarker against 
which two specific ABs exist. Our results show that the compact QD–AB conjugates have a 
large potential for improving diagnostic applications, and given the multiplexing capability of 
Tb–QD FRET [145,150], we are confident that these small nanoparticle–AB fluorescent probes 
will become important players in clinical in vitro diagnostics.  
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5. Multiplexed detection of tumor markers 
 
5.1 Introduction 
Tumor markers which may also be called biomarkers are produced by tumors or by the body in 
response to cancers or of benign conditions [36]. In 2012 worldwide, the International Agency 
for Research on Cancer recorded 14.1 million new cancer cases with estimates for cancer deaths 
to be 8.2 million with a mortality rate of 22000 deaths per day. Cancer which is responsible of 
one in seven deaths worldwide totaling more deaths than AIDS, tuberculosis, and malaria 
combined, is believed to raise to 21.7 million new cancer cases and 13 million cancer deaths by 
2030 simply because of our growing and ageing population. The three most diagnosed cancers 
for both genders in economically developed countries were prostate (among males); breast 
(among females), lung and colorectal while in economically developing countries they were 
lung, liver, and stomach in males and breast, cervix uteri and lung in females  [185,186]. Thus, 
for cancer diagnosis, drug choice, and their early detection for patients long-term survival, such 
biomarkers represent ideal markers. Today there is a clear need for the simultaneous detection 
of different tumor markers from a single sample in order to provide clinicians with a more 
accurate and detailed picture of a disease state thus providing high quality care, and at the 
same time decreasing the time and cost of such diagnostics. Among existing multiplexing 
technologies such as quantitative reverse transcription-polymerase chain reaction (qRT-PCR) 
and enzyme-linked immunosorbent assay (ELISA), recent results have demonstrated the 
sensitive and multiplexed detection of different microRNAs using Tb-to-dye and Tb-to-QD 
FRET [145,152]. Despite the fact that qRT-PCR and ELISA are highly sensitive, they are time-
consuming, limited concerning high-throughput (qRT-PCR) and require washing and 
separating steps (ELISA).  
Up to now, LLC-to-dye FRET immunoassays have been demonstrated for the multiplexed 
detection of five different tumor markers in a single 50 µL serum sample. The authors were 
faced to biological crosstalk between the antibodies and the tumor markers, and optical 
crosstalk due to the overlapping of the broad emission spectra of the dyes used. In order to 
decode the FRET signal corresponding to each FRET-pair, a complex mathematical matrix 
correction was required [11]. Here we attempt a multiplexed LLC-to-QD FRET immunoassay 
involving 3 color quantum dots with emission maxima at 605 nm (QD605), 650 nm (QD650) 
and 705 nm (QD705) for the detection of carcinoembryonic antigen (CEA), neuron-specific 
enolase (NSE) and PSA from a single serum based sample. CEA and NSE are among the tumor 
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markers, for which the levels are monitored in combination with other tumor markers to get a 
clear diagnosis of small-cell lung cancer (SCLC) and/or non-small-cell lung cancer (NSCLC) 
[187,188]. In addition to CEA and NSE, we propose to detect PSA which is a biomarker used for 
characterizing and risk-access of prostate cancer prior to therapy [173,184,189,190]. As results 
from Chapter 3 suggested that for different clinical cut-off values QD705 should be used for 
the biomarker with the lowest cut-off and QD605 for the one with the highest cut-off, 
antibodies against CEA, NSE and PSA have been conjugated to QD650, QD605 and QD705 
respectively. Among these antigens, NSE has the highest cut-off level (12.5 ng/mL) [191,192] 
followed by CEA (5.0 ng/mL) [190,192] and PSA (4.0 ng/mL) [173,184,190]. Monoclonal 
antibodies used for specific biological recognition to their antigens have been verified. QDs used 
have allowed fitting the narrow PL bands in between and beyond the well-separated Tb 
emission bands resulting in minimal optical crosstalk and requiring no matrix correction. 
Homogeneous FRET immunoassays using the QD conjugates have been performed in a time-
gated mode achieving detection limits in 50 µL volume samples in the subnanomolar 
concentration range of the differently sized antigens. All LODs were below their clinical cut-off 
levels, showing the capability of our system for the simultaneous detection of various tumor 
markers where their corresponding ABs exist.  
                                      
5.2 Materials and Methods 
5.2.1 Materials 
Commercial eFluor quantum dots (discontinued) denoted as eQD605 and eQD650, emission 
maxima at 605 nm and 650 nm respectively, were kindly provided by the company 
Affymetrix/eBioscience as part of a sulfhydryl-reactive conjugation kit. Qdot® ITK™ amino 
PEG 705, referred as iQD705, emission maxima at 750 nm, were purchased from Life 
Technologies/Thermo Fisher Scientific and possess amine-derivatized polyethylene glycol 
ligands covalently attached to the amphiphilic coating rendering them water soluble and 
compatible for the attachment of biomolecules. eQD605 and eQD650 possess maleimide 
functional groups on the surface which selectively bind to free sulfhydryl groups. The reactive 
amino groups of the ligand on the surface of the iQD705 allow for the attachment of 
biomolecules via N-hydroxysuccinimide (NHS) ester conjugation. The NHS-activated terbium 
complex Lumi4-Tb was kindly provided by Lumiphore in lyophilized form. Tumor 
markers/biomarkers/antigens carcinoembryonic antigen (CEA, 180kDa), neuron-specific 
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enolase (NSE, 95 kDa), prostate specific antigen (PSA, 32 kDa) and monoclonal primary 
antibodies against CEA (IgGs “GFR44” and “G15”), NSE (IgGs “E15” and “E20”), PSA (IgGs 
“PSR222” and “PSS233”) were provided by Cezanne/Thermo Fisher. IgGs were fragmented to 
F(ab’)2 using a Pierce™ Mouse IgG F(ab′) F(ab′)2 preparation kit and following the instructions 
provided by the supplier (Thermo Fisher Scientific). Bovine calf serum was provided by 
Cezanne/Thermo Fisher Scientific. Sulfo-EMCS (a water-soluble heterobifunctional amine-to-
sulfhydryl cross-linker that contains NHS ester on one end and a maleimide reactive group on 
the other end) used to transform the amino-reactive QDs into maleimide-reactive QDs was 
purchased from Sigma-Aldrich. Bovine serum albumin (BSA), Tris(hydroxylmethyl)-
aminomethane (TRIS/Cl), sodium tetraborate (borate), phosphate buffer saline (PBS) and 
Tris(2-carboxyethyl)phosphine (TCEP) were also purchased from Sigma-Aldrich. 
5.2.2 Methods 
5.2.2.1 Preparation of Tb-AB conjugates 
Lumi4-Tb-NHS was dissolved to 8 mM in anhydrous DMF and reacted individually in molar 
excess to available primary amines of “GFR44”, “E15” and “PSR222” IgG antibodies by mixing 
the solutions in 100 mM carbonate buffer (pH 9). The mixtures were incubated for 2 h at room 
temperature while rotating at 30 rpm using an ELMI Intelli-Mixer. The IgG-Tb conjugates 
were purified and washed 4 times with 100 mM TRIS/Cl pH 7.4 using 50 kDa molecular weight 
cut-off (MWCO) spin columns from Millipore, to remove the unbound Tb-complex. The purified 
conjugate was stored at 4 °C. 
Tb concentrations were determined by absorbance measurements at 340 nm using a molar 
absorptivity of 26 000 M-1 cm-1 as provided by the manufacturer. Antibodies were quantified by 
absorbance measurements at 280 nm using a molar absorptivity of 210 000 M-1 cm-1. The 
labeling ratios were estimated by linear combination of the respective absorbance values of Tb 
and antibodies within the Tb-antibody conjugates. 
5.2.2.2 Preparation of QD-AB conjugates 
IgGs “G15”, “E20” and “PSS233” were fragmented to F(ab’)2 using Pierce™ Mouse IgG F(ab′) 
F(ab′)2 preparation kit following the instructions provided by the supplier. eQDs 605 and 650 
provided in lyophilized form was reconstituted according to the conjugation kit protocol. The 
fragmented antibodies against CEA and NSE in 1× PBS buffer were mixed directly with      
eQD 650 and eQD605 respectively. Conjugation of F(ab’)2 to iQD705 was performed using sulfo-
EMCS where disulfide bonds (S-S) on the F(ab’)2 against PSA were reduced to sulfhydryls    (S-
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H) using 45 min of incubation (rotating at 30 rpm) with 5 mM of TCEP in 1x PBS buffer (pH 
7.4). Maleimide-activated iQD705 and reduced F(ab’)2-PSS233 were purified 2 times with        
1x PBS from excess sulfo-EMCS and TCEP using a 30 kDa MWCO spin column from Millipore 
at 1000 g and 4000g respectively. The resulting purified solutions were mixed and all QD 
conjugations were incubated for 6 h while rotating at 30 rpm in the dark at room temperature. 
The QD-conjugates were washed 4 times against unbound F(ab’)2 with 100 mM borate buffer 
(pH 8.4) at 1000g and the purified QD-conjugates were further centrifuged at 4000 g where 
supernatants were taken and stored at 4 °C. 
QD-AB conjugates concentrations were calculated by absorbance measurements using molar 
absorptivities of 2.5 × 105 M-1 cm-1 (at 594 nm) for eQD605, 1.1 × 106 M-1 cm-1 (at 641 nm) for 
eQD650 and 8.3 × 106  M-1 cm-1 at (405 nm) for iQD705 [176,193]. F(ab’)2 concentrations were 
determined using a molar absorptivity of 140 000 M-1 cm-1 at 280 nm. The labeling ratios were 
estimated by linear combination of the respective absorbance values of QDs and ABs within the 
QD-AB conjugates.   
5.2.2.3 Optical characterization 
Absorption spectra were measured on a Lambda 35 UV/Vis spectrometer from PerkinElmer. PL 
spectra and decay curves were recorded on a FluoTime 300 lifetime fluorescence spectrometer 
from PicoQuant using as excitation sources a continuous-wave Xe lamp for spectra acquisition, 
a Xe flash lamp (100 Hz repetition rate) for Tb decay curves, and a 405 nm diode laser 
(Edinburgh Instruments) for QD decay curves. Tb-conjugates and QD-conjugates were 
measured in 100 mM TRIS/Cl buffer (pH 7.4) and 100 mM borate buffer (pH 8.4) respectively. 
PL decay curves were acquired directly from the FRET immunoassay samples on the modified 
“KRYPTOR compact plus” and the EI plate reader using as excitation source a 20 Hz nitrogen 
laser operating at 337.1 nm. Spectral separation in the detection channels was performed by 
optical bandpass filters, where the number after the center wavelength represents the 
guaranteed minimum bandwidth (GMBW) for Semrock filters and full-width-at-half-maximum 
(FWHM) for Delta filters: 494 / 20 nm (Semrock) for Tb, 607 / 8 nm (Delta) for eQD605,         
660 / 13 nm (Semrock) for eQD650 and 707 / 16 nm (Semrock) for iQD705.  
5.2.2.4 FRET immunoassays 
All FRET assays were measured in black 96-well microtiter plates with an optimal working 
volume of 150 µL after an incubation time of 180 min at 37°C. Tb-AB and QD-AB conjugates 
were each dissolved in 50 µL of 10 mM TRIS/Cl buffer (pH 7.4) containing 0.5 % of BSA. To this 
100 µL solution of Tb-AB/QD-AB, 50 µL of varying concentrations of CEA, NSE or PSA 
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(dissolved in serum) were added. All samples were prepared in triplicates except for the 
antigen-free samples, which were prepared 10 times and measured 3 times. Time-gated (100 – 
900 µs) and time-resolved PL intensity measurements were acquired on a modified “KRYPTOR 
compact plus” and EI plate reader respectively. 
 
5.3 Results and discussion  
5.3.1 Tb-AB and QD-AB conjugates characterization 
Tb-AB characterization 
Lumi4-Tb-NHS complexes were directly labeled to available primary amines of “GFR44”, “E15” 
and “PSR222” IgG ABs. Tb per IgG conjugation ratios of 10 ± 2 (Tb-GFR44), 13 ± 3 (Tb-E15) 
and 10 ± 2 (Tb-PSR222) were determined by UV-Vis absorption spectroscopy using the molar 
absorptivities of Lumi4-Tb and IgGs as mentioned in the Methods section 5.2.2.1 and Beer–
Lambert's law (Figure 5.1, left). The results are summarized in Table 5.1. Upon excitation at 
365 nm the PL spectrum of Tb–AB shows the characteristic Tb emission lines at 495 nm, 545 
nm 585 nm and 625 nm which are more prominent than the emission lines ranging from ca. 
650 nm to 700 nm. Due to the forbidden 4f-4f transitions, the obtained decay curves have an 
almost single exponential decay with an average PL lifetime of ca. 2.6 ms (Figure 5.1, right). 
 
 
 
 
 
 
Figure 5.1. Left: absorption (black, red and blue lines) and PL (green, excitation wavelength 365 nm) 
spectra of Tb–AB conjugates. Right: Tb–AB conjugates normalized PL decay curves (490 ± 0.5 nm) upon 
pulsed excitation at 365 nm with a repetition rate of 100 Hz. Amplitude-averaged decay time ca. τ(Tb) = 
2.6 ms. 
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QD-AB characterization 
As FRET is highly distance dependent, the choice of F(ab’)2 conjugation to QDs would result in 
a shorter separation distance between the QDs and Tb in sandwich immunoassays, hence 
higher FRET efficiencies and sensitivities than when using IgGs. Furthermore, the small size 
of the F(ab’)2 together with its 2 binding sites for more binding opportunity, would also be 
beneficial to the increasing biomarker sizes (32 kDa to 180 kDa) in the FRET immunoassays 
[25]. All QD-AB conjugations were performed through sulfhydryl chemistry. F(ab’)2 of “E20”, 
“G15” were conjugated to eQD605 and eQD650 respectively while F(ab’)2 of “PSS233” to 
iQD705. Fragmented ABs of “E20” and “G15” were not conjugated to iQD705 because of the 
relatively large size of their antigens and the thick polymer/PEG coating of the iQDs causing 
inefficient FRET for their detection. QD-AB conjugates concentrations were calculated by UV-
Vis absorption spectroscopy using molar absorptivities of eQDs, iQD705 and F(ab’)2 mentioned 
in the Methods section 5.2.2.2. The calculated concentrations and labeling ratios are 
summarized in Table 5.1. Emission spectra and PL decay curves were measured upon 
excitation at 405 nm using a Xe-CW lamp and a 405 nm diode laser (Edinburgh Instruments) 
respectively and are shown in Figure 5.2.  
The QDs emission spectra show narrow and Gaussian shape of the emission bands with a 
broader FWHM for iQD705 compared to the eQDs. Detection of the QD PL with a low PL 
background of Tb oriented our choice to QDs605/650/705 which allowed to fit the QDs PL 
spectra in between (for eQD605/650) or beyond (for iQD705) the Tb PL bands. The PL decays of 
all QDs are multi-exponential with amplitude averaged decay times of 7.4 ± 0.9 ns for eQD605, 
17.4 ± 2.5 ns for eQD650, and 63.5 ± 10.8 ns for iQD705. The spectral overlap integrals 
(Equation (2.4)) and the Förster distances (Equation (2.3)) were calculated using the QD 
molar absorptivity spectra and the normalized area Tb PL spectrum. Large R0 and spectral 
overlap resulted due to the high extinction coefficients and broad absorption range of QDs. As 
expected from the spectral overlaps in Figure 5.3 the Tb-iQD705 FRET-pair provided the 
largest Förster distance (R0 = 11.2 ± 0.6 nm), followed by the Tb-eQD650 FRET-pair (R0 = 10.8 
± 0.5 nm), and the Tb-eQD605 FRET-pair (R0 = 7.6 ± 0.4 nm).  
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Figure 5.2. Optical characterizations of QD-AB conjugates. (A) Absorption (dash dotted lines) and PL 
(solid lines) of eQD605 (orange), eQD655 (red) and iQD705 (purple). (B) Pulsed (405 nm diode laser at 1 
MHz for eQD605/650 and 0.5 MHz for iQD705) excitation was used to measure the PL decay curves at 
the respective PL peaks of the QDs. The multi-exponential decay curves (same colors as in (A) gave 
amplitude-averaged decay times of τ(eQD605) = 7.4 ± 0.9 ns, τ(eQD655) = 17.4 ± 2.5 ns, and τ(QD705) = 
63.5 ± 10.8 ns. 
 
 
 
 
 
 
 
Figure 5.3. Overlap between QDs absorption spectra (eQD605: orange; eQD650: red; eQD705: purple)) 
and area-normalized Tb emission spectra (olive green). Förster distances: Tb-eQD605 = 7.6 ± 0.4 nm,   
Tb-eQD650 = 10.8 ± 0.5 nm and Tb-iQD705 = 11.2 ± 0.6 nm. 
 
Table 5.1. Overview of the concentration of donor-AB and acceptor-AB conjugates with their respective 
labeling ratio. 
Donor-AB 
[Tb] 
(µM) 
[AB] 
(µM) 
Tb/AB Acceptor-AB 
[QD] 
(nM) 
[AB] 
(µM) 
AB/QD 
Tb-GFR44 33.6 3.5 9.7 ± 2.0 eQD650-F(ab’)2 480 2.0 4.2 ± 2.0 
Tb-E15 43.8 3.5 12.5 ± 3.0 eQD605- F(ab’)2 200 0.7 3.8 ± 2.0 
Tb-PSR222 33.0 2.8 9.9 ± 2.0 iQD705- F(ab’)2 190 2.8 14.9 ± 7.0 
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5.3.2 Single quantitative detection of tumor markers        
The clinical cut-off level of CEA, NSE and PSA being 5 ng/mL, 12.5 ng/mL and 4 ng/mL 
respectively, our acceptor-AB conjugates were chosen as such, i.e eQD605-G15; eQD650-E20; 
iQD705-PSS233, based on the results obtained in Chapter 3 where we concluded that for 
different clinical cut-off values QD705 should be used for the biomarker with the lowest cut-off 
and QD605 for the one with the highest cut-off.   
Within all FRET experiments the concentrations of the donor-AB and acceptor-AB were kept 
constant at 1.5 nM (for Tb-GFR44 and Tb-E15), 3 nM (for Tb-PSS233) and 1.5 nM (for all the 
QD-AB conjugates) while the antigens’ concentrations were increased. 50 µL of each donor-AB 
and acceptor-AB were mixed with 50 µL of the antigen prepared in serum, totaling a working 
volume of 150 µL. FRET immunoassays were measured on the “KRYPTOR compact plus” in a 
time-gated mode ranging from 100 µs to 900 µs and  fitted with the appropriate bandpass 
filters for spectral separation in the Tb (494 / 10 nm) and QDs (607 / 8 nm for eQD605, 660 / 13 
nm for eQD650 and 707 / 16 nm for iQD705) detection channels. As shown in Figure 5.4, the 
calibration curves correspond to the detection of the biomarkers using one FRET-pair and one 
biomarker at increasing concentrations. All three sensors exhibit significant FRET-ratio 
increase with increasing antigen concentration due to FRET sensitization of the QDs by Tb-
donors. The dynamic range differs depending on the QDs used, ranging from 30 pM to ca. 3 nM 
for eQD605 and ca. 5 nM for eQD650, and 5 pM to ca. 6 nM for iQD705. One reason could be of 
the different labeling ratio of active AB per QDs. From Figure 5.4, we can observe the best 
sensitivity for the FRET sensor Tb-iQD705 where the FRET-ratio at maximum is ca. one order 
of magnitude higher than for the Tb-eQD605 FRET-pair. The PL decay curves (Figure 5.5) of 
the QDs and Tb measured on the EI plate reader show FRET sensitization of the QDs with 
increasing antigen concentration and a lower spectral crosstalk of Tb in the iQD705 detection 
channel. Stable Tb signals in the Tb detection channel reveal no obvious quenching due to 
FRET with increasing antigen concentration and are favorable for ratiometric measurements in 
multiplexing. Quenching of Tb signals in a mixture of Tb conjugates would make it difficult to 
perform ratiometric measurements as we would not be able to discriminate which FRET-pairs 
caused the quenching. The long decay component in the QDs detection channel comes from the 
optical crosstalk of Tb in these channels. Due to the biological recognition of the antibodies to 
its antigen, the close proximity of Tb and QD lead to a new decay time component (in the 10 to 
100 µs range) with increasing intensity generated by FRET.   
To compare the sensitivity of the Tb-to-QD FRET pairs for the different antigens, LODs were 
calculated using the slope of the linear part (red data points for statistical analysis) of the 
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calibration curve (Figure 5.4), the standard deviation of 30 measurements of samples without 
any antigen and Equation 2.3. The LODs (summarized in Table 5.2) of the FRET 
immunoassays were all in the subnanomolar antigen concentration range and well below the 
clinical cut-off values of CEA, NSE and PSA.             
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4. FRET-ratio and rel. FRET-ratio (normalized to unity at 0 nM antigen concentration) as a 
function of antigen concentration in a time-gated mode between 0.1 - 0.9 ms. The increase in FRET-ratio 
is caused by FRET until a saturation where no further FRET sensitization occurs. (A) Tb-eQD650 FRET-
pair for the detection of CEA (B) Tb-eQD605 FRET-pair for the detection of NSE and (C) Tb-iQD705 
FRET-pair for the detection of total PSA. Note: Only linear part of red data points were used for LOD for 
(C)  
Table 5.2. Förster distance and LODs (in nM and ng/mL) for the single detection of the biomarkers CEA, 
NSE and PSA in homogeneous FRET immunoassays. 
Donor-AB Acceptor-AB Antigen R0 (nm) LOD (nM) LOD (ng/mL) 
Tb-GFR44 eQD650- F(ab’)2 CEA 11 0.007 1.2 
Tb-E15 eQD605- F(ab’)2 NSE 8 0.016 1.5 
Tb-PSR222 iQD705- F(ab’)2 PSA 11 0.006 0.2 
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Figure 5.5. PL decay curves of the different QD channels and Tb of the singleplex FRET immunoassays 
showing sensitization of the QDs due to FRET with stable Tb intensities. PL decay curves of (A) eQD605 
(607 / 8 nm filter) (B) eQD650 (660 / 13 nm filter) (C) iQD705 (707 / 16 nm filter) and (D-F) Tb (494 / 20 
nm filter) with increasing concentration of NSE, CEA and TPSA respectively. Black curves represent the 
FRET-pairs containing no antigen in solution. (A-C) Short decay component (in the µs range) arise from 
the direct excitation of QDs and a long Tb component (in the ms range) from spectral crosstalk of Tb in 
the QDs detection channels. With increasing antigen concentration, a new FRET decay component in the 
tens to hundreds of µs range can be observed with increasing intensity as indicated by the black arrows. 
(D-F) Stable Tb signals show negligible quenching due to FRET which is favorable for ratiometric 
measurements when performing multiplexing.    
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5.3.3 Multiplexed quantitative detection of tumor markers 
We challenged our singleplex FRET immunoassay which yielded LODs in the subnanomolar 
range, in an attempt to detect the three antigens from a single sample. The detection of 
multiple biomarkers from a single sample in FRET immunoassays requires careful testing for 
biological and optical crosstalk. These control measurements will give us an indication whether 
or not a spectral crosstalk correction has to be applied.   
Biological crosstalk 
Biological crosstalk may arise in our case when ABs for an intended antigen bind to another 
antigen, leading to a false response of the assay and an overestimation or underestimation of 
the concentrations. To investigate such possible crosstalk we designed immunoassays to test 
the specificity of CEA-AB FRET-pairs (in eQD650 detection channel), NSE-AB FRET-pairs (in 
eQD605 detection channel) and PSA-AB FRET-pairs (in iQD705 detection channel). As shown 
in Figure 5.6, the addition of CEA antigen with CEA-AB FRET-pairs resulted in a classical 
homogeneous FRET immunoassay with increasing FRET-ratio caused by the binding of CEA-
ABs to CEA antigen, while the addition of NSE and PSA antigens caused no change in the 
FRET-ratio. The same results were obtained when using the other FRET-pairs to detect CEA 
and PSA. This proves that virtually no biological crosstalk exists between the ABs and the 
antigens if they were to be used in a multiplexed format. We could also expect these results 
since we are using monoclonal antibodies that were already optimized for FRET assays in 
commercial kits supplied by the company Cezanne/Thermo Fisher.  
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Figure 5.6. Biological crosstalk evaluation of different FRET-pairs for different antigens (AG). (A) CEA 
ABs used to detect CEA, NSE, and TPSA and measured in eQD650 detection channel. (B) NSE ABs used 
to detect CEA, NSE, and TPSA and measured in eQD605 detection channel. (C) TPSA ABs used to detect 
CEA, NSE, and TPSA and measured in iQD705 detection channel. 
Optical crosstalk 
Optical crosstalk (or bleedthrough) is a phenomenon that can occur when the fluorescence of a 
fluorophore is detected in other detection channel because part of the photons goes through the 
“wrong optical” path, often caused by spectral overlap of 2 different fluorophores emission 
profiles and inefficient spectral separation. Here, we will test the optical crosstalk by inspecting 
the influence of: eQD605 in the eQD650 and iQD705 detection channel fitted with bandpass 
filters 660 / 13 nm and 707 / 16 nm; eQD650 in the eQD605 and iQD 705 detection channel 
fitted with filters 607 / 8 nm and 707 / 16 nm; and iQD705 in the eQD605 and eQD650 
detection channels fitted with filters 607 / 8 nm and 660 / 13 nm. We therefore devised 
immunoassays (Figure 5.7), in which all FRET sensors (CEA ABs, NSE ABs and PSA ABs) 
with one antigen (CEA, NSE or PSA) in increasing concentrations were present and detected in 
the QD detection channels. For example, to an increasing concentration of CEA antigen, CEA-
0 20 40 60 80 100 120 140 160 180 200
1.0
1.2
1.4
1.6
1.8
2.0
2.2
2.4
 NSE AB + NSE AG
 NSE AB + CEA AG
 NSE AB + TPSA AG
re
l.
 F
R
E
T
-r
a
ti
o
AG (ng/mL)
0 20 40 60 80 100 120 140 160 180 200
1.0
1.2
1.4
1.6
1.8
2.0
2.2
2.4
 CEA AB + TPSA AG
 CEA AB + NSE AG
 CEA AB + CEA AG
re
l.
 F
R
E
T
-r
a
ti
o
AG (ng/mL)
A 
A 
A 
C 
B 
 
112 
 
AB+NSE-AB+PSA-AB were added and the sensitized emission of the eQD650 was measured in 
eQD605, eQD650 and iQD705 detection channels. The same immunoassay was performed by 
changing the antigen from CEA to NSE and to PSA. In the eQD605 detection channel, we can 
observe a relatively low spectral crosstalk from eQD650 and no bleedthrough from iQD705. In 
the eQD650 detection channel we can observe a constant and low optical crosstalk from iQD705 
and very low bleedthrough from eQD605. The iQD705 detection channel shows no crosstalk 
from eQD605 and negligible bleedthrough from eQD650. We can conclude from these findings 
that the low spectroscopic crosstalk arising from the choice of QDs with narrow and 
symmetrical wavelength spectra selected to fit in between and/or beyond the well separated Tb 
emission bands, requires no optical crosstalk or matrix correction for the determination of the 
antigens’ concentration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7. Spectral crosstalk: (A) eQD650 channel for detection of CEA with negligible bleedthrough 
from the other sensitized QDs (B) eQD605 channel for detection of NSE with low spectral crosstalk from 
the sensitized eQD650 and no bleedthrough from the sensitized iQD705 (C) iQD705 channel for detection 
of TPSA showing no crosstalk from sensitized eQD605 and negligible bleedthrough from sensitized 
eQD650.     
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Multiplexing for the detection of CEA, NSE and PSA 
From the calibration curves (Figure 5.7 and reformatted Figure 5.8) we calculated the LODs 
in presence of all FRET-pairs and single antigen to compare with the singleplex immunoassays 
where only one FRET-pair and one antigen were present. The LODs (Table 5.3) determined 
when all FRET-pairs were present show an increase of LOD for CEA and NSE antigens from 
1.2 ng/mL and 1.5 ng/mL in the singleplex format to 3.1 ng/mL and no deviation of LOD for 
PSA. One reason for these elevated LODs could be caused by the three times higher donor 
signal bleeding through the eQD605/650 channels conveying more noise in the measurements 
favoring a less steep slope as compared to the singleplex format. The iQD705 detection channel 
is spared from the influence of the Tb donor signal as there is negligible emission of Tb in the 
700 nm wavelength range.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8. “Singleplex” FRET immunoassay calibration curves for (A) CEA; LOD: 3.1 ng/mL (B) NSE; 
LOD: 3.1 ng/mL (C) TPSA; LOD: 0.2 ng/mL, with all FRET-pairs and one antigen present in solution.   
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Following the control measurements, we proceed to the triplex detection of CEA, NSE and PSA 
from a single sample. For each measurement, 50 µL of serum-based solutions containing 
increasing concentration of CEA, NSE and PSA were mixed to solutions of 100 µL of the donor 
and acceptor ABs containing constant concentration of the probes, similar to the singleplex 
immunoassays. As it can be observed in Figure 5.9, the FRET-ratio increased as a result of the 
specific recognition of the ABs to their respective antigens, allowing close proximity of Tb and 
QDs, even though 6 different types of ABs were present in a single serum-based solution. In 
comparison to the “singleplex” format where all FRET-pairs and one antigen is present, the 
FRET-ratios for the triplex format is higher for the Tb-eQD605/650 FRET-pairs and a nearly 
perfect overlap of the calibration curves for the Tb-iQD705 FRET-pair. This intensity offset in 
the eQD605 and eQD650 calibration curves is caused by a lower Tb intensity when all the AGs 
are present (Tb intensity is quenched stronger than for singleplexed assay). The lower Tb 
intensity (in the denominator of the FRET-ratio) increases the FRET-ratio. This assumption 
was confirmed by comparing the delta (Δ) FRET-ratio curves (Δ FRET-ratio reflects the specific 
signal, obtained by subtracting the background from the signal [194]) of the “singleplex” and 
triplexed format for which, we observed very similar slopes. The calculated LODs (Table 5.3) 
followed the steepness of the slopes with 3.6 ng/mL for CEA, 3.5 ng/mL for NSE and 0.3 ng/mL 
for PSA, which are all well below the clinical cut-off levels (5.0 ng/mL for CEA, 12.5 ng/mL for 
NSE and 4.0 ng/mL for TPSA) of the tumor markers. 
The probability of measuring the same concentration of tumor markers in a single serum 
sample is usually low. We therefore performed a “worst-case scenario” assay where we 
challenged our immunoassay with a combination of high and low target concentrations. Seven 
different samples of the antigens at varying concentrations ranging from 0.2 nM to 2 nM were 
prepared and measured using the three FRET-ratio vs AG concentration curves of the triplexed 
immunoassay (Figure 5.9 A-C, black data points). For calculation of the prepared antigen 
concentrations from the calibration curves shown in Figure 5.10, calibration curves A and C 
were fit to a straight line and calibration curve B was fit to a quadratic function. Dashed lines 
in Figure 5.11 represent known concentrations within the 7 samples containing the different 
antigens while the symbols with arrow bars are the estimated concentrations from the 
triplexing calibration curves of CEA, NSE and PSA. Overall, CEA, NSE and PSA could be 
detected with high precision with minor deviations from known concentrations. The 
concentration of the samples could be directly estimated from the calibration curves without 
the need of a matrix correction making our triplexing immunoassay easy and simple to 
produce.     
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Figure 5.9. FRET-ratio and Δ FRET-ratio curves for the “singleplex” format (all FRET-pairs with only 
one antigen) and triplexed format in function of their respective antigen concentrations. Red and black 
data points represent “singleplex” and triplexing FRET immunoassays respectively. We can observe an 
unusual high FRET-ratio between the 2 immunoassays (A-C). By plotting the specific signal in function 
of the antigens’ concentration, we find a less steep slope from the triplexing in comparison to the 
“singleplex” format (D-E). Negligible deviation of the sensitivity for TPSA (F).     
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Figure 5.10. Triplexed FRET immunoassay calibration curves for (A) CEA; LOD: 3.6 ng/mL (B) NSE; 
LOD: 3.5 ng/mL and (C) TPSA; LOD: 0.3 ng/mL. Calibration curves (A) and (C) were fit to a straight line 
and calibration curve (B) was fit to a quadratic function, for the estimation of the calculated 
concentrations.  
 
 
 
 
 
 
Figure 5.11. Triplexed "worst-case scenario" assay with a combination of high and low concentrations of 
antigens ranging from 0.2 nM to 2 nM. Dash lines and data points with error bars are color coded. Dash 
lines represent known prepared concentrations. Data points were estimated from triplexing calibration 
curves and error bars resulted from triplicate measurements.  
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Table 5.3. LODs overview of singleplex, “singleplex” and triplex format of the FRET immunoassays. All 
the LODs are below the clinical cut-off levels – 5.0 ng/mL for CEA, 12.5 ng/mL for NSE and 4.0 ng/mL for 
TPSA. 
Donor-AB Acceptor-AB Antigen LOD (nM) LOD (ng/mL) 
Singleplex format 
Tb-GFR44 eQD650-F(ab’)2 CEA 0.007 1.2 
Tb-E15 eQD605-F(ab’)2 NSE 0.016 1.5 
Tb-PSR222 iQD705-F(ab’)2 TPSA 0.006 0.2 
“Singleplex” format – all FRET-pairs / 1 antigen only 
Tb-GFR44 eQD650-F(ab’)2 CEA 0.017 3.1 
Tb-E15 eQD605-F(ab’)2 NSE 0.033 3.1 
Tb-PSR222 iQD705-F(ab’)2 TPSA 0.006 0.2 
Triplex format 
Tb-GFR44 eQD650-F(ab’)2 CEA 0.020 3.6 
Tb-E15 eQD605-F(ab’)2 NSE 0.035 3.5 
Tb-PSR222 iQD705-F(ab’)2 TPSA 0.009 0.3 
 
5.4 Conclusions 
Our multiplexed homogeneous FRET immunoassay necessitating no washing or purification 
steps has been able to simultaneously detect 3 differently sized tumor markers from a single 
serum sample of CEA (180 kDa), NSE (95 kDa) and PSA (32 kDa) using Tb and QD probes 
conjugated to their respective monoclonal antibodies conferring no biological crosstalk. Taking 
advantage of the narrow and Gaussian emission spectra of the QDs and the well separated Tb 
emission bands together with the appropriate optical bandpass filters, allowed for negligible 
optical crosstalk. Therefore, no matrix correction was necessary to determine the tumor marker 
concentrations. Monoclonal antibodies used were able to detect specifically their respective 
targets bringing their FRET-pairs in close proximity and the excitation of Tb at 337 nm allowed 
the sensitization of multiple QDs at the same time due to FRET. After a delay of several µs, a 
time-gated window between 0.1 – 0.9 ms was applied to the measurements in order to 
eliminate background signals coming from the autofluorescence of the biological samples and 
the direct excitation of the QDs. LODs calculated in 50 µL volume samples were all below the 
clinical cut-off levels of the tumor markers, where higher LODs we observed for the triplexed 
format as compared to the singleplex format except for PSA. The contamination of the 
eQD605/650 detection channels from the 3 times more Tb signal resulted in an increase in LOD 
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whereas virtually no Tb emission can be detected in the iQD705 detection channel. Detection 
limits of the tumor markers in the subnanomolar range (few ng/mL) within a complex 
environment as in serum and containing 9 different biomolecules demonstrated the immediate 
applicability to diagnostic applications for sensitive multiplexed measurements. 
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6.  Upconverting nanoparticles for bio-sensing 
 
6.1 Introduction 
Upconversion is a process where low energy light (near-infrared (NIR) or infrared (IR)) is 
converted to higher energies (UV to NIR) by means of stepwise absorption and energy transfer 
processes. Similar to lanthanide complexes, lanthanide-doped upconversion nanoparticles 
(UCNPs) possess very narrow emission bands in the broad wavelength region spanning the UV, 
visible and NIR allowing them to function as energy donors with an assortment of acceptors in 
FRET-based biosensing [16–19]. The large anti-Stokes shift, long luminescence lifetime, 
extreme photostability and NIR excitation of UCNPs results in the efficient reduction of 
background fluorescence arising from cells and biomolecules normally occurring at higher 
energy excitation. Another advantage in addition to less autofluorescence is lower phototoxicity 
compared to UV or blue light used for the excitation of most common dyes [95,111,195].  
In this work we performed a detailed structural and optical characterization of three types of 
PEGylated erbium and ytterbium doped NaGdF4 UCNPs, namely NaGdF4:Er3+,Yb3+ core only 
(core-doped) as well as core-shell nanostructures composed of either a NaGdF4:Er3+,Yb3+ core 
and an undoped NaGdF4 shell (core-doped/shell, NaGdF4:Er3+,Yb3+/NaGdF4) or an undoped 
NaGdF4 core and a Er3+/Yb3+ doped NaGdF4 shell (core/shell-doped, NaGdF4/NaGdF4:Er3+,Yb3+). 
All UCNPs were synthesized via a thermal decomposition of trifluoroacetate precursors in 1-
octadecene and oleic acid by our collaborators from Institut National de la Recherche 
Scientifique (INRS – Centre Energie Matériaux Télécommunication), Varennes (QC), Canada 
[73,97,107]. The characterization of morphological and photophysical properties, and in 
particular their photoluminescence (PL) decays are a prerequisite for selecting suitable FRET 
donor candidates [161]. The three types of PEGylated UCNPs were characterized by 
transmission electron microscopy (TEM), powder X-ray diffraction (XRD) and time-resolved 
spectroscopy to gain information on the PL decay times of the UNCPs. TEM images reveal 
rather spherical UNCPs of sizes ranging from ca. 11 nm to 23 nm while XRD patterns show a 
hexagonal (-) phase of NaGdF4. PL decay analysis at the green (540 nm) and red (660 nm) 
upconversion emission of the Er3+ ions was performed on a fluorescence plate reader with a 980 
nm diode laser excitation. Intensity averaged decay times ranged from ca. 84 – 160 µs at 540 
nm and ca. 180 – 360 µs at 660 nm. The longest lifetimes were observed for the core/shell-doped 
UCNPs. Combination of Er3+ donor ions close to the UCNP surface and the long decay times 
suggest that these UCNPs may be highly interesting FRET donors with suitable FRET 
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acceptors for bio-sensing. As a proof-of-principle, we attempt a homogeneous UCNPs-to-dye 
FRET assay, which was based on the hybridization between oligonucleotides conjugated on the 
UCNPs and the complementary organic dye Cy3.5 labelled oligonucleotides.  
6.2 Materials and Methods  
6.2.1 Materials 
Starting materials such as lanthanide oxides (Gd2O3, REacton®, 99.999 %, < 10 Micron Powder; 
Yb2O3, REacton®, 99.998 %, Powder; Er2O3, REacton®, 99.99 %, Powder, Alfa Aesar, Ward Hill, 
USA), sodium trifluoroacetate (CF3COONa, 98 %, Sigma Aldrich, St. Louis, USA), 
trifluoroacetic acid (CF3COOH, 99 %, Alfa Aesar, Ward Hill, USA), 1-octadecene 
(CH3(CH2)15CH=CH2, tech. 90 %, Alfa Aesar, Ward Hill, USA), oleic acid 
(CH3(CH2)7CH=CH(CH2)7COOH, tech. 90 %, Alfa Aesar, Ward Hill, USA), N2H-PEG-COOH (α-
amino ω-carboxy terminated poly(ethylene, N2H-CH2CH2O-[CH2CH2O]n- CH2CH2COOH, Mn = 
700, Polymer Source Inc., Montreal, Canada), and hydrochloric acid (HCl, Reagent A.C.S., 
Fisher Scientific, Nepean, Canada) were used without further purification. 
Tris(hydroxymethyl)-aminomethane, bovine serum albumin, and HEPES were purchased from 
Sigma-Aldrich. Oligonucleotides were purchased HPLC purified from Eurogentec. The 
synthesis of the UCNPs was carried out in a well-ventilated fume hood as described previously 
in the references [107,196].  
6.2.2 Methods 
6.2.2.1 Instruments 
Analysis of size and shape was measured by TEM with a Philips CM200 high-resolution 
transmission electron microscope (HRTEM). XRD pattern for crystallinity and phase 
determination was performed on a Bruker D8 Advanced Diffractometer (Cu Kα radiation). For 
FTIR spectroscopy, aqueous solutions of UCNPs were dropped on Real Crystal® NaCl IR cards 
(9.5 mm aperture, International Crystal Laboratories) and spectra were recorded after drying 
by use of a Nicolet 6700 FTIR spectrometer from Thermo Electron Corporation. The 
hydrodynamic diameter of the PEGylated UCNPs was measured by dynamic light scattering 
(DLS) on a Malvern Zetasizer NanoZS. Multiple runs (>3) were performed and the 
hydrodynamic diameters were averaged. The data were collected in automatic mode and 
expressed in number %. For upconversion emission measurements, dispersions of the 
nanoparticles were transferred into glass cuvettes and placed into a temperature-controlled 
cuvette holder (qpod 2e by Quantum Northwest, Washington, USA) allowing for wireless 
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temperature control through USB using the Q-Blue software (Quantum Northwest). Spectra 
were recorded under 980 nm excitation using a Thorlabs fibre-coupled laser diode (maximum 
power 330 mW). The laser was focused on the sample using a lens to obtain a spot with a 
Gaussian intensity distribution with a 0.4 mm diameter. The emitted light was collected by a 
lens in a 90° configuration, and then transferred to a spectrophotometer (Avaspec - 2048L - 
USB2) by use of an optical fibre. Decay curves were measured at the green and red 
upconversion emissions using bandpass filters 542 / 20 nm and 660 /13 nm (Semrock) on a 
prototype fluorescence plate reader (developed during a joint project) from Edinburgh 
Instruments (EI) equipped with a 2W 980 nm laser from Changchun New Industries (CNI) and 
a PM-1 laser modulator box from (EI) for controlling the pulsing parameters of the CNI laser.    
6.2.2.2 Preparation of lanthanide trifluoroacetate precursors 
For the synthesis of Er3+/Yb3+ doped NaGdF4, lanthanide trifluoroacetate precursors were 
prepared in a 50 mL three-neck round-bottom flask (reaction vessel) by mixing 0.975 mmol of 
Gd2O3 (353.4 mg), 0.25 mmol of Yb2O3 (98.5 mg, corresponding to 20 mol % doping rate) and 
0.025 mmol of Er2O3 (9.6 mg, corresponding to 2 mol % doping rate), to 5 mL of distilled water 
and 5 mL of trifluoroacetic acid. The mixture was refluxed under magnetic stirring at 80°C 
until a clear solution was obtained. To slowly evaporate residual water and trifluoroacetic acid, 
the temperature was lowered to 60°C and the precursor was obtained as a white solid. For the 
synthesis of undoped NaGdF4, the amount of Gd2O3 used was 453.22 mg and the same 
synthesis protocol was followed with no erbium or ytterbium oxide added. The chemical 
reaction taking place during the synthesis of the precursors are shown in Figure 6.1.  
 
Figure 6.1. Chemical reaction taking place during synthesis of the precursors. 
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6.2.2.3  Synthesis of NaGdF4:Er3+,Yb3+ nanoparticles (core-doped) 
For the preparation of core (NaGdF4) doped UCNPs with 2 mol % Er3+ and 20 mol % Yb3+, 12.5 
mL of each the high boiling solvent 1-octadecene and of the coordinating oleic acid were mixed 
in a 100 mL three-neck round-bottom flask and degassed for 30 mins at 150°C under vacuum 
and magnetic stirring. Meanwhile, 2.5 mmol of sodium trifluoroacetate (340 mg) together with 
7.5 mL of each 1-octadecene and oleic acid were added to the as-prepared precursor. The 
mixture was degassed at 125°C under vacuum and magnetic stirring. Next, the reaction vessel 
containing the degassed 1-octadecene and oleic acid was heated to 315°C under gentle argon 
flow. The hot precursor solution was then added dropwise to the reaction vessel using a syringe 
and pump system (Harvard Apparatus, Pump 11 Elite) at an injection rate of 1.5 mL/min. 
Following injection, the solution was maintained at 315°C and stirred for a further 60 mins 
under argon flow before allowing to cool to room temperature. The obtained nanoparticles were 
precipitated by addition of ethanol and recovered by centrifugation at 5500 rpm for 10 mins. 
The recovered white powder was washed twice with a mixture of hexane and ethanol (1:4 v/v) 
followed by centrifugation. The resultant oleate-capped core-doped nanoparticles were finally 
redispersed in hexane for storage.  
6.2.2.4  Synthesis of NaGdF4:Er3+,Yb3+/ NaGdF4 nanoparticles (core-doped/shell) 
The synthesis of core-doped/shell UCNPs followed the same protocol as described for core-doped 
UCNPs with one additional injection step in order to grow the shell around the core-doped 
UCNP. 
For the synthesis of doped-core/undoped shell UCNPs, in first step, the doped core was 
synthesized as described for the core-only UCNPs. Subsequently, instead of cooling the reaction 
mixture to room temperature after 60 min of reaction time, the shell precursor solution 
containing the previously synthesized lanthanide trifluoroactetates, 2.5 mmol of sodium 
trifluoroacetate (340 mg), and 4 mL each of 1-octadecene and oleic acid (degassed at 125°C for 
30 min under vacuum and magnetic stirring) was added dropwise to the reaction vessel 
containing the core-doped (NaGdF4:Er3+,Yb3+) nanoparticles (injection rate of 1.5 mL/min). 
Following injection, the solution was maintained at 315°C and stirred for a further 60 mins 
under argon flow. The solution was then allowed to cool to room temperature and the obtained 
UCNPs were precipitation by addition of ethanol and recovered by centrifugation at 5500 rpm 
for 10 mins. The white powder obtained was washed 2 times with a mixture of hexane and 
ethanol (1:4 v/v) followed by centrifugation. The resultant oleate-capped core-doped/shell 
nanoparticles were finally redispersed in hexane for storage. 
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6.2.2.5 Synthesis of NaGdF4/ NaGdF4:Er3+,Yb3+ nanoparticles (core/shell-doped) 
Synthesis of core/shell-doped UCNPs followed the same protocol as the synthesis of core-
doped/shell nanoparticles, except that the precursor used for the core was not doped with any 
erbium or ytterbium. The erbium and ytterbium containing precursor was used for the second 
injection in order to grow the shell. . Scheme 6.1 and Figure 6.2 illustrate the set-up and the 
thermal decomposition mechanism for the synthesis of the UCNPs respectively. 
 
Scheme 6.1. Scheme of the set-up for the synthesis of the UCNPs. The syringe contains the precursor 
dissolved in a mixture of octadecene and oleic acid which is slowly injected in the reaction vessel 
containing a mixture of octadecene and oleic acid. Around the flask is a heating mantle and a magnetic 
stirrer is placed under the flask (omitted for clarity).    
 
Figure 6.2. Suggested thermal decomposition mechanism based on Y. Yoshimura et al., J. Alloys Comp. 
2006, 408-412 [197], 573-576 and F.Vetrone et al., Adv. Funct. Mater. 2009, 19, 2924-2929 [107]. 
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6.2.2.6  Preparation of water-dispersible ligand-free UCNPs 
Oleate-capped UCNPs are hydrophobic in nature, and are therefore not dispersible in aqueous 
solvents, which is a requirement for biomedical applications. Water dispersibility is also 
essential for further surface modification (such as with PEG in this study) for subsequent 
biological functionalization. In order to obtain water-dispersible ligand-free UCNPs, typically 
60 mg of the prepared oleate-capped UCNPs were dispersed in 5 mL of hexane and added to an 
aqueous solution of HCl which was adjusted to a ca. pH 4. The mixture was stirred at room 
temperature for 3 hours followed by separation of the aqueous phase containing the 
nanoparticles from the organic phase by use of a separation funnel. The UCNPs were collected 
by centrifugation at 5500 rpm for 15 mins after precipitation with acetone. The obtained 
particles were stirred for a further 2 hours in a 5 mL HCl aqueous solution maintaining the pH 
at 4. After the reaction, protonating of the carboxylate groups of the oleate ligand was 
completed and the ligand-free nanoparticles were recovered by centrifugation at 5500 rpm for 
15 mins after precipitation with acetone. The precipitate was finally redispersed in distilled 
water.  
6.2.2.7  Surface modification by PEGylation 
Surface modification of the UCNPs with amino-PEG-COOH for biomolecule coupling was 
performed through electrostatic interaction between the negatively charged COO- of the 
polymer and the positively charged Ln3+ on the surface of the UCNPs. An aqueous solution of 
amino-PEG-COOH was added to an aqueous dispersion of ligand-free UCNPs followed by 
stirring at room temperature overnight. The estimated concentrations that have been applied 
to prepare the PEGylated UCNPs were 50 mg/mL of a stock solution of PEG, 76 mg/mL of core-
doped, 84 mg/mL of core-doped/shell and 60 mg/mL of core/shell-doped ligand-free UCNPs. The 
PEG-modified UCNPs were precipitated with acetone and collected by centrifugation at 7000 
rpm for 25 mins. In order to remove excess PEG, the UCNPs were redispersed in water and 
precipitated with acetone before collection by centrifugation. The PEGylated UCNPs were 
finally redispersed in water with a final estimated maximum concentration of 50 mg/mL.  
6.2.2.8  UCNPs DNA conjugate  
As a proof-of-principle FRET immunoassay, only the core-doped UCNPs have been conjugated 
to thiolated-oligonucleotides (23 base pairs with thiol on the 3’ position), due to the presence of 
Er3+ ions close to the surface of the UCNPs. Conjugation of the oligonucleotides containing a 
thiol functional group to amino-PEGylated core-doped UCNPs was performed using sulfo-
EMCS crosslinkers. A several-fold molar excess of sulfo-EMCS was added and mixed to an 
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aqueous solution (pH 7) of the UCNPs at 30 rpm for 1 hour in the dark using an Intelli-Mixer. 
Disulfide bonds (S-S) on the oligonucleotides were reduced to sulfhydryls (S-H) using 30 min of 
incubation (rotating at 30 rpm) with 5 mM of Tris(2-carboxyethyl)phosphine (TCEP) in 50 mM 
sodium phosphate, 150 mM NaCl buffer (pH 6.5). Maleimide-activated UCNPs were purified 2 
times with pure water from excess sulfo-EMCS using a 100 kDa MWCO spin column from 
Millipore at 1000 g for 6 mins. SH-oligonucleotides were purified 2 times with 50 mM sodium 
phosphate, 150 mM NaCl (pH7.4) from excess TCEP using Zeba 7K desalting columns 
according to the manufacturer’s protocol. The obtained purified maleimide-UCNPs and thiol-
oligonucleotides were then mixed and incubated for 6 hours while rotating at 30 rpm. The core-
doped UCNPs DNA conjugate was finally washed against excess unbound oligonucleotides 4 
times with pure water using a 100 kDa MWCO spin column from Millipore at 1000g. The 
purified UCNPs conjugate was finally stored at 4°C. 
6.2.2.9  FRET hybridization assay 
Within all hybridization assays, the UCNPs-oligo conjugate was kept at fixed concentration (ca.         
2 mg/mL of core-doped UCNPs) to which increasing concentrations of the complementary oligo 
labeled to Cy3.5 in hybridization buffer (20 mM TRIS/Cl, 500 mM NaCl, 0.1% BSA, pH 8.0) was 
added. The solutions were then incubated at room temperature in a black 96-well microtiter 
plates for 30 minutes with an optical working volume of 150 µL. Decay curves were measured 
on the EI plate reader equipped with a 2W 980 nm laser from Changchun New Industries 
(CNI) and a PM-1 laser modulator box from (EI) for controlling the pulsing parameters of the 
CNI laser. Emissions of UCNPs-oligo and Cy3.5 were measured using appropriate bandpass 
filters at 542 / 20 nm (Semrock) and 607 / 8 nm (Delta) respectively.    
 
6.3 Results and discussion 
Sodium gadolinium fluoride (NaGdF4) was used in this study as host lattice for the doping of 
Er3+ and Yb3+ principally due to its relatively low multiphonon relaxation processes and low 
vibrational energies, as well as efficient upconversion emission [107,198,199]. It also possesses 
favorable bimodal properties for magnetic resonance and optical imaging [200].     
6.3.1 Morphological characterization 
Morphologies and sizes of the core-doped, core-doped/shell and core/shell-doped UCNPs were 
characterized by transmission electron microscopy. We can observe from Figure 6.3, that all 
the prepared UCNPs have uniform sizes and shapes. UCNPs appear to be rather spherical in 
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shapes with average diameters (determined based on 150 particles by use of ImageJ software) 
of 17 ± 2 nm for core-doped, 24 ± 3 nm for core-doped/shell and 15 ± 3 nm for core/shell-doped 
(Table 6.1). The X-ray diffraction patterns as shown in Figure 6.4 for the three types of 
UCNPs clearly reveal that the particles crystallized in the hexagonal - phase, which is 
believed to be the more efficient phase for upconversion emission for the NaGdF4 host material 
[201]. 
        
 
 
 
 
    
 
 
 
 
 
 
 
Table 6.1. Overview of UCNPs’ size and shell thickness as estimated from TEM measurements.  
UCNPs Core diameter (nm) 
Core-shell 
diameter (nm) 
Shell thickness 
(nm) 
Core-doped 17 ± 2 --  
Core-doped/shell 19 ± 2 24 ± 3 2.5 
Core/shell-doped 11 ± 2 15 ± 3 2 
 
 
Figure 6.3. Top : TEM images of the synthesized UCNPs revealing uniform sizes and rather 
spherical shapes. Bottom: Histogram of the particle size distribution. (A) Core-doped samples:         
17 ± 2 nm; (B) Core-doped/shell samples: 24 ± 2 nm total diameter and 2.5 nm shell thickness: (C) 
Core/shell-doped samples: 15 ± 3 nm total diameter and 2 nm shell thickness. 
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Figure 6.4. X-ray diffraction patterns of (A) core-doped (B) core-doped/shell (C) core/shell-doped UCNPs. 
In green: reference file for - NaGdF4 [00-027-0699]. 
6.3.2 Optical characterization 
The UCNPs were rendered hydrophilic by protonation of the carboxylate groups of the oleate 
ligand at low pH, which allows to detach them the UCNPs’ surface. The resulting ligand-free 
UCNPs were soluble in water and were further functionalized with an amino-PEG-COOH 
polymer through electrostatic interaction between the negatively charged COO- of the polymer 
and the positively charged lanthanide ions (Ln3+) on the surface of the UCNPs. The primary 
amines  (-NH2) functional group now available on the UCNPs surface make it possible for 
biomolecules attachment through different conjugation strategies. FTIR measurements were 
performed on the UCNPs in order to verify the presence of the polymer on their surface. From 
the FTIR spectra (only core-doped/shell and core/shell-doped are presented here) shown in 
Figure 6.5, we can clearly observe the characteristic vibrational stretching of the O-H bond 
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and C=O bond of the carboxyl group at around 3400 cm-1 and 1640 cm-1 respectively.        
Figure 6.5, also reveals the presence of C-O-C bond from the PEG at 1119 cm-1.  
 
 
 
 
 
 
 
 
 
Figure 6.5. FTIR spectra of core-doped/shell (blue) and core/shell-doped (green) of the UCNPs. 
Characteristic bands of the carboxyl group are clearly visible, around 3400 cm -1 for O-H bond and around 
1640 cm-1 for C=O bond. C-O-C bond corresponding to PEG at 1119 cm-1 is also present on the spectra for 
the UCNPs.  
The stability and dispersibility in various buffers of the PEGylated-UCNPs are important for 
their biological applications in bioconjugation (to proteins or DNA) and immunoassays, among 
other applications. Colloidal stability of the PEGylated-UCNPs was evaluated by dynamic light 
scattering (DLS) in water, 1× (10 mM) PBS pH 7.4 and 100 mM borate buffer pH 8.4. Both PBS 
and borate buffers are commonly used in biological research. The average hydrodynamic 
diameters were estimated from the analysis of three different measurements and are 
summarized in Table 6.2. Estimation of the hydrodynamic diameter of the PEGylated-UCNPs 
allows to assess aggregation behavior in different aqueous buffers as compared to TEM which 
provides only a picture of the nanoparticle’s structure in dry state, yet does not provide any 
information about the hydrodynamic diameter or tendency to aggregate. From Figure 6.6, we 
can clearly observe aggregation with the increase in hydrodynamic diameters of the UCNPs as 
a result of change in media. The low stability of these nanoparticles in aqueous buffers is 
therefore not optimum for biomedical applications and will has to be improved in future work 
(e.g. by optimized surface modification). 
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Table 6.2. Hydrodynamic diameter of the PEGylated UCNPs in different aqueous media indicating 
aggregation. Hydrodynamic diameters were estimated from a set of 3 measurements.  
PEG-modified UCNPs 
Hydrodynamic diameter (nm) 
Water 1× PBS pH 7.4 100 mM borate pH 8.4 
NaGdF4:Er3+,Yb3+ 
(Core-doped) 
69 ± 20 1374 ± 237 1005 ± 208 
NaGdF4:Er3+,Yb3+/NaGdF4 
(Core-doped/shell) 
66 ± 20 1080 ± 212 1122 ± 232 
NaGdF4/NaGdF4:Er3+,Yb3+ 
(Core/shell-doped) 
51 ± 17 3029 ± 478 1005 ± 178 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Upon continuous excitation at 980 nm NIR radiation, the synthesized UCNPs undergo 
upconversion emission in the visible range as it can be observed from Figure 6.7. The 
upconversion emission spectra normalized to the green peak emission for the core-doped, core-
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Figure 6.6. DLS measurement of (A) core-doped (B) core-doped/shell and (C) core/doped/shell 
PEGylated-UCNPs. UCNPs were measured in (black) water, (red) PBS buffer and (blue) borate buffer. 
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doped/shell and the core/shell-doped display the typical Er3+ emission bands in the visible range 
and also suggest the influence of a core/shell structure on the UCNPs green and red light 
emission. Emissions in the green wavelength region between 512 nm and 535 nm as well as 
between 535 nm and 570 nm are assigned to the transitions 2H11/2  4I15/2 and 4S3/2  4I15/2 
respectively. A red emission assigned to the transition state 4F9/2  4I15/2 was also visible 
between 635 nm and 685 nm. Excitation with a 980 nm photon brings the Yb3+ ion from its 2F7/2 
ground state to its single 2F5/2 excited state where energy transfer occurs to an Er3+ ion in close 
proximity bringing it from its 4I15/2 ground state to the 4I11/2 excited state. Simultaneously, the 
Yb3+ ion returns to its 2F7/2 ground state. Subsequently, another Yb3+ ion gets excited to its 
single excited state in the neighborhood of the excited Er3+ ion by a 980 nm photon. Energy is 
thus transferred to the Er3+ ion in the 4I13/2 excited state further promoting it to the 4F7/2 state, 
followed by the Yb3+ ion decaying back to its 2F7/2 state. Green emissions are thus obtained by 
non-radiative decay through the transitions (2H11/2, 4S3/2)  4I15/2. The Er3+ ion in the 4S3/2 excited 
state can alternatively decay to the next lower-lying 4F9/2 state through non-radiative decay 
processes, which allows for red upconversion emission corresponding to the radiative            
4F9/2  4I15/2 transition (Figure 6.8) [199]. The upconversion spectra of the three types of 
UCNPs further reveal that the highest luminescence is observed from the core-doped/shell 
nanoparticle. In fact, the application of an undoped shell has previously been suggested in 
order to enhance the upconversion emission of UCNPs, which is based on the fact that the shell 
protects the optically active Ln3+ centers in the core from the environment, thus surface-related 
quenching effects are minimized [107].  
 
 
 
 
 
 
 
Figure 6.7. Upconversion emission spectra normalized at the green peak emission of (black) core-doped 
(red) core-doped/shell and (blue) core/shell-doped upon 980 nm excitation. Green emission occurred at the 
transition states (2H11/2, 4S3/2)  4I15/2 while red emission is assigned to the 4F9/2  4I15/2 transition. 
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Figure 6.8. Relevant NaGdF4:Er3+, Yb3+ energy levels with radiative (full arrows) and non-radiative 
(dashed arrows) processes. Curved dashed arrows represent energy transfer [202]. 
The average intensity and amplitude decay times have been determined for all the PEGylated 
UCNPs, measured in a 96 –well microtiter plate with an optimal working volume of 150 µL on 
the EI fluorescence plate reader. The obtained lifetimes are summarized in Table 6.3. The 
lifetimes of the nanoparticles were measured at the green and red upconversion emissions 
using bandpass filters 542 / 20 nm and 660 / 13 nm (Semrock) respectively by pulsed excitation 
at 980 nm and are represented in Figure 6.9. We can distinguish longer lifetimes for the 
core/shell-doped and the core-doped/shell as compared to the core-doped only UCNPs. In 
comparison to the core/shell UCNPs, the lifetime of the core-doped UCNPs is shorter, which can 
be attributed to surface-quenching effect of the Er3+ based emission. For instance, high 
vibrational energy modes of OH groups from the surrounding solvent are effective quenchers of 
the upconversion emission. Growing a shell around the doped-core, greatly suppresses these 
surface-quenching effects as the shell brings a better protection between the core and the 
surrounding environment. From the lifetime analysis of the core-doped/shell and core/shell-
doped UCNPs, we observe an unexpected increase in lifetime for the latter as we would assume 
quenching of Er3+ ions on the shell surface by the surrounding aqueous environment. We can 
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exclude any protecting effect provided by the PEG coating against quenching effect of the 
aqueous media because the ligand-free UCNPs gave similar lifetimes (data not shown). One 
explanation could be that during the synthesis of the core/shell-doped nanoparticles a part of 
the sensitizer (Yb3+) and activator (Er3+) ions migrate into the superficial and/or inner part of 
the core, resulting in a non-homogeneous distribution of the ions in the nanoparticle. It would 
therefore act as core-doped/shell-doped UCNPs and upon excitation at 980 nm, the excited Yb3+ 
ions on the shell can effectively transfer energy to Er3+ ions present on the shell and in the core 
through excitation energy migration. Further studies (for instance the synthesis of an undoped 
core / Er3+/Yb3+ doped shell / second Yb3+ doped shell architecture employing the concept of 
active core-shell systems [107]) would therefore be indispensable to support this claim and to 
understand the underlying mechanism.  
Above described findings are important for FRET based applications as they suggests that the 
core/shell-doped UCNPs are suitable as FRET-donors since we believe that most of the Er3+ ions 
are on the surface of the nanoparticle, thus providing close proximity to an acceptor molecule 
for efficient energy transfer and long luminescence lifetimes suggest higher QY, which is 
advantageous for Förster distance. 
 
 
 
 
 
 
 
 
 
 
Figure 6.9. Upconversion decay lifetimes of (A) core-doped (B) core-doped/shell and (C) core/shell-doped. 
Green and red curves are the decay curves obtained using bandpass filters at 540/20nm and at 660/13 
nm respectively.  
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Table 6.3. Overview of the average amplitude and intensity decay times of core-doped, core-doped/shell 
and core/shell-doped UCNPs. 
PEG-modified UCNPs 
<> amplitude <> intensity 
@540/20 nm @660/13 nm @540/20 nm @660/13 nm 
NaGdF4:Er3+,Yb3+ 
(Core-doped) 
74.4 µs 144 µs 83.6 µs 180 µs 
NaGdF4:Er3+,Yb3+/NaGdF4 
(Core-doped/shell) 
101 µs 207 µs 144 µs 217 µs 
NaGdF4/NaGdF4:Er3+,Yb3+ 
(Core/shell-doped) 
128 µs 324 µs 161 µs 361 µs 
 
6.3.3 FRET hybridization assay 
Even though we observed low stability of the UCNPs in different aqueous solutions, we tried to 
establish a proof-of principal hybridization system between two complementary single stranded 
DNA based on UCNPs-to-dye FRET assay. As described in the Materials section 6.2.2.8, a 23 
base pair oligonucleotide was conjugated to the core-doped UCNPs (core/shell-doped UCNPs 
was not used as donor due to its low brightness and recovery after purification against excess 
oligos) and used as energy transfer donors to the Cy3.5 organic dye labelled on complementary 
oligonucleotides. We believe upon hybridization the Cy3.5 on the 3’ position will become close to 
the core-doped UCNPs surface where FRET can take place. Cy3.5 has an emission maximum at 
around 605 nm and its absorption spectrum overlaps the UCNPs PL in the green between    
512 nm and 535 nm and between 535 nm and 570 nm corresponding to the transition states     
2H11/2  4I15/2 and 4S3/2  4I15/2 respectively. This spectral overlap (Figure 6.12 left) shows that 
upon excitation in the NIR at 980 nm, energy transfer can take place between the UCNPs 
donor and Cy3.5 acceptor if they are in the Förster distance range assuming they follow the 
FRET-theory similar to the Tb-to-QD system. The Förster distance (R0) and overlap integral 
can be calculated by Equations 2.5 and 2.6 in the overlap range between ca. 500 nm to       
570 nm. 
The fluorescence QY of the UCNPs-donor in the absence of the acceptor for the green emission 
is not very high. Recently, R0 was calculated for an UCNP-to-QD FRET system by using an 
estimated minimum and maximum QY of 0.1 % and 1 % respectively and an overall QY of the 
UCNPs (because the donor QY should be Er3+ ions inside the UCNPs) of 5 % [161]. R0 for our 
UCNP-to-Cy3.5 FRET system was calculated as 2.1 nm for a QY of 0.1 %, 3.1 nm for a QY of     
1 % and an even larger Förster distance of 4.1 nm with 5 % QY [161]. Since only a fraction of 
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the Er3+ ions near the surface of the UCNPs can participate in energy transfer to a single dye, 
there will not be a strong difference between the quenched and unquenched PL decay curves 
UCNPs. However, since excitation in the NIR at 980 nm does not directly excite the Cy3.5 dyes 
but only the UCNPs-donor and due to the absence of photoluminescence background, FRET-
sensitized emission of Cy3.5 dyes can only be caused by energy transfer thus can be sensitively 
measured. Upon addition of the increasing concentration of the complementary oligo-Cy3.5 to 
the constant concentration of UCNPs-oligo, no obvious FRET-sensitization of the dye could be 
observed in the nM range but increasing the Cy3.5 dye concentration to the µM range yielded 
obvious sensitized emission due to energy transfer as it can be seen in Figure 6.10. 
Nevertheless, as control measurements using non-complementary oligo-Cy3.5, we also have an 
observable FRET-sensitized emission of the dye (Figure 6.11). One possible explanation could 
be direct binding of the oligonucleotides on the surface of the UCNPs independent of the 
sequence in both cases possibly replacing the original ligand. The phosphate groups are able to 
bind to UCNPs much stronger than carboxylic acids. Figure 6.12 right represents the relative 
PL ratio as a function of the concentration of oligonucleotide labeled with Cy3.5 
(complementary and non-complementary) measured in a time-gated window between 100 µs to 
300 µs after pulsed-excitation of the acceptor channel from Figure 6.10 B and Figure 6.11 B.   
 
 
   
  
 
 
 
 
Figure 6.10. (A) PL decay curves of core-doped UCNPs and core-doped UCNPs conjugate upon addition 
of increasing concentration (nM to µM) of complementary oligonucleotide labelled with Cy3.5, measured 
at 542 / 20 nm upon excitation at 980 nm. No quenching of the donor can be observed. (B) Decay curves 
measured at 607 / 8 nm of the complementary oligonucleotide labelled with Cy3.5 alone and in the 
presence of the core-doped UCNPs conjugate. At higher micromolar concentration range, visible increase 
of the PL intensity of the mixture oligos-UCNPs can be observed which can be an indication of energy 
transfer from the donor to the Cy3.5 dye.   
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Non-complementary oligonucleotide 
 
 
 
 
 
 
 
 
 
Figure 6.11. PL decay curves of core-doped UCNPs and core-doped UCNPs conjugate upon addition of 
increasing concentration of non-complementary oligonucleotide labelled with Cy3.5 in the µM range, 
measured at 542 / 20 nm upon excitation at 980 nm. No quenching of the donor can be observed. (B) 
Decay curves measured at 607 / 8 nm of the non-complementary oligonucleotide labelled Cy3.5 in the 
presence of the core-doped UCNPs conjugate. Visible increase of the PL intensity of the mixture oligos-
UCNPs can be observed similar to the complementary oligo-UCNPs mixture.   
 
 
 
 
 
 
 
 
Figure 6.12. (Left) Spectral overlap between absorption spectrum of the oligonucleotide labeled with 
Cy3.5 dye and the normalized area emission of the core-doped UCNPs. R0 was calculated in the spectral 
region of 500 – 570 nm which corresponds to the green overlapping region of the UCNPs. (Right) Relative 
PL ratio of the acceptor channel for the complementary and non-complementary oligonucleotides in 
presence of the core-doped UCNPs conjugate, measured in a time window between 100 – 300 µs.  
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6.4 Conclusions 
Core-doped, core-doped/shell and core/shell-doped UCNPs were synthesized via a thermal 
decomposition technique from trifluoroacetate precursors in 1-octadecene and oleic acid. 
Ligand-free UCNPs were obtained by treating the oleic acid coated UCNPs with HCl at pH 4. 
In acidic pH, the oleate ligands are protonated and are detached from the UNCPs’ surface 
resulting in hydrophilic nanoparticles. Surface functionalization with amino-PEG-COOH was 
performed through electrostatic interaction in order to generate functional groups on the 
surface of UCNPs for possible biomolecule attachment. TEM measurements of the UCNPs 
showed rather spherical particles with mean diameters for core-doped 17 ± 2 nm, core-
doped/shell 24 ± 3 nm with a shell thickness of ca. 2.5 nm and core/shell-doped 15 ± 3 nm with a 
shell thickness of ca. 2 nm. XRD patterns of the UCNPs showed that they are crystalline and 
phase-pure with hexagonal - structure of NaGdF4 as the only crystalline phase. Further, FTIR 
spectra confirmed the presence of the amino-PEG-COOH polymer on the surface of the UCNPs. 
DLS measurements showed that the three types of PEGylated-UCNPs suffered from poor 
dispersion solubility in the various buffers tested, including physiological buffers, indicating 
aggregation. Hence, more surface functionalization strategies should be envisaged in order to 
provide good dispersibility in buffers as conjugation to biomolecules often requires the use of 
buffers of different pH. Growing a shell around the core of an UCNPs provided protection 
against surface quenching of the luminescence of Er3+ ions. Moreover, the core/shell-doped 
nanoparticles showed unexpected long luminescent lifetimes as compared to the core-
doped/shell nanoparticles, favoring them to be potential FRET-donors as the presence of Er3+ 
ions on the surface would result in efficient FRET to an acceptor molecule in close distance. The 
FRET hybridization assays involving the core-doped-oligo and its complementary and a non-
complementary oligo labeled with Cy3.5 resulted in both cases to energy transfer possibly due 
to direct binding of the oligonucleotides on the surface of the core-doped UCNP thereby 
observing sensitization of the Cy3.5 upon excitation of the FRET systems with 980 nm NIR 
light.      
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7.  Summary and Outlook 
7.1 Summary 
This thesis presents the successful application of FRET as a transduction signal for the 
sensitive detection of cancer biomarkers using lanthanide complexes (LLC) and QDs as donor 
and acceptor respectively. All FRET immunoassays for the sensitive detection of the antigens 
were based on homogeneous time-resolved (TR) measurements, which were possible as a result 
of the unique photophysical properties of the LLC donor and QD acceptor. The Tb complex we 
used as donor has an average luminescent decay time of around 2.6 ms, which is several fold 
longer than the nanosecond lifetimes of the used QDs, which allowed time-resolved 
measurements for the efficient suppression of transient background from the directly excited 
QDs and sample autofluorescence (in the nanosecond to microsecond range) especially when 
excited in the UV. For a nearly background free measurement of our FRET signals, we applied 
a gating of 800 µs with a delay of 100 µs after pulsed excitation at 337 nm with a nitrogen laser 
operating at 20 Hz. In the FRET immunoassays for biomarker (antigen) detection, the donor 
and acceptor concentrations were kept constant with increasing concentration of the antigens, 
showing that any new appearance of a short time decay component and quenching/sensitization 
can only be caused by non-radiative energy transfer from Tb to QD. Ratiometric measurements 
were involved to build the calibration curves as they help to reduce well-to-well variations by 
offering an instantaneous suppression of sample and excitation source fluctuations.  
Fluorometric sandwich FRET-based immunoassays require two types of antibody bioconjugates 
which need to be stable, sensitive and specific for the detection of antigens. The marriage of 
stable and controlled bioconjugation techniques with suitable donor and acceptor probes will 
give rise to extremely sensitive FRET-based sensing. In a first study, Tb-AB conjugates were 
obtained by a fully random labeling of Tb-NHS via various amino groups available on the 
antibody surface. For a less random coupling, using a generic and easily applicable 
bioconjugation method, we converted three commercially available amino QDs possessing a 
thick polymer PEG coating (QD605, QD655 & QD705) from Life Technologies to maleimide-
activated QDs with sulfo-EMCS, which is a heterobifunctional linker. The maleimide-activated 
QDs were further conjugated to IgGs and fragmented antibodies F(ab) where the maleimide 
targets the disulfide bridges at the antibody hinge region. We tested the performance of these 
bioconjugates in a Tb-to-QD TR-FRET immunoassay for the detection of PSA and only the 
F(ab)-QD bioconjugates yielded successful calibration curves and sub-nanomolar LOD. As 
FRET is strongly distance dependent (r-6), the large IgG and the bulky polymer PEG coating on 
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the QDs (IgG conjugated only to QD705) results in negligible FRET. An important finding is 
that all Tb-QD FRET pairs provide LODs in a concentration range that is clinically relevant 
and that the 50 µL serum samples present clinically relevant solutions. Duplexing capability 
was demonstrated in PSA assays containing both QD655 and QD705 AB conjugates. The 
comparison of LODs for the same biomarker is an important tool for a relative comparison of 
the FRET-pairs in order to adapt the FRET-probes to the required concentration range of 
different biomarkers (most biomarkers have different cut-off values) in a multiplexed assay and 
based on these results, QD705 (highest sensitivity) should be used for the biomarker with the 
lowest cut-off and QD605 for the one with the highest cut-off.  
The next step concerned the development of high quantum yield, water soluble and 
biocompatible compact QDs having a thin coating as compared to the thick PEG coating of the 
Life Technologies QDs, which limits their use as probes in FRET immunoassays. Three types of 
QDs were used InPZnS/ZnSe/ZnS (QD530), CdSe/ZnS (QD605), and CdSeTe/ZnS (QD705) 
core/shell QDs. QD605 and QD705 possess the same core/shell as the Life Technologies QDs 
and differ mainly in their surface coating. Aqueous phase transfer of the QDs was conducted by 
surface ligand exchange with penicillamine and post-functionalized with a bifunctional ligand 
(Mal1) containing a lipoic acid function spaced by three PEG moieties from a maleimide group. 
The lipoic acid function was anchored on the surface of the QDs and the maleimide group was 
made available for subsequent bioconjugation to free sulfhydryl groups of antibodies. Both the 
penicillamine and Mal1 functionalized QDs were colloidally stable for more than two years in 
aqueous buffer and did not lose their initial quantum efficiency. F(ab) were conjugated via 
Mal1 to QD530, QD605 and QD705 while IgG, F(ab’)2 and F(ab) were directly attached to the 
surface of QD705 (highest sensitivity) via metal affinity of thiol to zinc. The successful 
conjugation of the antibodies were verified in Tb-to-QD FRET immunoassays for the detection 
of PSA. QD530 bearing a low spectral overlap with Tb donor emission could not be used for 
LOD quantification and the low concentration recovery of the QD-F(ab’)2 was not enough for 
statistical evaluation in an immunoassay. The other QD conjugates yielded LODs below the 
cut-off of PSA with a 25 fold sensitivity improvement using the direct attachment of F(ab) on 
the surface of the QD (2 ng/mL LOD for QD705 from Life Technologies vs  0.08 ng/mL LOD for 
QD705 having a compact coating).  
We also designed a FRET immunoassay for the sensitive and simultaneous detection of three 
differently sized cancer biomarkers from a single serum sample. NSE, CEA, and TPSA were 
chosen as biomarkers and monoclonal antibodies against these biomarkers were labelled to Tb 
and QDs (from eBioscience). Based on the findings of the first study, where QD705 should be 
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used for the biomarker with the lowest cut-off and QD605 for the one with the highest cut-off, 
antibodies against TPSA were conjugated to QD705, those against CEA to QD650 and against 
NSE to QD605. Due to the use of monoclonal antibodies and QDs having narrow and Gaussian 
emission spectra, no biological crosstalk and negligible optical crosstalk could be observed. All 
LODs of the biomarkers were below their clinical cut-off levels even though a large background 
of Tb luminescence was present in the acceptor detector channels (except QD705 channel). A 
technical “worst case scenario” was constructed, where a combination of high and low 
concentrations of the biomarkers were present in a single sample, and resulted that CEA, NSE 
and PSA could be detected with high precision at low nM concentrations with minor deviations 
from known concentrations. 
In an attempt to investigate new nanoparticles for FRET applications, three types of UCNPs, 
namely NaGdF4:Er3+,Yb3+ (core-doped), NaGdF4:Er3+,Yb3+/NaGdF4 (core-doped/shell) and 
NaGdF4/NaGdF4:Er3+,Yb3+ (core/shell-doped) were synthesized via the thermal decomposition 
technique and rendered water soluble by obtaining ligand-free nanoparticles. These UCNPs 
were surface functionalized with an amino-PEG-COOH linker through electrostatic interaction 
in order to generate functional groups on the surface of UCNPs for possible biomolecule 
attachment. TEM measurements of the UCNPs showed rather spherical particles and XRD 
patterns of the UCNPs showed that they are highly crystalline and possess a hexagonal - 
structure of NaGdF4. FTIR spectra confirmed presence of the amino-PEG-COOH polymer on 
the surface of the UCNPs. DLS measurements showed that the three types of PEGylated-
UCNPs were not at all stable in various buffers including physiological buffers where 
aggregation was observed. Growing a shell around the core of an UCNPs showed protection 
against surface OH-vibrational quenching of the luminescence of Er3+ ions. Moreover, the 
core/shell-doped UCNPs showed unexpected long luminescent lifetimes as compared to the 
core-doped/shell nanoparticles, favoring them to be suitable FRET-donors as the presence of 
Er3+ ions on the surface would result in efficient FRET to an acceptor molecule in close distance 
FRET assays involving a core-doped-UCNP-DNA and its complementary DNA as well as a non-
complementary DNA labeled with cy3.5 resulted in both cases to non-specific interactions, 
thereby observing sensitization of the cy3.5 upon excitation of the FRET systems at 980 nm. 
More surface functionalization strategies of the UCNPs should be envisaged in order to produce 
good dispersibility in buffers as conjugation to biomolecules often requires using buffers of 
different pH. 
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7.2  Outlook 
The use of QDs emitting in the 700 nm region has shown so far to be the most sensitive probes 
in Tb-to-QD FRET systems due to negligible Tb PL emission beyond 700 nm. QDs emitting in 
the NIR region would thus be ideal for FRET immunoassays in order to yield sensitive 
biomarker detection with very low LOD with the adequate NIR-IR PMT. The compact QDs 
obtained by phase transfer offers the possibility to bind biomolecules that have free sulfhydryl 
groups on its surface, which decrease the donor-acceptor distance and lead more FRET-
efficiency. These compact QDs could be used for multiplexed detection either for micro-RNA or 
protein biomarkers.  
We already started to work on procalcitonin (PCT) and mid regional pro-adrenomedullin (MR-
proADM), which are two biomarkers for the diagnosis of bacterial infection. For the moment 
their antibodies are conjugated to commercially available QD705 from Life Technologies and 
detected in a Tb-to-QD FRET immunoassay which does not yield the desired sensitive 
detection. The polyclonal antibodies, as they as known to be unstable, against PCT and MR-
proADM should be carefully conjugated to the compact QDs, with optimized and improved 
purification techniques. A duplex format should then be performed to simultaneously detect 
these two biomarkers from a single sample as their combination can maximize patient safety 
by accurately accessing the immediate risk of septic infection. A last, but not least step would 
be to measure real patients samples (CEA, NSE, TPSA, PCT & MR-proADM) from our 
calibration curves either by using our already established FRET system involving commercial 
QDs or by using the compact QDs and also to measure in a multiplexed format on the approved 
KRYPTOR clinical fluorescence plate reader.     
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8. Appendix 
8.1 Abbreviations 
AB – antibody 
AG - antigen 
BSA – bovine serum albumin 
CEA – carcinoembryonic antigen 
ChA – acceptor channel 
ChB – donor channel 
CTC – circulating tumor cells 
Da – Dalton 
DHLA – dihydrolipoic acid 
D—A – donor to acceptor distance 
DLS – dynamic light scattering 
DNA – deoxyribonucleic acid 
EI – Edinburgh instruments 
eQD – eBioscience quantum dot 
ESA – excited state absorption 
ETU – energy transfer upconversion 
FDA – food and drug administration 
FRET – Förster resonance energy transfer 
FTIR – Fourier transform infrared 
FWHM – full width at half maximum 
GMBW – guaranteed minimum bandwidth 
IgG – immunoglobulin G 
iQD – ITK (Life Technologies) quantum dot 
IR – infrared 
IRF – instrument response function 
LED – light emitting diode 
LLC – luminescent lanthanide complexes 
Ln – lanthanide 
LOD – limit of detection 
LOQ – limit of quantification 
MCS – multi channel scalers 
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ms- millisecond 
MWCO- molecular weight cut-off 
ns – nanosecond 
NP - nanoparticle 
NSE – neuron-specific enolase 
PA – photon avalanche 
Pen – penicillamine 
PEG – polyethylene glycol 
PL – photoluminescence 
PMT – photomultiplier tube 
QD – quantum dot 
QY – quantum yield 
RNA – ribonucleic acid 
SD – standard deviation  
SDS-PAGE - sodium dodecyl sulfate polyacrylamide gel electrophoresis 
sm-FRET – single molecule-FRET 
ssDNA – single stranded DNA 
Tb – Lumi4-terbium complex 
TCSPC – time correlated single photon counting 
TEM – transmission electron microscopy 
TPSA – total prostate specific antigen 
TR – time resolved 
UCNP – upconversion nanoparticle 
UV – ultraviolet 
Vis – visible 
XRD – X-ray diffraction 
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8.2 Antibody fragmentation SDS-PAGE 
8.2.1 Fragmentation of CEA antibody G15 to F(ab’)2 
 
Figure 8.1. SDS-PAGE image of CEA F(ab')2. M: MW marker, 1: reduced IgG, 2: reduced F(ab')2, 3: non-
reduced IgG, 4: non-reduced F(ab')2, 5. non-reduced protein A column elution 1, 6: non-reduced protein A 
column elution 2, 7: non-reduced protein A column elution 3. 
8.2.2 Fragmentation of NSE antibody E20 to F(ab’)2  
 
Figure 8.2. SDS-PAGE image of NSE F(ab')2. M: MW marker, 1: reduced IgG, 2: reduced F(ab')2, 3: non-
reduced IgG, 4: non-reduced F(ab')2, 5. non-reduced protein A column elution 1, 6: non-reduced protein A 
column elution 2, 7: non-reduced protein A column elution 3. 
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8.2.3 Fragmentation of TPSA antibody PSR222 to F(ab’)2 and F(ab) 
 
 
Figure 8.3. SDS-PAGE image of TPSA (top) F(ab')2 and (bottom) F(ab). M: MW marker, 1: reduced IgG, 
2: reduced F(ab')2, 3: non-reduced IgG, 4: non-reduced F(ab')2, 5. non-reduced protein A column elution 1, 
6: non-reduced protein A column elution 2, 7: non-reduced protein A column elution 3.  
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8.3 Decay curve fitting 
8.3.1 Decay curve fitting of QD705-d-Fab 
Donor Channel R0 = 11 nm 11 
Fitted from 0.04 to 8 ms (fixed Tb background decay 
time) 
# QD (nM) 
 
1 FRET1 A1 DA*1 DA1

2 FRET2 A2 DA*2 DA2
0 0.00 D in the absence of A (double-exponential) 790 0.64 1057 0.13 1.00 
F3 0.30                     
F4 0.60                     
F5 1.00                     
F6 3.00 180 0.92 778 0.09 0.18 1300 0.41 3556 0.39 0.82 
F7 4.00 240 0.89 862 0.10 0.18 1300 0.41 4006 0.45 0.82 
F8 6.00 390 0.82 1198 0.13 0.21 1400 0.36 4547 0.51 0.79 
F9 9.00 330 0.85 1075 0.12 0.18 1400 0.36 4783 0.54 0.82 
F10                       
F11                       
average 2-9 290 0.87     0.19 1350 0.38     0.81 
distance r (nm) 8.0 8.0   fraction: 19% 11.9 11.9   fraction: 81% 
 
             
 
   
fixed 
         # QD (nM) 
  
0 A0 DA*0
  

z(D) DA FRET>  0 0.00 
  
2400 7225 0.87 
  
2190 
 F3 0.30 
  
      
  
        
 F4 0.60 
  
      
  
        
 F5 1.00 
  
      
  
        
 F6 3.00 
  
2400 4737 0.52 
  
1780 0.08 1120 0.49 
 F7 4.00 
  
2400 4051 0.45 
  
1700 0.07 1140 0.48 
 F8 6.00 
  
2400 3140 0.35 
  
1620 0.05 1210 0.45 
 F9 9.00 
  
2400 3025 0.34 
  
1610 0.05 1230 0.44 
 F10   
  
      
  
        
 F11   
  
      
  
        
 average 2-9 
  
2400     
  
    1180 0.46 
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distance r (nm) 
  
>>R0 
    
  
 
11.3 11.3 
 
Acceptor Channel R0 = 11 nm 11 Fitted from 0.05 to 5 ms (fixed Tb background decay time) 
   
# 
QD 
(nM) 
 
1 FRET1 A1 AD*1 kFRET1 AD1

2 FRET2 A2 AD*2 kFRET2 AD2

3 FRET3 A3 AD*3 kFRET3 AD3
F3 0.30                                       
F4 0.60                                       
F5 1.00                                       
F6 3.00 40 0.98 
390
6 
0.88 0.0245 0.136 330 0.85 417 0.09 0.00257 0.14   1800 0.18 84 0.02 0.00010 0.73 
F7 4.00 40 0.98 
381
1 
0.87 0.0245 0.134 330 0.85 444 0.10 0.00257 0.15   1700 0.22 109 0.02 0.00013 0.72 
F8 6.00 42 0.98 
353
9 
0.85 0.0234 0.093 360 0.84 461 0.11 0.00232 0.12   1800 0.18 126 0.03 0.00010 0.79 
F9 9.00 40 0.98 
386
7 
0.86 0.0245 0.109 330 0.85 477 0.11 0.00257 0.13   1700 0.22 145 0.03 0.00013 0.76 
F10               0             0 1.00         
F11               0             0 1.00         
average 1-9 41 0.98       0.118 225 0.85       0.134   1167 0.47       0.748 
distance r 5.7 5.7 
  
fraction: 12% 7.7 8.3 
  
fraction: 13% 
 
11.2 11.2 
  
fraction: 75% 
  
 
         
    
   
  
 
   
fixed 
                  
# 
QD 
(nM) 
 
0 A0 AD*0
   


z(A) DA FRET>
         F3 0.30   
 
      
   
        
         F4 0.60   
 
      
   
        
         F5 1.00   
 
      
   
        
         F6 3.00   
 
2400 33 0.008 
   
120 0.0011 1359 0.38 
         F7 4.00   
 
2400 29 0.007 
   
130 0.0010 1273 0.42 
         F8 6.00   
 
2400 22 0.005 
   
140 0.0008 1461 0.33 
         F9 9.00   
 
2400 21 0.005 
   
140 0.0007 1344 0.39 
         F10     
 
      
   
        
         F11     
 
      
   
        
         average 1-9   
 
2400     
    
  1359 0.38 
         distance r 
  
>>R0        
11.9 11.9 
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8.3.2 Decay curve fitting of QD705-d-IgG 
Donor Channel R0 =11 nm 11 Fitted from 0.04 to 8 ms (fixed Tb background decay time) 
# QD (nM) 
 
1 FRET1 A1 DA*1 DA1

2 FRET2 A2 DA*2 DA2

 0 0.00 D in the absence of A (double-exponential) 370 0.83 945 0.11 1.00 
 G3 0.15                     
 G4 0.30                     
 G5 1.50                     
 G6 3.00 20 0.99 7515 0.46 0.90 550 0.75 799 0.05 0.10 
 G7 4.50 18 0.99 10206 0.54 0.92 650 0.70 870 0.05 0.08 
 G8 6.00 23 0.99 5664 0.40 0.86 730 0.67 916 0.06 0.14 
 G9 12.00 25 0.99 4839 0.36 0.85 710 0.67 860 0.06 0.15 
 G10 18.00 18 0.99 9708 0.53 0.92 710 0.67 886 0.05 0.08 
 G11 24.00 24 0.99 4585 0.35 0.84 710 0.67 882 0.07 0.16 
 average 2-9 20 0.99     0.88 630 0.69     0.12   
distance r (nm) 5.0 5.1   fraction: 88% 9.5 9.6   fraction: 12% 
 
 
               
 
   
fixed 
           # QD (nM) 
  
0 A0 DA*0
  

zD DA FRET>    0 0.00 
  
2400 7867 0.89 
  
2180 
   G3 0.15 
  
      
  
        
   G4 0.30 
  
      
  
        
   G5 1.50 
  
      
  
        
   G6 3.00 
  
2400 7991 0.49 
  
1210 0.06 50 0.98 
   G7 4.50 
  
2400 7786 0.41 
  
1030 0.05 50 0.98 
   G8 6.00 
  
2400 7635 0.54 
  
1350 0.06 100 0.95 
   G9 12.00 
  
2400 7726 0.58 
  
1440 0.07 110 0.95 
   G10 18.00 
  
2400 7756 0.42 
  
1060 0.05 60 0.97 
   G11 24.00 
  
2400 7693 0.58 
  
1460 0.07 120 0.94 
   average 2-9 
  
2400     
  
    80 0.96 
   distance r (nm) 
  
>>R0 
    
  
 
6.4 6.4 
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  Acceptor Channel R0 = 11 nm 11 Fitted from 0.05 to 5 ms (fixed Tb background decay time) 
   
# 
QD 
(nM) 
 
1 FRET1 A1 AD*1 kFRET1 AD1

2 FRET2 A2 AD*2 kFRET2 AD2

3 FRET3 A3 AD*3 kFRET3 AD3
G2 0   

  

  

  

  

  

   

  

  

G3 0.15                                       
G4 0.30                                       
G5 1.50                                       
G6 3.00 36 0.98 4788 0.90 0.0273 0.153 250 0.89 399 0.07 0.00355 0.10   1800 0.18 86 0.02 0.00010 0.75 
G7 4.50 35 0.98 5028 0.89 0.0281 0.117 260 0.88 412 0.07 0.00339 0.08   1800 0.18 124 0.02 0.00010 0.80 
G8 6.00 38 0.98 3709 0.86 0.0259 0.076 290 0.87 396 0.09 0.00299 0.07   1800 0.18 162 0.04 0.00010 0.85 
G9 12.00 37 0.98 4388 0.88 0.0266 0.108 280 0.87 400 0.08 0.00312 0.08   1700 0.23 165 0.03 0.00013 0.81 
G10 18.00 37 0.98 4597 0.89 0.0266 0.096 310 0.86 374 0.07 0.00277 0.07   1800 0.18 151 0.03 0.00010 0.83 
G11 24.00 36 0.98 4548 0.88 0.0273 0.114 280 0.87 395 0.08 0.00312 0.09   1700 0.23 157 0.03 0.00013 0.80 
average 1-9 37 0.98       0.111 278 0.87       0.082   1767 0.20       0.807 
distance r 5.6 5.6 
  
fraction: 11% 8.0 8.0 
  
fraction: 8% 
 
13.9 13.9 
  
fraction: 81% 
  
 
         
    
   
  
 
   
fixed 
                  
# 
QD 
(nM) 
 
0 A0 AD*0
   
 z(A) DA FRET>
         1 0.06   
 
      
   
        
         2 0.10   
 
      
   
        
         3 0.15   
 
      
   
        
         4 0.20   
 
2400 57 0.011 
   
110 0.0012 1378 0.37 
         5 0.25   
 
2400 56 0.010 
   
110 0.0011 1473 0.33 
         6 0.30   
 
2400 55 0.013 
   
160 0.0014 1562 0.29 
         7 0.40   
 
2400 55 0.011 
   
140 0.0012 1402 0.36 
         8 0.50   
 
2400 55 0.011 
   
130 0.0012 1521 0.31 
         9 0.60   
 
2400 55 0.011 
   
130 0.0012 1389 0.37 
         average 1-9   
 
2400     
    
  1454 0.34 
         distance r 
  
>>R0        
12.3 12.3 
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8.4 Calibration curves for LOD calculation 
8.4.1 Linear part of calibration curves from Chapter 4 
 
Figure 8.4. Linear part of calibration curve from Figure 4.11 B corresponding to Tb-QD605-Mal1 
FRET-pairs 
 
Figure 8.5. Linear part of calibration curve from Figure 4.11 C corresponding to Tb-QD705-Mal1 
FRET-pairs 
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Figure 8.6. Linear part of calibration curve from Figure 4.12 D corresponding to Tb-QD705-d-IgG 
FRET-pairs 
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Figure 8.7. Linear part of calibration curve from Figure 4.12 D corresponding to Tb-QD705-d-IgG 
FRET-pairs 
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Figure 8.8. Linear part of calibration curve from Figure 4.5 B corresponding to Tb-eQD605 FRET-pairs 
 
Figure 8.9. Linear part of calibration curve from Figure 4.5 A corresponding to Tb-eQD650 FRET-pairs 
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Figure 8.10. Linear part of calibration curve from Figure 4.5 C corresponding to Tb-eQD650 FRET-
pairs 
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Résumé : La haute sensibilité et l’analyse 
simultanée de plusieurs biomarqueurs (multiplexage) 
sont des enjeux essentiels pour permettre des 
avancées significatives pour le diagnostic médical. 
De telles avancées permettraient d’augmenter la 
précocité des diagnostics pour de nombreuses 
maladies comme le cancer ou des maladies 
cardiaques. Les immunodosages de FRET (transfer 
d’énergie par resonance de type Förster) sont basées 
sur la reconnaissance de biomarqueurs par des 
anticorps marqués avec des fluorophores et le FRET 
qui résulte du processus de reconnaissance 
immunologique. Aujourd’hui des telles 
immunodosages sont établis en utilisant des 
lanthanides comme donneurs de FRET et des 
fluorophores organiques comme accepteurs de 
FRET. 
 
Néanmoins, ils ne permettent pas de réaliser un 
multiplexage efficace car l’utilisation de plusieurs 
différents fluorophores organiques résulte dans un 
recouvrement spectral. Ce projet a pour but de mettre 
en application les propriétés optiques exceptionnelles 
des complexes de terbium (Tb) et des boîtes 
quantiques (QDs) pour parvenir à des analyses 
biologiques de FRET multiplexées et ultrasensibles. 
Nous avons également étudié les propriétés optiques 
et morphologiques de nouvelles nanoparticules à 
conversion ascendante de type coeur et 
coeur/coquille dopées à l'ytterbium (Yb) et des ions 
d'erbium (Er) comme donneurs de FRET.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10. Synthèse en français 
Le but de cette thèse est d’utiliser les propriétés photophysiques exceptionnelles des 
complexes de terbium (Tb) et des boîtes quantiques (QDs) pour la détection des marqueurs 
cancéreux protéiniques par des immunodosages multiplexés ultrasensibles de transfert 
d’énergie par résonance de type Förster résolue en temps (TR-FRET), ainsi que l’étude des 
propriétés optiques et morphologiques de nouvelles nanoparticules à conversion ascendante de 
type cœur et cœur/coquille dopées à l'ytterbium (Yb) et des ions d'erbium (Er) comme donneurs 
de FRET potentiel pour des biocapteurs. Le FRET est un transfert d'énergie non radiatif entre 
deux molécules et est fortement dépendant de la distance. Le transfert d'énergie non radiatif se 
produit à partir d'une molécule excité (donneur de FRET) vers une molécule acceptrice 
(accepteur de FRET) dans son état fondamental par des interactions dipôle-dipôle à longue 
portée. Le donneur de FRET doit être un fluorophore et l'accepteur de FRET doit être capable 
d'absorber la lumière à la (les) longueur (s) d'émission du donneur mais n'a pas nécessairement 
besoin de réémettre des photons. Pour que le FRET se produise, le spectre d'émission du 
donneur doit se recouvrir avec le spectre d'absorption de l'accepteur, il faut donc prendre grand 
soin en choisissant les paires de FRET appropriées pour les expériences planifiées. Ce 
recouvrement spectral peut être décrit en termes de distance de Förster (R0), qui définit la 
distance entre le donneur et l'accepteur pour lequel l'efficacité de FRET est de 50%. Il existe 
une multitude de paires de FRET pour la bioanalyse, parmi lesquelles on peut trouver des 
colorants organiques, des protéines fluorescentes, des chélates métalliques (par exemple des 
complexes de lanthanides) et des nanocristaux semi-conducteurs (boîtes quantiques). Le R0 
typique entre les colorants et/ou les protéines fluorescentes est généralement compris entre 2 et 
5 nm et peut s'étendre jusqu'à 11 nm en utilisant des lanthanides et des boîtes quantiques. La 
forte dépendance en distance de r-6, où r correspond à la distance entre les paires de FRET, 
permet d'obtenir des informations sur des petits changements structurels dans les processus 
biologiques, des données cinétiques de réactions et des interactions de liaison biologiques entre 
autres. Le FRET se déroule généralement à une distance c.a 1-10 nm qui est comparable aux 
dimensions de la plupart des interactions biologiques. Dans le cas d'une reconnaissance 
anticorps-antigène, lorsqu'une paire de FRET marquée sur des anticorps spécifiques pour une 
reconnaissance spécifique de la cible (antigène) est rapprochée, des changements dans les 
propriétés photophysiques des paires de FRET apparaissent du fait du transfert d'énergie, qui 
dépend de la distance entre les paires de FRET [6-9]. Pour les immunodosages de TR-FRET, 
des anticorps monoclonaux (ABs) contre des marqueurs biologiques (antigènes) de différente 
masse moléculaire – antigène carcinoembryonnaire (CEA), énolase spécifique des neurones 
 
 
 
(NSE) et antigène prostatique spécifique (TPSA) – ont été marqués aux Tb (donneur de FRET) 
et aux QDs (accepteurs de FRET) émettant à différentes longueurs d’ondes. En présence des 
antigènes, l’immunodosage provoque la formation de [AB-donneur]-antigène-[AB-accepteur] qui 
résulte en un rapprochement de Tb et QD suivi de FRET. Il convient de noter que dans notre 
immunodosage de FRET, l'efficacité de FRET pour plusieurs Tb-donneur par QD-accepteur ne 
change pas par rapport à un système donneur / accepteur unique. Cependant, il y a une 
probabilité accrue de QDs qui soient sensibilisés par le FRET avec un nombre croissant de Tb-
donneurs en raison de la longue durée de vie luminescente du Tb [18, 19]. L'utilisation de QDs  
avec des revêtements épaisses et de grandes biomolécules telles que les IgG et des antigènes 
relativement grands, dans un format [AB-donneur]-antigène-[AB-accepteur], pourrait affecter 
l'efficacité du FRET, par conséquent la sensibilité de détection due à la forte dépendance de 
distance entre les paires de FRET [7].  
La première étude (Chapitre 3) démontre la possibilité de surmonter les grandes 
distances dans des immunodosages de FRET homogènes et de fournir simultanément une 
grande sensibilité et capacité de multiplexage dans l'utilisation de complexes de terbium 
luminescents en tant que donneurs de FRET pour des QD revêtus d’un polymère 
poly(éthylène)glycol (PEG)  épais comme accepteurs. Les conjugués Tb-AB ont été obtenus par 
un marquage entièrement aléatoire de Tb-NHS via divers groupes amino disponibles sur les 
anticorps. Dans un couplage moins aléatoire, trois QDs disponibles dans le commerce avec des 
longueurs d’ondes maxima d’émission à 605, 655 et 705 nm (dénommés respectivement QD605, 
QD655 et QD705) de Life Technologies possédant un revêtement épais de polymère PEG 
fonctionnalisé par des amines (QD-amino) ont été conjugués à des anticorps fragmentés (F(ab)) 
par la chimie sulfhydryle [20]. Ces QD-amino ont été convertis en QD-maléimide en utilisant le 
réticulant hétérobifonctionnel sulfo-EMCS possédant les groupes NHS ester et maléimide [21]. 
Les QDs activés par la maléimide ont été conjugués au F(ab), par l'intermédiaire de groupes 
sulfhydryle libres, qui se révèlent avantageux pour les immunodosages de FRET en raison de 
leur plus petite taille et de la plus grande quantité d'ABs par QD [20]. La performance de nos 
immunodosages a été évaluée avec les QD605, QD655 et QD705 comme accepteurs avec Tb 
comme donneurs de FRET car les variations de formes, de tailles, de chevauchement spectral et 
de leur photoluminescence conduisent à des différences en efficacité de FRET et de détection. 
Les propriétés photophysiques (stationnaire et résolue en temps) des conjugués Tb-AB et QD-
AB, et leurs performances dans les immunodosages de FRET pour la détection de PSA dans de 
faibles volume de sérum ont été réalisées. Une telle caractérisation et évaluation dans des 
immunodosages comparables pour le même antigène sont indispensables pour concevoir et 
optimiser de tels immunodosages de FRET homogènes, en particulier pour la détection 
 
 
 
multiplexée. Le calcul des intégrales de recouvrement a abouti à un R0 important pour tous les 
systèmes Tb-QD et a permis une sensibilisation mesurable du QD par FRET dans le système 
[Tb-AB]-PSA-[QD-AB], même avec un revêtement épais des QDs. Les trois systèmes de FRET, 
Tb-à-QD, montraient des signaux de FRET à sélection temporelle croissants avec des 
concentrations de PSA croissantes. Les courbes d'étalonnage correspondant aux trois 
immunodosage de FRET ont pu être tracées avec succès et les limites de détection (LOD) 
calculées à l'aide de ces courbes d'étalonnage ont montré la sensibilité la plus élevée (faible 
LOD) pour le système Tb-QD705 suivi des systèmes Tb-QD655 et Tb-QD605. Nous montrons 
également que des facteurs comme les rapports de marquage, R0 et le bruit de fond de la 
photoluminescence du terbium influent sur la sensibilité de détection. On a aussi démontré la 
capacité de multiplexer en utilisant différentes paires de FRET de Tb-QD en préparant un 
immunodosage duplexé contre la PSA qui contenait deux conjugués de QDs (QD655 et QD705) 
avec les LOD les plus faibles. Leurs courbes d'étalonnage suivaient une tendance similaire 
qu’avec les paires de FRET dans un immunodosage simple. Les LOD pour la PSA dans 50 μL 
d'échantillons de sérum mesurés sur un lecteur de plaques de fluorescence clinique disponible 
dans le commerce se situaient dans la gamme de concentration sub-nanomolaire et inférieure à 
la valeur de seuil clinique de 4 ng/mL pour les paires de FRET basées sur QD655 et QD705. 
Comme la plupart des biomarqueurs ont des valeurs de seuil clinique différentes, nous avons 
également conclu que QD705 devrait être utilisé pour le biomarqueur avec la plus faible 
coupure et QD605 pour celui avec le plus haut seuil. La capacité de duplexage a été démontrée 
dans des dosages de PSA contenant à la fois des conjugués QD655-AB et QD705-AB. Nos 
résultats fournissent des informations importantes concernant le développement 
d'immunodosages de FRET basés sur les QDs pour le diagnostic clinique multiplexé parce que 
la méthode de conjugaison avec les anticorps que nous avons développée est applicable à tous 
les QDs fonctionnalisés à l'amine disponible dans le commerce, qui existe dans beaucoup 
d'autres couleurs que les trois utilisés dans cette étude. 
La deuxième étude se porte sur une nouvelle approche de fonctionnalisation et 
bioconjugaison de QD, qui a abouti à des QDs compactes et stables, et des conjugués QD-AB 
hautement luminescents afin d’améliorer l'immunodosage de TR-FRET Tb-QD contre le PSA. 
Ces QDs ont été synthétisés par le laboratoire INAC-SyMMES, du CEA Grenoble. Sur la base 
des résultats de la première étude mettant en jeu des QD avec un revêtement polymère épais 
qui montrent la possibilité de détecter la PSA dans une gamme de concentration sub-
nanomolaire, la conception de QD compacts permettrait de surmonter les limitations majeures 
pour le développement d'immunodosages de FRET basés sur des QDs avec des LOD 
concurrentielles à des kits commerciaux qui sont: (i) une stabilité colloïdale insuffisante des QD 
 
 
 
compacts dans les milieux biologiques, (ii) des revêtements de surface QD épais (par exemple 
PEG, polymères ou des revêtements lipidiques qui protègent la QD inorganique de 
l'environnement biologique et les rendent hydrosolubles) (iii) les stratégies limitées de 
conjugaison avec des anticorps pour les QDs avec des couches organiques plus minces. Pour 
cela, le transfert de phase aqueuse des QDs InPZnS/ZnSe/ZnS émettant à 530 nm (QD530) et 
des QDs commerciales CdSe/ZnS hydrophobes (Life Technologies) émettant à 605 et 705 nm 
(QD605 et QD705 respectivement) a été effectué par échange de ligands avec la pénicillamine 
zwitterionique (Pen). La post-fonctionnalisation a été réalisée pour produire des QDs activés 
par maléimide en utilisant un ligand bifonctionnel Mal1 contenant une fonction d'ancrage 
d'acide lipoïque, espacé par trois fragments PEG avec un groupe fonctionnel maléimide pour la 
conjugaison avec les thiols des F(ab). Nous montrons également pour la première fois une autre 
stratégie de post-fonctionnalisation qui impliquait le couplage direct d’anticorps (IgGs, F(ab')2 
et F(ab)) à la surface du QD705 compacte (sensibilité la plus élevée) sans aucun agent de 
réticulation, qui a pour objectif de réduire d’avantage la distance de transfert d'énergie entre 
Tb-donneur et QD-accepteur. L'analyse par TEM a été réalisée sur les QDs pour confirmer leur 
taille et leur dispersibilitée tandis que les spectres infrarouges à transformée de Fourier (FTIR) 
et gel-agarose ont prouvé la fonctionnalisation et la conjugaison réussies avec Mal1 et F(ab) 
respectivement. Pour ces couples Tb-QD FRET, on a calculé des R0 élevés révélant un R0 le plus 
grand pour QD705 et de petites variations des propriétés photophysiques des QD à différents 
stades de transfert de phase, post-fonctionnalisation avec Mal1 et lors de la conjugaison avec   
F(ab) ont été observé. Dans cette étude, seule une caractérisation photophysique complète de la 
conjugaison directe des IgG à QD705 a été réalisée en raison des faibles concentrations 
collectées après purification provenant de la conjugaison directe avec F(ab')2 et de F(ab). Les 
immunodosages de FRET contre la PSA dans des échantillons à base de sérum, en utilisant des 
QD conjugués à F(ab) via Mal1, correspondant aux systèmes Tb-QD605/705, ont permis la 
quantification de la LOD, alors que l'essai Tb-QD530 a donné un signal de FRET très faible 
probablement liée au R0 petit (6,1 nm), qui n'a pas pu être utilisé pour calculer un LOD. Les 
dosages de FRET de Tb-QD705 en utilisant la conjugaison directe des anticorps à la surface du 
QD a fourni des sensibilités encore meilleures comparés aux Mal1. LODs des deux 
immunoessais Tb-QD FRET (utilisant des QDs émettant à 605 nm et 705 nm) sont non 
seulement bien en deçà de la valeur seuil clinique du PSA (4 ng/mL), mais l'utilisation des 
conjugués QD-AB compacts ont également fourni une amélioration de la sensibilité de 6,2 et 25 
fois par rapport aux mêmes QD disponibles dans le commerce avec un revêtement à base de 
PEG/polymère standard comme utilisé dans la première étude. Ces immunodosages Tb-à-QD 
FRET hautement sensibles et homogènes conviennent à tout autre biomarqueur contre lequel 
 
 
 
deux anticorps spécifiques existent. Nos résultats montrent que les conjugués QD-AB compacts 
ont un grand potentiel pour améliorer les applications diagnostiques et compte tenu de la 
capacité de multiplexage de Tb-QD FRET, nous sommes convaincus que ces nano-sondes 
fluorescentes deviendront des acteurs importants du diagnostic clinique in vitro. 
Dans la troisième étude, nous tentons de détecter les antigènes CEA, NSE et TPSA se 
trouvant dans un seul échantillon à base de sérum. L'importance de détecter plusieurs 
biomarqueurs réside dans le fait qu'un seul biomarqueur ne contient pas suffisamment 
d'informations pour établir un diagnostic clair sur une maladie et que la combinaison de 
différents biomarqueurs augmente le contenu des informations sur l'état ou le type de cancer. 
Le CEA et le NSE sont parmi les marqueurs tumoraux où leurs niveaux sont surveillés en 
combinaison avec d'autres marqueurs tumoraux pour obtenir un diagnostic clair de cancer du 
poumon à petites cellules (SCLC) et / ou de cancer du poumon non à petites cellules (NSCLC) et 
TPSA (somme du PSA libre et du PSA lié à des protéines) qui est un marqueur tumoral pour le 
cancer de la prostate. Comme le FRET est très dépendant de la distance, le choix de la 
conjugaison avec F(ab')2 aux QDs donnerait une distance de séparation plus courte entre les QD 
et Tb dans les immunodosages de FRET « en sandwich », donc des efficacités et des sensibilités 
de FRET plus élevées que lors de l'utilisation des IgG. En outre, la petite taille des F(ab')2 
simultanément avec ses 2 sites antigéniques pour une plus grande probabilité de liaisons avec 
les antigènes, serait bénéfique pour les tailles de biomarqueurs croissantes (32 kDa à 180 kDa) 
dans les immunodosages de FRET. On a réalisé des caractérisations photophysiques des paires 
de FRET (Tb-donneur et QD-accepteur) et les rapports de marquage de Tb/AB et QD/AB ont été 
estimés par spectroscopie d'absorption UV/Vis. Comme la première étude a suggéré que pour 
différentes valeurs de seuil clinique QD705 devrait être utilisé pour le biomarqueur avec la plus 
faible coupure et QD605 pour celui avec la plus haute coupure, les anticorps contre CEA, NSE 
et TPSA ont été conjugués aux QDs provenant de eBioscience : eQD650, eQD605 ; et Life 
Technologies QDs iQD705 respectivement. Notre immunodosage de Tb-QD FRET multiplexé a 
été capable de détecter simultanément 3 marqueurs tumoraux de taille différente à partir d'un 
seul échantillon de sérum de CEA (180 kDa), NSE (95 kDa) et PSA (32 kDa) en utilisant des 
sondes Tb et QD conjuguées à leur anticorps monoclonaux respectifs ne conférant aucune 
interférence biologique. En utilisant les spectres d'émission étroits et Gaussiens des QD et les 
bandes d'émission de Tb bien séparées avec des filtres passe-bande appropriés, a permis une 
interférence optique négligeable. Par conséquent, aucune correction matricielle n'a été 
nécessaire pour déterminer la concentration des marqueurs tumoraux. Les LODs calculées 
dans des échantillons à base de sérum de volume 50 μL étaient toutes en dessous des limites de 
seuil clinique des marqueurs tumoraux, où des LOD plus élevées ont été observées pour le 
 
 
 
format triplexé par rapport au format simple sauf pour TPSA. La contamination des canaux de 
détection eQD605/650 avec un signal de Tb 3 fois plus élevé (pour le format triplexé) a entraîné 
une augmentation de LOD alors que pratiquement aucune émission de Tb ne peut être détectée 
dans le canal de détection de l’iQD705. Un «scénario le plus défavorable» a été effectué lorsque 
nous avons testé notre dosage immunologique de FRET avec une combinaison de 
concentrations cibles élevées et faibles. Dans l'ensemble, le CEA et la TPSA pouvaient être 
détectés avec une grande précision, avec des écarts mineurs par rapport aux concentrations 
connues, à l'exception de la NSE qui présentait une sous-estimation dans ses concentrations 
dans une gamme de concentration spécifique avec une combinaison de concentrations élevées et 
faibles de CEA et de faibles concentrations de TPSA. Les limites de détection des marqueurs 
tumoraux dans la gamme sub-nanomolaire (quelques ng/mL) dans un environnement complexe 
comme dans le sérum et contenant 9 biomolécules différentes prouvent l'applicabilité 
immédiate aux applications de diagnostic pour des mesures multiplexées sensibles. 
La quatrième étude a consisté à étudier des fluorophores de nouvelle génération, connus 
sous le nom de nanoparticules à conversion ascendante (UCNP). La conversion ascendante est 
un processus où la lumière à basse énergie (proche infrarouge (NIR) ou infrarouge (IR)) est 
convertie en énergie plus élevée (ultraviolette ou visible) au moyen d'absorptions multiples de 
photons ou de transferts d'énergie, dans un processus non linéaire [22,23]. Cette propriété 
(entre autres) leur permet de posséder un grand potentiel dans l’imagerie et la biodétection 
dans des applications in vitro et in vivo [22]. Similaires aux complexes de lanthanides, les 
UCNP dopés par les lanthanides possèdent des bandes d'émission très étroites dans le visible, 
ce qui leur permet de fonctionner comme donneurs d'énergie avec un assortiment d'accepteurs 
dans la biodétection à base de FRET. Trois types d'UCNPs ont été analysés dans cette thèse 
afin de choisir le meilleur candidat en tant que donneur de FRET. Nos collaborateurs de 
l'Institut National de la Recherche Scientifique (INRS) du Québec Canada, ont synthétisé des 
UCNPs de type cœur et cœur/coquille - NaGdF4:Er3 +,Yb3 + (cœur-dopé), NaGdF4:Er3 +,Yb3 +/ 
NaGdF4 (cœur-dopé/coquille) et NaGdF4/NaGdF4:Er3 +,Yb3 + (cœur/coquille-dopé). Ces UCNPs 
ont été rendues « ligand-free » et la fonctionnalisation de surface avec l'amino-PEG-COOH a été 
réalisée par interaction électrostatique afin de générer des groupes fonctionnels à la surface des 
UCNPs pour une éventuelle conjugaison avec des biomolécules. Les mesures TEM des UCNPs 
ont montré des particules plutôt sphériques et les graphes XRD ont montré qu'ils sont 
cristallins et la comparaison avec le modèle de référence a révélé une structure hexagonale - 
de NaGdF4. Les spectres FTIR ont confirmé la présence du polymère amino-PEG-COOH à la 
surface des UCNP. Les mesures DLS ont montré que les trois types de PEGylated-UCNPs 
 
 
 
n'étaient pas du tout stable dans divers tampons, y compris les tampons physiologiques où des 
agrégats ont été observés. Par conséquent, des stratégies optimisées de fonctionnalisation de 
surface doivent être envisagées afin de produire une bonne dispersibilité dans des tampons car 
la conjugaison avec des biomolécules nécessite souvent l'utilisation de tampons de pH différent. 
On a observé une émission de conversion ascendante dans le visible du spectre 
électromagnétique pour les trois UCNPs après excitation à 980 nm. Les émissions dans le vert 
se sont produites aux états de transition suivants: (2H11/2, 4S3/2)  4I15/2 et l’émission dans le 
rouge : 4F9/2  4I15/2. En comparaison avec les UCNPs cœur/coquille, le temps de vie des 
nanoparticules cœur-dopé est plus petite et peut être attribuée à l'effet d’atténuation des ions 
Er3+ à la surface du cœur par des modes d'énergie vibrationnelle élevés des groupes OH 
correspondant au solvant environnant. L’enrobage du cœur-dopé par une coquille supprime 
grandement les effets d’atténuation de surface et apporte une meilleure protection entre le 
cœur et le solvant environnant. Les nanoparticules cœur/coquille-dopé ont montré des temps de 
vie luminescente longue et inattendue par rapport aux nanoparticules cœur-dopé/coquille, ce 
qui les favorise pour être des donneurs de FRET adéquats, car la présence d'ions Er3+ à la 
surface donnerait un FRET efficace avec une molécule accepteur proche de cette surface. 
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Résumé : La haute sensibilité et l’analyse 
simultanée de plusieurs biomarqueurs (multiplexage) 
sont des enjeux essentiels pour permettre des 
avancées significatives pour le diagnostic médical. 
De telles avancées permettraient d’augmenter la 
précocité des diagnostics pour de nombreuses 
maladies comme le cancer ou des maladies 
cardiaques. Les immunodosages de FRET (transfer 
d’énergie par resonance de type Förster) sont basées 
sur la reconnaissance de biomarqueurs par des 
anticorps marqués avec des fluorophores et le FRET 
qui résulte du processus de reconnaissance 
immunologique. Aujourd’hui des telles 
immunodosages sont établis en utilisant des 
lanthanides comme donneurs de FRET et des 
fluorophores organiques comme accepteurs de 
FRET. 
 
Néanmoins, ils ne permettent pas de réaliser un 
multiplexage efficace car l’utilisation de plusieurs 
différents fluorophores organiques résulte dans un 
recouvrement spectral. Ce projet a pour but de mettre 
en application les propriétés optiques exceptionnelles 
des complexes de terbium (Tb) et des boîtes 
quantiques (QDs) pour parvenir à des analyses 
biologiques de FRET multiplexées et ultrasensibles. 
Nous avons également étudié les propriétés optiques 
et morphologiques de nouvelles nanoparticules à 
conversion ascendante de type coeur et 
coeur/coquille dopées à l'ytterbium (Yb) et des ions 
d'erbium (Er) comme donneurs de FRET.  
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Abstract : Combining high sensitivity with 
simultaneous analysis of numerous biomarkers 
(multiplexing) is an essential requirement for 
significantly improving the field of biomedical 
diagnostics. Such progresses would allow earlier 
diagnosis, which is required for numerous diseases 
such as cancer or cardiac diseases. FRET-
immunoassays are based on biomolecular 
recognition events that occur between biomarkers 
and two specific antibodies conjugated with 
different fluorophores. The spatial proximity of the 
two fluorophores can lead to Förster resonance 
energy transfer (FRET), which can be detected for 
biomarker quantification. To date, such assays are 
established using lanthanide complexes as FRET 
donors and fluorescence dyes as FRET acceptors. 
 
However, these assays do not provide sufficient 
multiplexing capability due to spectral overlap, 
when several acceptor dyes are used. This project 
aims at exploiting the exceptional photophysical 
properties of terbium complexes (Tb) and 
semiconductor quantum dots (QDs) to provide 
ultrasensitive multiplexed FRETimmunoassays. We 
also studied the optical and morphological 
properties of novel core and core/shell upconverting 
nanoparticles doped with ytterbium (Yb) and 
erbium (Er) ions as possible FRET-donors for 
biosensing. 
 
 
